All language subtitles for nibib051722

WELCOME TO THE 59th MEETING OF

THE NATIONAL ADVISORY COUNCIL

FOR BIOMEDICAL IMAGING AND

BIOENGINEERING.

I'M DAVID GEORGE, NIBIB

ASSOCIATE DIRECTOR, EXECUTIVE

SECRETARY OF THIS COMMITTEE.

THIS COUNCIL MEETING IS OPEN TO

THE PUBLIC, EXCEPT FOR THE

REVIEW OF PENDING GRANT

APPLICATIONS WHICH WILL TAKE

PLACE LATER IN THE AFTERNOON.

THE OPEN SESSION OF THE COUNCIL

MEETING IS BEING LIVE BROADCAST

ON THE NIH VIDEOCAST NETWORK,

AND RECORDED FOR NIH ARCHIVES.

THE COMMITTEE AND PRESENTERS ARE

PARTICIPATING VIA VIDEO

CONFERENCE.

I'D LIKE TO WELCOME OUR COUNCIL

MEMBERS, EX OFFICIOS, SPECIAL

GUESTS, THANK YOU TO ALL

WATCHING ON THE VIDEOCAST.

MEMBERS OF THE PUBLIC WHO WISH

TO EXPRESS VIEWS ON ANY ITEMS

DISCUSSED DURING THIS MEETING

MAY DO SO IN WRITING WITHIN THE

NEXT TEN DAYS, BY E-MAILING ME

AT INFO@NIBIB.NIH.GOV.

PLEASE PUT NIBIB COUNCIL IN THE

SUBJECT LINE OF AN E-MAIL.

FOR OUR ATTENDEES AND PRESENTERS

TODAY IN TERMS OF SOME BEST

PRACTICES FOR VIDEO

CONFERENCING, I'LL REMIND YOU TO

PLEASE MUTE YOURSELF WHEN NOT

SPEAKING.

WHEN YOU SPEAK, STATE YOUR NAME

ESPECIALLY IN HOLLYWOOD SQUARES

MODE.

PEOPLE ON THE VIDEOCAST CAN'T

TELL WHO IS SPEAKING SO IT HELPS

IF YOU MENTION YOUR NAME AND I

WITH BRUCE WILL CALL YOU OUT TO

MAKE THAT EASIER.

FOR COLLEAGUES AND GUESTS

PRESENTING, REMINDER TO PRESENT

FROM A FILE LOCATED ON YOUR

COMPUTER'S HARD DRIVE RATHER

THAN THROUGH A NETWORK DRIVE.

LOG OFF VPN WHILE YOU'RE

PRESENTING.

ALSO SHUT OFF ANY UNNEEDED

SOFTWARE TO MAXIMIZE RESOURCES

AND BAD WIDE -- BANDWIDTH.

THE CHAT IS FOR OUR COLLEAGUE

MANAGING THE VIDEO CONFERENCE,

YOU CAN CHAT IF YOU HAVE

TECHNICAL PROBLEMS.

YOU CAN LET HIM KNOW BY THAT.

ALSO, YOU CAN REACH RYAN BY

E-MAIL DURING THE MEETING, RYAN.

DAVA@NIH.GOV.

BEFORE WE MOVE ON, ANY QUICK

QUESTIONS ABOUT THAT?

IN TERMS OF ANNOUNCEMENTS WE

HAVE A QUORUM FOR TODAY'S

MEETING. I'D LIKE TO THANK PAM

GLICKMAN AND SPECIALIST ALICIA

HOPKINS FOR THEIR FANTASTIC WORK

IN ORGANIZING THE MEETING.

THEY DO A FANTASTIC JOB THREE

TIMES A YEAR.

I'D LIKE TO THANK OUR I.T.

COLLEAGUES, ALL THE SPECIAL

ARRANGEMENTS THEY MAKE FOR THE

ZOOM, AND THE VIDEOCAST, THE

EXTRA WORK INVOLVED WITH THAT.

THANK YOU VERY MUCH.

THESE PROCEEDINGS ARE GOVERNED

BY FACA, AND GOVERNMENT IN THE

SUNSHINE ACT.

CONSEQUENTLY THIS MEETING IS

ANNOUNCED TO THE PUBLIC IN THE

FEDERAL REGISTER AND LATER ON

THERE WILL BE A CLOSED SESSION

FOR DISCUSSION OF INDIVIDUAL

APPLICATIONS.

WE ANTICIPATE ADJOURNING THE

OPEN SESSION AT 2:45 P.M.

FUTURE COUNCIL DATES, THEY ARE

LISTED AT THE BOTTOM OF THE

AGENDA, FOR COUNCIL MEMBERS IT

WAS FOUND UNDER THE ELECTRONIC

COUNCIL BOOK IN THE CURRENT

COUNCIL TAB.

PLEASE REVIEW THE DATES AND MAKE

SURE IT DOESN'T CLASH WITH A

CONFERENCE THAT WOULD TAKE AWAY

COUNCIL MEMBERS.

NEXT MEETING IS SEPTEMBER 13,

2022, AGAIN HELD BY VIDEO

CONFERENCE.

I'D LIKE TO MOVE INTO

CONSIDERATION OF MINUTES FROM

THE LAST MEETING AND COUNCIL

OPERATING PROCEDURES.

I WOULD ASK THE COUNCIL MEMBERS

TO PLEASE UNMUTE YOURSELVES IN

PREPARATION FOR A VOICE VOTE.

MINUTES ARE MADE AVAILABLE TWO

WEEKS AGO IN THE ELECTRONIC

COUNCIL BOOK.

ARE THERE ANY COMMENTS OR

MODIFICATIONS THAT YOU'D LIKE TO

MAKE TO THE MINUTES?

HI, PAULA, AND WELCOME.

HEARING NONE I'LL ENTERTAIN A

MOTION TO APPROVE.

>> SO MOVED.

>> AND SECOND?

>> SECOND.

>> SECOND.

ALL IN FAVOR, AYE?

>> AYE.

>> AYE.

>> AYE.

>> ALL OPPOSED, NAY?

THANK YOU, MOVING TO

CONSIDERATION OF COUNCIL

OPERATING PROCEDURES, AGAIN

THESE ARE MADE AVAILABLE A

COUPLE WEEKS AGO IN ECB.

AS I MENTIONED IN MY

COMMUNICATION WE DIDN'T CHANGE

THEM, JUST ADDED A PARENTHETICAL

PHRASE TO CLARIFY SOMETHING BUT

THE POLICY WASN'T CHANGED.

ARE THERE ANY COMMENTS OR

MODIFICATIONS THAT YOU WOULD

LIKE TO MAKE TO THE OPERATING

PROCEDURES?

HEARING NONE I'LL ENTERTAIN A

MOTION TO APPROVE THEM.

>> SO MOVED.

>> I SECOND.

>> A SECOND, THANK YOU.

ALL IN FAVOR, AYE.

>> AYE.

>> AYE.

>> AYE.

>> AYE.

>> ALL OPPOSED, NAY.

OKAY.

VERY GOOD.

WITH THOSE ADMINISTRATIVE

MATTERS TAKEN CARE OF I'LL TURN

THE PROCEEDINGS OVER TO OUR

DIRECTOR, DR. BRUCE TROMBERG.

>> THANK YOU, DAVID.

AND I WOULD LIKE TO REITERATE

THANK YOU TO PAM AND TO ALICIA

AND TO OUR I.T. COLLEAGUES FOR

GETTING US ALL TOGETHER AND

SETTING THIS UP.

SO, IF WE COULD TAKE YOUR SLIDE

DOWN WE'RE GOING TO DO SOME

SLIDE GYMNASTICS FOR A FEW

MINUTES.

MEMBER WE CAN DO OUR CUSTOMARY

HELLO.

GIVE A WARM WELCOME.

YOU TOO, SUSAN, WHERE WE ALL SAY

HI.

WE'RE EMULATING THE REAL ROOM,

SO IF YOU WERE IN A REAL ROOM

WITH US WE WOULD BE THANKING YOU

FOR COMING AND SAYING HI AND

RECONNECTING WITH MANY

COLLEAGUES WHOM YOU KNOW WELL.

SO THANK YOU SUSAN.

NOW I WILL SHARE MY SCREEN AND

BRIEFLY -- LET'S SEE.

OKAY.

NORMALLY YOU WOULD SEE A

DIRECTOR'S REPORT HERE BUT WE'RE

GOING TO INTERRUPT AT THE

BEGINNING BECAUSE WE HAVE THE

OPPORTUNITY TO HAVE DR. SUSAN

MARGUILES.

I THINK EVERYONE KNOWS SUSAN AND

HER WORK ARE PIONEERING WORK,

SHE'S DIRECTOR OF THE

ENGINEERING DIRECTORATE AT THE

NATIONAL SCIENCE FOUNDATION, AND

PRETTY NEW TO THE GOVERNMENT.

ONLY SINCE JULY OF 2021.

WELCOME, SUSAN.

VERY EXCITING TIME TO JOIN THE

GOVERNMENT.

HER TALK WILL BE TRANSFORMING

THE WORLD THROUGH ENGINEERING

OPPORTUNITIES FOR PARTNERSHIP

WITH NIBIB.

WE HAVE EXTENSIVE PARTNERSHIPS,

SO WE'RE EXCITED TO HEAR FROM

HER, HER IDEAS.

SUSAN IS -- EVERYONE KNOWS, AN

SOLUTION VISIONARY AND WE'RE

FORTUNATE FOR OUR COMMUNITY TO

HAVE HER AS DIRECTOR OF THE

ENGINEERING DIRECTORATE AT NSF.

PRIOR TO JOINING NSF SUSAN WAS A

PROFESSOR AND CHAIR OF THE

COULTER DEPARTMENT OF BIOMEDICAL

ENGINEERING AT GEORGIA TECH AND

EMORY, PRIOR TO THAT FOR NEARLY

25 YEARS SHE WAS A PROFESSOR OF

BIOENGINEERING AND NEUROSURGERY

AT THE UNIVERSITY OF

PENNSYLVANIA, SO SHE'S DONE WORK

REALLY IN DEPTH IN BOTH

BIOMECHANICS OF PEDIATRIC

TRAUMATIC BRAIN INJURY AND LUNG

INJURY, ASSOCIATED WITH

MECHANICAL VENTILATORS AND

BIOLOGY IN MEDICINE OF THESE

PHENOMENA, AND HER WORK HAS BEEN

RECOGNIZED BY MANY, MANY AWARDS

INCLUDING BEING A FELLOW OF THE

NAE, NAM, AMBI, SMEE SMBS,

TRAINING IN MECHANICAL AND

AEROSPACE ENGINEERING AS

UNDERGRADUATE AT PRINCETON, GRAD

OPPORTUNITY AT PENN, AND IN FACT

OVERLAPPED WITH OUR VERY OWN

DAVID GEORGE AS A GRAD

OPPORTUNITY AT THE UNIVERSITY OF

PENNSYLVANIA, SOME YEARS AGO.

I WON'T GO INTO EXACTLY WHEN

THAT WAS.

BUT WE'RE SO FORTUNATE TO HAVE

SUSAN.

SUSAN, BEFORE I TURN IT OVER TO

YOU WHILE WE HAVE YOU HERE JUST

TO SHOW OFF A FEW OF OUR

COLLABORATIONS WITH NSF, WE HAVE

AT LEAST NINE MEMBERS OF OUR

STAFF PROGRAM DIRECTORS AND

SCIENTIFIC REVIEW OFFICERS,

PROBABLY MORE, WHO ARE ENGAGED

IN THESE COLLABORATIONS IN

COMPUTATIONAL NEUROSCIENCE,

COLLABORATIVE RESEARCH, NATIONAL

ROBOTICS, CYBER PHYSICAL

SYSTEMS, WORK IN SMART CONNECTED

HEALTH TOGETHER, BUT THAT'S NOT

ALL.

SHE ALSO HAVE BEEN WORKING

TOGETHER SINCE THE VERY

BEGINNING OF NIBIB ON THE

INTERAGENCY MODELING AND

ANALYSIS GROUP, MORE RECENTLY

THE BRIDGE TO A.I. WHICH IS A

COMMON FUND INITIATIVE THAT

SUPPORTS A.I.-BASED APPROACHES,

AND GETTING A.I., DIVERSE A.I.

DATASETS.

THE BRAIN INITIATIVE WHICH

EVERYONE KNOWS ABOUT AND NEEDS

NO FURTHER INTRODUCTION.

AS WELL AS AN EMERGING EFFORT IN

MEDICAL IMAGING, THE PHANTOM

LIBRARY, COLLABORATION WITH

NIST, AND WORKING ON DEVELOPING

MORE PARTNERSHIPS WITH NSF.

SO, I WILL STOP THERE.

AND HAND IT OVER TO SUSAN.

WE'RE SO GRATEFUL FOR YOU TO

COME HERE AND LOOKING FORWARD TO

BUILDING ON THESE WONDERFUL

COLLABORATIONS THAT WE'VE HAD

TOGETHER OVER THE YEARS.

>> THANK YOU, BRUCE.

ATLANTIC YOU -- THANK YOU FOR

MAKING TIME IN THE SCHEDULE FOR

THIS CONVERSATION AND I LOOK

FORWARD TO IT.

LET ME SHARE MY SLIDES.

HOW DOES THAT LOOK?

SOMEBODY NEEDS TO SAY SOMETHING

BECAUSE I TURNED OFF YOUR --

>> LOOKS GOOD.

>> LOOKS GOOD.

>> WONDERFUL.

SO WHAT I'D LIKE TO DO TODAY IS

TO GIVE YOU A COMPRESSED

WHIRLWIND TOUR OF THE

ENGINEERING DIRECTORATE WITHIN

THE NATIONAL SCIENCE FOUNDATION,

AND TO SHARE WITH YOU SOME

PROGRAMS, INITIATIVES,

SOLICITATIONS, WHERE I THINK OUR

INTERESTS COULD ALIGN.

MY PERSPECTIVE IS THAT WHILE

I'VE HAD A GREAT DEAL OF

NATIONAL SCIENCE FOUNDATION FROM

MY RESEARCH IN THE PAST, MY OWN

RESEARCH IN HEAD INJURY AND IN

VENTILATOR-ASSOCIATED LUNG

INJURY WAS NOT ACTUALLY FUNDED

BY NIBIB AT NIH.

IT WAS FUNDED BY NHLBI AND

NINDS.

I'M FULLY AWARE THAT THE

POTENTIAL INTERACTIONS FOR

ENGINEERS AT THE INTERFACE

BETWEEN MEDICINE AND ENGINEERING

COULD BE AT MANY DIFFERENT

PLACES WITHIN NIH.

BRUCE AND I HAVE FELT THAT THE

IMPORTANT CONVERSATION BEGINS

WITH NIBIB.

AS THE DIRECTORATES WITH

ENGINEERING IN OUR NAMES, IT'S

VERY IMPORTANT, AND I WANT TO

HIGHLIGHT THAT BRUCE IS NOW A

MEMBER OF THE ENGINEERING

DIRECTORATE ADVISORY COMMITTEE,

VERY MUCH LIKE YOUR COMMITTEE,

AND I THINK IT'S REALLY AN

IMPORTANT STEP TO ENSURING

GREATER UNDERSTANDING OF THE

MISSION OF EACH OF OUR AGENCIES,

AND OUR SPECIFIC DIRECTORATES OR

INSTITUTES IN NIH'S CASE, AND TO

REALLY IDENTIFY ENDURING WAYS

THAT WE CAN PARTNER ON ACHIEVING

OUR MISSIONS.

LET ME SEE IF I CAN MANAGE THE

SLIDES.

GREAT.

THE NSF MISSION, SOME PEOPLE

REALLY FEEL NSF DOESN'T FUND

THINGS THAT MIGHT RELATE TO

HEALTH AND DISEASE BUT I WANT TO

POINT OUT THAT IN THE NSF

MISSION STATEMENT YOU HAVE THE

WORD NATIONAL HEALTH.

SO WE DO INDEED ACROSS THE

AGENCY ENGAGE IN RESEARCH

RELATED TO HEALTH AND DISEASE

AND MEDICINE.

I HAVE THIS SLIDE UP FROM FISCAL

21 TO HIGHLIGHT IN THE UPPER

LEFT-HAND CORNER THAT UNLIKE

NIH, WHICH HAS AN INTRAMURAL

PROGRAM, AT NSF THERE'S NO

INTRAMURAL RESEARCH SO 93% OF

THE BUDGET GOES OUT THE DOOR IN

TAX PLAYER DOLLARS FUNDING

RESEARCH EDUCATION AND RELATED

ACTIVITIES.

ACROSS NSF WE EMBRACE SCALE FROM

A SINGLE INVESTIGATOR TO

MID-SIZE AND LARGE CENTERS AND

NETWORKS.

THE BREADTH FROM A SINGLE

DISCIPLINE THROUGH CONVERGENT

RESEARCH, CAREER STAGE, WE TOUCH

ON UNDERGRADS AND AS YOU'LL SEE

PROGRAMS THAT HIGHLIGHT HIGH

SCHOOL STUDENTS, AND EVEN

EARLIER, THROUGH GRADUATE

STUDENTS, POSTDOCS TO EARLY AND

EVEN LATE CAREER IS FUNDED.

THE INNOVATION CYCLE BEGINS WITH

BASIC RESEARCH IN CUTTING EDGE

ENGINEERING AND THROUGH

TRANSLATIONAL RESEARCH.

YOU'LL SEE IT SPANS QUITE A

RANGE.

THE NSF ORGANIZATION IS WITH NOW

AS OF LATE MARCH WE HAVE A NEW

DIRECTORATE, LOWER RIGHT-HAND

CORNER, TECHNOLOGY, INNOVATION,

AND PART, OR TIP.

YOU CAN SEE OUTLINED IN RED ALL

THE DIRECTORATES IN DARK BLUE

THAT HAVE RELATIONSHIPS WITH

NIH.

AND EVEN ONE OF OUR PARTNERING

OFFICES, ONE OF THE OFFICES,

OFFICE OF DIRECTOR,

INTERNATIONAL SCIENCE AND

ENGINEERING.

YOU CAN SEE THAT NSF TAKES

DIVERSITY IN ITS LEADERSHIP

SERIOUSLY AND I HAVE NEVER BEEN

A PART OF A LEADERSHIP TEAM WITH

AS MANY WOMEN AND HISTORICALLY

UNDERREPRESENTED MEMBERS OF OUR

COMMUNITY.

AND IT'S A REALLY EMPOWERING

OPPORTUNITY.

I WOULD SAY THAT ALL THE OFFICES

IN THE UPPER RIGHT, MOST OF

WHICH LED BY WOMEN, BLACKS OR

HISPANICS.

WITHIN THE ENGINEERING

DIRECTORATE I WANT TO GIVE A

SENSE OF THE ENGINEERING

DISCIPLINES COVERED BUT ALSO HOW

THEY ARE EMBODIED IN CLUSTERS,

CLUSTERS OF PROGRAMS.

SO, WITHIN THE OFFERS OF THE

ASSISTANT DIRECTOR WE HAVE THE

EMERGING FRONTIERS AND

MULTI-DISCIPLINARY ACTIVITY.

AND THAT'S LED BY YOUR OWN

COUNCIL MEMBER, AND WITHIN THAT

WE HAVE THE EMERGING FRONTIERS

AND RESEARCH INNOVATION, THESE

ARE BASICALLY CROWD SOURCED

TOPICS THAT ARE SOLICITATIONS

THAT LAST FOR TWO YEARS, AND

THEN ARE EXPECTED AFTER BUILDING

A COMMUNITY IN THESE EMERGING

AREAS TO BE FUNDED BY CORE

WITHIN OUR DIRECTORATE.

ERVA IS BRAND NEW, IN ITS FIRST

YEAR, ENGINEERING RESEARCH

VISIONING ALLIANCE, SHINING NOT

LIKE EFRRI IN THE NEAR FUTURE

BUT 10, 15, PERHAPS FURTHER OUT

WHERE ENGINEERING SHOULD BE

HEADED.

CHRISTIAN THE CBET I HIGHLIGHT

CLUSTERS RELATED TO NIH INTEREST

IN HEALTH, MEDICINE, DESCRIES.

IN THE TWO CLUSTERS ENGINEERING,

BIOLOGY AND HEALTH AND

ENVIRONMENTAL ENGINEERING AND

SUSTAINABILITY.

IN CMMI YOU CAN SEE DISCIPLINES

OF ENGINEERING ARE EMBODIED

WITHIN CLUSTERS.

AGAIN, THREE CLUSTERS HERE

ASSOCIATED WITH FUNDING RESEARCH

AND HEALTH, MEDICINE, AND

DISEASE.

ECCS FOCUSES ON DEVICES,

ELECTRONICS, PHOTONICS,

MAGNETICS, COMMUNICATION IN

HEALTH AND DISEASE BENEFITS.

ENGINEERING EDUCATION AND

CENTERS DIVISION IS IMPORTANT,

WHEN WE WERE ESTABLISHED AS A

DIRECTORATE IN 1981, WE WERE

ESTABLISHED TO SERVE THE NATION

IN ENGINEERING RESEARCH, AS WELL

AS ENGINEERING EDUCATION AND

WORKFORCE TRAINING.

SO ENGINEERING EDUCATION IS PART

OF OUR DNA, IF YOU WILL.

OUR ENGINEERING CENTERS WHICH

I'LL BE HIGHLIGHTING TODAY AS

POTENTIAL AREAS OF COLLABORATION

AND OUR ENGINEERING WORKFORCE

DEVELOPMENT ARE TWO OF THE AREAS

WHERE I THINK WE COULD BE

ENRICHING OUR COLLABORATIONS

EVEN FURTHER.

WHEN I SHOW BY THE NUMBERS THIS

IS WITHOUT THE HISTORIC

CONTRIBUTIONS OF THE ENGINEERING

DIRECTORATE PROGRAMS THAT HAVE

NOW MOVED TO TIP.

OUR BUDGET WITH THOSE PROGRAMS

WERE IN EXCESS OF A BILLION

DOLLARS LAST YEAR.

FISCAL 21.

BUT WHEN YOU FOCUS ON THE

PROGRAMS THAT ARE STILL WITHIN

THE DIRECTORATE YOU CAN SEE THAT

IT NEARLY $800 MILLION.

WHAT I WANT TO FOCUS ON IS 20%

COMPETITIVE AWARD RATE WHICH IS

PRETTY MUCH LIKE NIBIB'S AWARD

RATE RIGHT NOW.

AND IS ACTUALLY PRETTY HIGHLY

SELECTIVE IN TERMS OF NSF AND

WE'RE LOOKING TO INCREASE

COMPETITIVE FUNDING RATE FOR OUR

INVESTIGATORS.

WE FUND IN A TYPICAL YEAR AS YOU

CAN SEE OVER 20,000 PEOPLE

SUPPORTED, YOU CAN SEE ON THE

FAR RIGHT THESE PEOPLE RANGE IN

SENIOR RESEARCHERS, DOCTORAL,

GRADUATE, UNDERGRADUATE

STUDENTS.

IN MY FIRST YEAR WE FOCUSED ON

WHERE ENG CAN LEAD IN THE

AGENCY, CROSS-AGENCY

COLLABORATIONS, AND WITH OTHER

AGENCIES AS WELL AS IN THE

NATION.

OUR STRATEGIC PLANS IMPORTANTLY

BEGINS WITH A NEW MISSION

STATEMENT, AND THAT IS TO

TRANSFORM OUR WORLD FOR A BETTER

TOMORROW BY DRIVING DISCOVERY,

INSPIRING, ENRICHING EDUCATION

AND ACCELERATING ACCESS.

IT WAS DEVELOPED IN OUR LAST

STRATEGIC PLANNING STRATEGIC

PLANNING EPISODE IN 2010 AND OUR

GOALS ARE TO PROPEL U.S.

LEADERSHIP IN TRANSFORMATIONAL

APPROACHES TO PROBLEMS FOR

SOCIETAL IMPACT, TO EXPAND

OPPORTUNITIES FOR PEOPLE AND TO

CATALYZE PURPOSEFUL

PARTNERSHIPS.

THAT LAST GOAL IS WHAT BRINGS ME

HERE TODAY.

I LOOK FORWARD TO OPPORTUNITIES

TO CATALYZE AND EXPAND OUR

PARTNERSHIPS WITH NIH AND

SPECIFICALLY NIBIB.

WE THEN REALLY TOOK A LOOK AT

WHERE ARE THE ENGINEERING

DIRECTORATES' STRENGTHS?

AND I THINK THIS IS IMPORTANT

BECAUSE IT REALLY HIGHLIGHTS

WAYS THAT WE CAN WORK TOGETHER,

SOMETIMES IN TANDEM WITH

RESEARCH BEGINNING AT NSF, AND

MOVING TO NIH FOR TRANSLATION TO

A SPECIFIC DISEASE, OR

APPLICATION IN MEDICINE.

AND SOMETIMES IT'S REALLY

CO-FUNDING BECAUSE WE'RE BOTH

INVESTED IN THESE AREAS OF

STRENGTH.

REALLY SPANNING FROM ENGINEERING

DISCOVERY, TRANSFORMATIONAL

RESEARCH THAT CREATES RADICAL

CHANGE OR NEW PARADIGMS, PROBLEM

OR QUESTION-DRIVEN RESEARCH, USE

INSPIRES AND SOLUTION ORIENTED

RESEARCH, INTEGRATIVE SYSTEMS,

ENGINEERING DESIGN AND

INNOVATION PROCESS AND CYCLE.

INDUSTRY ENGAGEMENT WHICH WE DO

A LOT IN THE ENGINEERING

DIRECTORATE AND I WILL SHARE

THAT WITH YOU.

VERY EARLY STAGE RESEARCH.

RESEARCH TRANSLATION FROM

FOUNDATIONAL DISCOVERY AND

APPLICATIONS TO USE, AND

PROOF-OF-CONCEPT, PROOF OF

FEASIBILITY, AND PROTOTYPING,

AND ENGINEERING EDUCATION AND

EXPERIENTIAL LEARNING WHERE I

THINK THERE'S AN OPPORTUNITY FOR

US TO PARTNER A GREAT DEAL, AND

TECHNOLOGY AND WORKFORCE

DEVELOPMENT.

AS A RESULT OF THIS STRATEGIC

PLANNING WE'VE IDENTIFIED FIVE

LARGE AREAS THAT CONNECT ACROSS

THE DIRECTORATES OF ENGINEERING.

CLEAN ENERGY TECHNOLOGY AND

POWER SYSTEMS, CLIMATE CHANGE

ADAPTATION MITIGATION,

BIOECONOMY FRONTIERS, NEXT

GENERATION MICROELECTRONICS,

WIRELESS COMMUNITIES.

EACH OF THESE FIVE AREAS ALSO

HAVE FOUR THEMES INDICATED IN

THE VERTICALS THAT CONNECT TO

IMPORTANT INITIATIVES.

NOT ONLY WITHIN THE ENGINEERING

DIRECTORATE BUT WITHIN THE

AGENCY OF NSF.

BROADENING PARTICIPATION IN

ENGINEERING, WHEN WE IDENTIFY

SOLUTIONS AND APPROACHES, THEY

SHOULD BE WITH EQUITY, JUSTICE,

ATTENTION TO ACCESS.

THEY SHOULD BE SUSTAIN AND

RESILIENT SOLUTIONS, AND CREATE

PATHWAYS TO PARTNERS FOR

TRANSLATION, ANOTHER REASON I'M

HERE TODAY.

JUST TO HIGHLIGHT ABOUT TIP, THE

NEW HORIZONTAL DIRECTORATE FOR

TECHNOLOGY, INNOVATION,

PARTNERSHIPS.

IT'S A HORIZONTAL DIRECTORATE

THAT BRINGS RESEARCH TO SOCIETY.

I THINK ABOUT TIP'S PROGRAMS,

IT'S REALLY ADDRESSING THE

VALLEY OF DEATH, THE PUBLIC

FUNDS HERE ON THE LEFT WITH GOAL

WHAT THE DIRECTORATE FUNDS, YOU

CAN SEE THAT EMBODIED FROM THE

PREVIOUS SLIDE FROM FOUNDATIONAL

RESEARCH THROUGH PROTOTYPE

DEVELOPMENT.

TIP'S PROGRAMS OVERLAP WITH

ENGINEERING AT SOME LEFT-HAND

SIDE HERE, BUT REALLY GOING

BEYOND WHERE ENGINEERING

PROGRAMS ARE, EXPANDING THE

OPPORTUNITY TO ENGAGE WITH

PRIVATE FUNDS AND LAUNCH.

WE HAVE A TRACK RECORD OF

LEADERSHIP AND TRANSFORMATIONAL

IMPACT IN MEDICINE, I'M GO TO

HIGHLIGHT A COUPLE HERE.

IN ADVANCED MANUFACTURING YOU

CAN SEE INVESTMENTS AT NSF, EVEN

BEFORE THE ENGINEERING

DIRECTORATE WAS CREATED IN 1981

1981 ACROSS THE TOP,

APPLICATIONS ACROSS THE BOTTOM,

AS A MECHANICAL ENGINEER

MODELING AND MANY OTHER THINGS

ON THE TOP ARE CERTAINLY TRUE

AND DEAR TO MY HEART, ELEMENTS

I'VE USED IN MY OWN RESEARCH AS

IT INTERSECT WAS MEDICINE.

3D PRINTING FOR PPE ON BOTTOM

RIGHT.

NANOTECHNOLOGY AGAIN A LONG

TIMELINE OF INVESTMENT BY NSF,

CREATING PAYOFFS THAT CONTINUE

TO BENEFIT SOCIETY TODAY.

IN TERMS OF BUILDING

BIOTECHNOLOGY REVOLUTION, YOU

CAN SEE EARLY INVESTMENTS OVER

20 YEARS AGO, IN THE ENGINEERING

RESEARCH CENTERS, ERCs, $50

MILLION INVESTMENTS BY NSF,

SPECIFICALLY IN THE ENGINEERING

DIRECTORATE THAT ARE EXPECTED TO

INTEGRATE INNOVATE AND

TRANSLATION, EARLY ON SYNTHETIC

BIOLOGY ENGINEER RESEARCH CENTER

WORKED AND REALLY DEVELOPED

ORGANOIDS AND BIOINFORMATICS,

PROTEIN DESIGN, SCAFFOLDS, THAT

LAY THE FOUNDATION FOR

ENGINEERING RESEARCH CENTERS IN

EXISTENCE TODAY.

BECAUSE OF THE GROUNDBREAKING

WORK THEY ARE DID OUR

COLLABORATION BETWEEN NSF AND

DEPARTMENT OF ENERGY FOR AGILE

BIOFROWNEDRY IS IMPORTANT IN

READYING LAB INNOVATIONS FOR

INDUSTRY.

LAUNCHING STARTUPS, VERY

IMPORTANT IN THE FUTURE,

BIOMANUFACTURING AND GINKO

BIOWORKS WAS LAUNCHED.

WASTE WATER SURVEILLANCE, A DEEP

INVESTMENT FOR THE LAST 20

YEARS, LED US TO IMPACT EVEN IN

TODAY'S PANDEMIC.

I'D LIKE TO HIGHLIGHT SOME OF

THE MORE RECENT INVESTMENTS,

THESE ARE GRANTS THAT WERE

AWARDED FROM THE ENGINEERING

DIRECTORATE IN, SAY, 2018, 2019,

AND HAVE PRODUCED PUBLICATIONS

WITH THESE HIGHLIGHTS THAT YOU

CAN SEE HERE.

SO, I'M GOING TO GO THROUGH AND

HIGHLIGHT QUICKLY THE ONES WITH

THE EXTRA SYMBOL ON THE LEFT AS

A BULLET.

SO THE SCOPE OF THE ENGINEERING

IMPACT IN BIOLOGY AND MEDICINE

INCLUDES NEUROPROSTHESES, NEURAL

PACEMAKERS, LOCALLY

MANUFACTURED mRNA THERAPEUTICS

PRODUCED ON DEMAND, BIOHYBRID

FISH MADE WITH CARDIAC SWIM

CELLS, ELIMINATING BIOPSIES BY

USING OPTICAL TECHNOLOGY FOR

NON-INVASIVE DIAGNOSIS AND

PRE-SCREENING OF CANCER.

IMAGING THE GENOME WITH DNA

RESOLUTION.

REPROGRAMMING STEM CELLS TO

INHIBIT CANCER CELL PLASTICITY.

IF I THINK ABOUT THE RECENT

AWARDS THAT WE'VE MADE IN 2020

AND 2021, I HIGHLIGHT THAT WE'RE

FUNDING NOW THE NEXT AREAS OF

FRONTIERS, IF YOU WILL, WHERE WE

EXPECT PAYOFF IN THE NEXT FEW

YEARS.

ROBUST SCALABLE LOW COST

BIOMANUFACTURING OF THERAPEUTIC

CELL THERAPIES, CELL CULTURE

MANUFACTURING FOR HEALTH CARE.

ON THE RIGHT, NON-INVASIVE

REMOTE NEUROTHERAPEUTIC DEVICES,

SENTINEL CELL SYSTEMS THAT

DETECT AND MITIGATE BIOLOGICAL

THREATS.

WHEN I THINK ABOUT OPPORTUNITIES

BETWEEN NIBIB AND THE

ENGINEERING DIRECTORATE I THINK

OF AN URGENT SETTING, WHAT COULD

WE COLLABORATE ON NOW AND HOW

COULD I HIGHLIGHT THESE FOR YOU?

ON THE LEFT I ORGANIZED WHAT I'M

GOING TO SHARE IN TERMS OF

THEMES.

THEN AT THE END WE'LL TALK ABOUT

THE MECHANISMS.

WE'LL OPEN IT UP FOR YOUR IDEAS.

ALONG THE WAY AS I TALK ABOUT

THEMES, I WANT TO HIGHLIGHT

QUICKLY LIKE A WHIRLWIND COULD

-- CURRENT SOLICITATIONS,

OPPORTUNITIES TO CO-FUND IDEAS

OR START PLANNING FOR CO-FUNDING

OR COLLABORATING ON

SOLICITATIONS THAT COME IN THE

NEAR FUTURE.

SO, IN THE AREA OF EMERGING

BIOTECHNOLOGIES, I WANTED TO

HIGHLIGHT THE AREAS OF

SOLICITATIONS IN THE AREAS OF

HARNESSING BIOLOGY FOR

ENGINEERING IMPACT, WHERE WE

FOCUS ON HARNESSING AND

UNDERSTANDING BIOLOGICAL

PROCESSES TO ENABLE FUTURE

INNOVATIONS IN THERAPEUTICS AND

BIOPHARMACEUTICALS,

BIOCHEMISTRY, AS WELL AS

BIOTECHNOLOGY INDUSTRIES.

I HIGHLIGHT TWO HERE CURRENT

SOLICITATIONS, IN FISCAL 22.

I HIGHLIGHT WE HAVE A

SOLICITATION THAT'S A TWO-YEAR

SOLICITATION, FIRST ONE FOR

PLANNING GRANTS, AND THOSE ARE

BEING SELECTED RIGHT NOW FOR

PREDICTIVE INTELLIGENCE FOR

PANDEMIC PREVENTION.

THAT INCLUDES AREAS OF

PREDICTION, MONITORING,

MITIGATION, PREVENTION.

RIGHT NOW WE'RE LOOKING AT THOSE

IN THE THEMES OF THOSE FOR

THEMES AWARDS BEING SELECTED

RIGHT NOW.

WE ANTICIPATE PHASE 2 CENTER

GRANT SOLICITATION GRANTS IF

THE FALL, FROM EFRI FOR

ENGINEERING LIVING SYSTEMS AND

AS YOU CAN SEE IN FOUR BULLETS

IN THE AREAS OF SUSTAINABLE AND

SAFE BUILT ENVIRONMENT,

ENVIRONMENTAL ENGINEERING,

BIOMINING AND CRITICAL RECOVERY

FROM WASTES, AND FUNDAMENTAL

INVESTIGATIONS, USING MICROBIAL

CONSORTIA.

WHY?

BECAUSE WE BELIEVE THAT THIS

CONVERGENCE RESEARCH DESIGN AND

BUILD DEMONSTRATE HOW WE CAN USE

LIVING SYSTEMS THAT ARE

ENGINEERED TO DESIGN AND

FABRICATE AND MANUFACTURE

SYSTEMS THAT CAN BE USED BEYOND

THEIR BIOLOGICAL USE.

QUANTUM SCIENCE IN ENGINEERING

IS AN AREA WHERE BOTH

INTERESTED, ABOUT USING

DESIGNING DEVICES, APPLICATION,

TOOLS AND SYSTEMS WITH QUANTUMS

BASED ADVANTAGES OVER CLASSICAL

COUNTERPARTS.

YOU CAN SEE HERE THE QUANTUMS

LEAP CHALLENGE WE AWARDED TWO

INSTITUTES IN FISCAL 21 WITH

HEALTH AND MEDICINE AREAS OF

FOCUS.

ONE OF THEM IS INDICATED HERE ON

THE RIGHT, I HIGHLIGHT THE ONE

THAT'S LED BY THE UNIVERSITY OF

CHICAGO WHERE QUBBE IS ADVANCING

NOVEL QUANTUM SENSING

TECHNOLOGIES FOR IMAGING AND

SINCING FOR BIOLOGICAL AND

MEDICAL USE.

WE HAD AN AGENCY SCIENCE

APPLICATIONS MEETING IN THE

FALL, AND YOU CAN SEE THERE ARE

TWO SOLICITATIONS THAT ARE

COMING DUE VERY SOON, EXPANDING

THE CAPACITY FOR QUANTUM

INFORMATION SCIENCE AND

ENGINEERING AND A DEAR COLLEAGUE

LETTER FOCUSING ATTENTION FOR

RAPID PROPOSALS AND USING EAGER,

THEY DON'T EVEN GO THROUGH MERIT

REVIEW.

ARTIFICIAL INTELLIGENCE, AN AREA

HIGHLIGHTED ALREADY IN BRUCE'S

PRESENTATION, AND THESE A.I.

RESEARCH INSTITUTES HAVE JUST

CLOSED ON THE LATEST

SOLICITATION.

AND THE SMART AND HEALTH AND

BIOMARKER RESEARCH IN THE AREA

OF ARTIFICIAL INTELLIGENCE AND

ADVANCE THE DATA SCIENCE, THAT

SOLICITATION WILL COME THIS

FALL.

AN INSTITUTE ON THE RIGHT IS

OPENING DOORS FOR CARE FOR

ELDERLY MEMBERS.

MY CONDUCTORS ON THE INTERFACE

BETWEEN ENGINEERING AND MEDICINE

WE WITH WORKSHOPS IN EARLY 2021

AND IDENTIFIED THREE AREAS WHERE

WE NEED TO FOCUS.

WE ANNOUNCED RIGHT NOW WE HAVE

JUST CLOSED A SEMI CONDUCTOR

SYNTHETIC BIOLOGY FOR

INFORMATION STORAGE, FUTURE OF

SEMICONDUCTORS, A TEAMING AWARD

JUST RELEASED FOR APPLICATIONS

DUE IN JULY.

INDUSTRY UNIVERSITY COOPERATIVE

RESEARCH CENTERS IS ONE AREA

THAT REALLY LACKS NIH

ENGAGEMENT.

I'D LIKE TO EXPLAIN THEM TO YOU.

THESE ARE IMPORTANT TYPES OF

MECHANISMS FOR GENERATING EARLY

STAGE RESEARCH IN COLLABORATION

WITH INDUSTRY.

IT'S ALL PRE-COMPETITIVE.

INDUSTRY SITS AT THE TABLE AS

INTERESTED PARTNERS, BECAUSE

THEY ACTUALLY PAY IN A

MEMBERSHIP FORMAT.

AND SO IN THIS PRE-COMPETITIVE

SETTING WHERE I.P. IS OWNED BY

THE UNIVERSITIES OF THE

INDUSTRY, EXCUSE ME, OF THE

UNIVERSITY PARTNERS, THESE

RELATIONSHIPS WITH INDUSTRY AND

ACADEMIA DRIVE TECHNOLOGY

INNOVATION, AND DEVELOP DIVERSE

AND SKILLED SCIENCE AND

ENGINEERING WORKFORCE, ALLOWING

SUSTAINMENT BETWEEN ACADEMIA,

INDUSTRY, GOVERNMENT.

WE HAVE 84 IUCRCs, PRIMARILY

IN THE ENGINEERING DIRECTORATE,

THEY ALREADY ENGAGE 110

UNIVERSITIES OVER 700 STUDENTS.

WE HAVE 750 INDUSTRY PARTNER

MEMBERS.

EACH PARTNER MEMBER PAYS IN

ABOUT $50,000 TO BE A PARTNER AT

THE TABLE OF A PARTICULAR IUCRC.

FEDERAL AGENCIES CAN ALSO BE

MEMBERS, AND THERE ARE OVER 20

FEDERAL AGENCIES, EVEN ENTER

NATIONAL AGENCIES.

NIH IS NOT A PARTNER IN ANY

SINGLE ONE OF THEM.

WHAT I WANTED TO DO IS HIGHLIGHT

A LITTLE BIT ABOUT THE ONES THAT

MIGHT BE OF INTEREST RIGHT NOW.

THESE ARE FUNDED FOR FIVE YEARS

TYPICALLY RENEWED FOR ANOTHER

FIVE YEARS, IF THEY HAVE BEEN

SUCCESSFUL FOR A TOTAL OF 10

YEARS OF FUNDING, OCCASIONALLY

EXTENDED FOR ANOTHER FIVE YEARS

TO 15 YEARS OF FUNDING.

CURRENT IUCRCs ENCOMPASS 42

UNIQUE JURISDICTIONS, 16 ARE

EPSCoR STATES, 15 MINORITY

SERVING INSTITUTES.

I WANT TO HIGHLIGHT FIVE THAT I

THINK WOULD BE INTERESTING FOR

PARTNERSHIPS WITH NIBIB OR OTHER

INSTITUTES AT NIH.

AMBIC FOR GENOME-BASED

TECHNOLOGY TO FAST TRACK

ADVANCED BIOMANUFACTURING

PROCESSES.

ON THE LEFT YOU SEE THE

UNIVERSITY PARTNERS IN THIS

IUCRC, ON THE RIGHT ALL THE

AGENCY PARTNERS.

OFTENTIMES WHAT HAPPENS AGENCIES

PROVIDE -- INDUSTRY RATHER

PROVIDES AN INTERESTING

PERSPECTIVE ON WHAT IS THE

ENABLING EXPERIMENTS THAT NEED

TO BE DONE TO ENABLE THAT

FOLLOW-ON INDUSTRY FUNDING,

WHICH MIGHT BE CORPORATE

SPONSORED RESEARCH DIRECTLY TO

AGENCY AND P.I

IUCRC EXAMPLES THAT EXTEND TO

OTHER AREAS OF HEALTH AND

MEDICINE AND DISEASE ARE SHOWN

ON THIS SLIDE WHICH INCLUDE A

BRAIN CENTER, EFFICACY SAFETY

AND LONG-TERM RELIABILITY OF

PATIENT-CENTERED

NEUROTECHNOLOGY.

C2SHIP FOR IN HOME TECHNOLOGY,

ROBOTS AND SENSORS FOR HUMAN

WELL-BEING, CENTER FOR

PHARMACEUTICAL DEVELOPMENT,

NOVEL APPROACHES FOR THE FINAL

THREE STAGES OF DRUG DEVELOPMENT

AND HOW CAN WE CREATE A PIPELINE

THAT ACTUALLY HELPS DE-RISK AND

DEMYSTIFY THOSE LAST THREE

STEPS.

OUR ENGINEERING RESEARCH CENTERS

ARE THE $50 MILLION INVESTMENTS

I MENTIONED OVER TEN YEARS, THE

PROGRAM IN EXISTENCE SINCE THE

'80s, SUPPORTING BROAD

MULTI-DISCIPLINARY HIGH IMPACT,

HIGH RISK AND HIGH PAYOFF

ENGINEERING RESEARCH.

THEY ALSO HAVE INDUSTRY MEMBERS.

NOW IN THE FOURTH GENERATION,

THEY HAVE ADDED EMPHASIS ON

INTEGRATING CONVERGENT RESEARCH,

MINDFUL OF INCORPORATING

ENGINEERING WORKFORCE

DEVELOPMENT THROUGHOUT, A

CULTURE OF DIVERSITY AND

INCLUSION, AND VALUE CREATION,

INNOVATION FOR SOCIETAL IMPACT.

SINCE THEY BEGAN, THERE HAVE

BEEN 75 ENGINEERING RESEARCH

CENTERS, ERCs, THAT HAVE BEEN

FUNDED.

YOU CAN SEE THE NUMBER OF

SPINOFFS, LICENSE, INVENTION

DISCLOSURES AND PATENTS THAT ARE

TYPICAL OF OUR ENGINEERING

RESEARCH CENTER MAJOR INVESTMENT

IN TRANSLATIONAL INNOVATION AND

TRANSLATION.

AND NEARLY 15,000 STUDENTS THAT

HAVE BEEN SUPPORTED.

RIGHT NOW THERE ARE 14 ERCs,

THREE ARE SUNSETTING, WE HOPE TO

FUND FOUR MORE.

OF THOSE 14 ERCs, THEY

INVOLVED 44 UNIQUE INSTITUTIONS,

SOME INSTITUTIONS ARE INVOLVED

IN MORE THAN ONE ERC.

AND 520 INDUSTRIAL PARTNERS

CURRENTLY IN THOSE 14 ERCs.

AGAIN, AS YOU CAN SEE, THE

STATISTICS, OF THE 14 CURRENTLY

FUNDED, THERE ARE FIVE CURRENT

ERCs THAT ARE IN THE HEALTH,

DISEASE, MEDICINE SPACE.

WE HAVE A CURRENT SOLICITATION

FOR ERCs, AND THERE'S AN

OPPORTUNITY TO THINK ABOUT

FUNDING WHERE THE AWARDS WOULD

BE MADE IN 2024, AND WE HOPE TO

AWARD UP TO SIX.

SO MAYBE THERE'S POTENTIAL FOR

NIH CO-FUNDING.

ALREADY, WE'RE IN CONVERSATION

WITH OTHER AGENCIES FOR THOSE

AWARDS THAT WILL BE MADE IN

2020.

SO I BELIEVE THAT THE CO-AGENCY

FUNDING IS A MODEL THAT WE'VE

DEVELOPED AND USED FOR ERCs

AND THAT BENEFIT BOTH NSF AND

OTHER AGENCIES.

JUST TO HIGHLIGHT A COUPLE OF

THOSE ERCs THAT ARE IN

EXISTENCE NOW THAT I MENTIONED,

FOR CELLULAR META MATERIALS,

CARDIAC PATCHES, FUNCTIONAL

VASCULATURE PERFUSED IN CULTURE

AND MAINTAIN STABLE FUNCTION.

THERE ARE FOUR MORE ERCs IN

THAT CURRENT LINEUP.

I SAID THERE WERE FIVE IN THE

CURRENT LINEUP OF 14, THAT

DEFINITELY HAVE APPLICATION IN

HEALTH AND DISEASE.

THESE ARE ALL NOT SUNSETTING,

THEY ARE CURRENT.

OPPORTUNITY TO CO-FUND IN

EXISTING ERCs.

WHEN I THINK ABOUT ADVANCEMENT,

BIOMANUFACTURING, SECOND THEME

AREA, I HAVE ONE SLIDE, A FUTURE

MANUFACTURING SOLICITATION,

ABOUT AREAS OF MANUFACTURING

THAT EITHER DO NOT EXIST TODAY

OR EXIST ONLY AT SUCH A SMALL

SCALE THEY ARE NOT VIABLE.

WE NEED TO DEVELOP AREAS OF

MANUFACTURING, ONE HIGHLIGHTED

IN BOLD IS IN BIOMANUFACTURING.

I'LL SHOW WHO CURRENT AWARDS

FROM 2021, IN THIS SOLICITATION.

IT'S A TWO-YEAR SOLICITATION,

WE'RE NOW IN OUR SECOND YEAR OF

THAT SOLICITATION.

THOSE THAT YOU SEE ON THE RIGHT

ARE DNA AND RNA DROPLETS FOR

MANUFACTURE OF BIOMOLECULES, TO

UCLA AND ONE TO STANFORD ON THE

RIGHT-HAND SIDE, BELOW ON THE

RIGHT-HAND SIDE, FOR GENETICALLY

TARGETED CHEMICAL ASSEMBLY, A

FUNCTIONAL STRUCTURE IN LIVING

CELLS IN ANIMALS AND TISSUES.

HIGHLIGHT AGAIN THAT IMPORTANT

CO-RELATIONSHIPS THAT WE HAVE.

IN THE AREA OF ENVIRONMENT AND

HUMAN HEALTH IT'S IMPORTANT TO

HIGHLIGHT THAT THERE HAVE BEEN

WHITE PAPERS AT NSF AND NIH,

WHERE THE IMPORTANCE OF REALLY

ADDRESSING HUMAN HEALTH AND

ENVIRONMENT IN THIS ERA OF

CLIMATE CHANGE, ENSURING

EQUITABLE ACCESS TO EDUCATION

AND HEALTH CARE, ENSURING THAT

OUR SOLUTIONS ARE CRITICAL AND

RESILIENT IN THEIR

INFRASTRUCTURE.

CIVIC INNOVATION CHALLENGE,

UNIQUE PARTNERSHIP BETWEEN NSF

AND DEPARTMENT OF ENERGY AND

DEPARTMENT OF HOMELAND SECURITY.

IN OUR CURRENT SOLICITATION, WE

HAVE TWO BULLETS ON THE BOTTOM.

THIS IS ABOUT LIVING IN CLIMATE

CHANGE, PRE-DISASTER ACTION,

BRIDGING THE GAP BETWEEN

ESSENTIAL RESOURCES,

COMMUNITIES, AND SURFACES.

YOU SEE ENABLING DISASTER

RESILIENCE IN AGING COMMUNITIES,

SECURE DATA EXCHANGES.

THE IMPORTANT THING OF THIS ONE

IS IT'S ABOUT REALLY LAUNCHING

FROM RESEARCH TO ACTION, JUST

ONE YEAR AWARDS, AFTER A PILOT

PERIOD, THEN IT'S EXPECTED THE

COMMUNITY WILL CONTINUE FUNDING.

SO THE COMMUNITIES ARE ACTUALLY

CO-FUNDING ALONG WITH THE

AGENCIES.

THE SUSTAINABLE RESEARCH

NETWORKS FOCUS ON REALLY

INTERSECTING NOW IN THE CASE OF

RURAL AND URBAN, AND INTERACTING

ON MULTIPLE LEVELS TO INVEST IN

UNDERSTANDING AND DESIGNING

SOLUTIONS THAT ENHANCE THE

SUSTAINABLE, EQUITY, RESILIENCE.

TWO THAT I HIGHLIGHT HERE HAVE

TO DO WITH THE FOOD SUSTAINABLE

FOOD SYSTEMS RESEARCH NETWORK,

WHICH TRYING TO ELIMINATE FOOD

WASTE AND COLLABORATE ACROSS

REGIONS THAT HAVE VERY DIFFERENT

GROWING SEASONS, WHETHER

CALIFORNIA OR MIDWEST, THE IDEA

OF COLLABORATING ACROSS REGIONS

BOTH FOR URBAN AS WELL AS RURAL

SOLUTIONS, AND YOU SEE FOOD,

ENERGY WATER SYSTEMS AT THE

BOUGHT.

WHAT'S NOT FUNDED IS ONE IN

HEALTH.

THERE'S AN OPPORTUNITY THERE.

WHEN I THINK ABOUT ENGINEERING

EDUCATION AND EXPERIENTIAL

LEARNING THERE'S A RICH AREA.

WE ALL KNOW THAT WE'RE NOT

MEETING THE NEED.

PROGRESS AND DIVERSITY IN

ENGINEERING AND IN SCIENCE AND

ENGINEERING IN GENERAL HAS BEEN

LANGUISHING.

WE NEED TO INCREASE THE NUMBER

OF WOMEN, HISPANIC, LATINO,

BLACK, AFRICAN AMERICAN AS WELL

AS AMERICAN INDIAN AND ALASKA

NATIVE.

ENGINEERING IS NO DIFFERENT.

IF WE TAKE A SNAPSHOT OF 2019 IN

GREEN ARE ENGINEERING AWARDS, IN

PURPLE ENGINEERING OCCUPATIONS,

AND U.S. ADULT POPULATION IN AGE

18 AND OVER IN DARK BLUE.

IN EACH AREA WE'RE NOT MEETING

THE NEED OF ENGAGING ALL OF THE

POTENTIAL OF OUR POPULATION.

WE HAVE A FUNDED PROGRAM FOR

ENGINEERING FOR US ALL.

WHICH IS ABOUT DEMOCRATIZING

ENGINEERING, TEACHING

ENGINEERING IN HIGH SCHOOLS,

ABOUT DESIGN BASICS, EXPERIENCE

AFFORDING STUDENTS THE

OPPORTUNITY TO EARN COLLEGE

CREDIT, THIS IS UNDERSTANDING

THAT YOU CAN TEACH ENGINEERING

CONCEPTS EVEN BEFORE THEY HAVE

HAD THE MATH AND SCIENCE COURSE

WORK.

THE GOAL IS TO TRAIN THE

TEACHERS AS WELL AS TRAIN THE

STUDENTS, AND IN ADDITION WE

ALSO ARE FUNDING TEACHER

ENGINEERING WHICH BANKS THOSE

WONDERFUL CURRICULA THAT HAVE

BEEN DEVELOPED, NOT JUST FOR

ENGINEERING FOR US ALL BUT ALSO

THE CURRICULA DEVELOPED IN OUR

CAREER AWARDS, THOSE EARLY STAGE

AWARDS THAT FUND OUTREACH AND

EDUCATIONAL INITIATIVES AS WELL

AS RESEARCH AND EARLY STAGE OF

FACULTY CAREERS.

REVOLUTIONIZING ENGINEERING

DEPARTMENTS IS REALLY ABOUT

APPROACHING, CATALYZING CHANGES

TO THE ENGINEERING IN HOW WE

EDUCATE THE NEXT GENERATION OF

ENGINEERS.

I WANT TO HIGHLIGHT THAT WE'VE

ADDED A NEW TRACK THIS YEAR FOR

RADICALLY NEW APPROACHES TO

ENGAGE TWO-YEAR INSTITUTIONS

WHICH INCLUDE NOT JUST COMMUNITY

COLLEGES BUT ALSO COLLEGES,

PROFESSIONAL TRAINING FOR

TECHNICIANS.

BROADENING PARTICIPATION AND

ENGINEERING HAS TWO NEW TRACKS,

INCLUSIVE MENTORING HUBS WHERE

ENWOULD HAVE -- EVERYONE NEEDS

TO COME ON BUILD TO BUILD HUBS,

ENGAGING OF K-12 THROUGH

INDUSTRY AS WELL AS SENIOR

FACULTY, ENGAGING IN BUILDING

SCHOOLS FOR LEADERSHIP

POSITIONS, ALL ALONG THE WAY.

CENTERS FOR EQUITY IN

ENGINEERING NEED TO BE HE LED BY

DEANS, CREATING REAL CHANGE

ACROSS ALL OF ENGINEERING MAJORS

ON CAMPUS.

INTERN PROGRAM WHERE THIS COULD

BE AN INTERESTING ONE FOR US TO

PARTNER IN, THIS IS PROVIDING

OPPORTUNITY FOR RESEARCH

INTERNSHIPS FOR GRADUATE

STUDENTS IN NON-ACADEMIC

SETTINGS, SO THE NON-ACADEMIC

SETTINGS INCLUDE GOVERNMENT

LABS, INDUSTRY, STARTUPS, I

THINK THERE'S THE POTENTIAL TO

PARTNER WITH NIBIB TO CREATE

INTERNSHIP OPPORTUNITIES IN THE

EMERGING PROGRAM.

EARLY CAREER SUPPORT IS ANOTHER

AREA WHERE WE MAY SHARE.

I'D LIKE TO HIGHLIGHT THE MIDDLE

BULLET, THIS IS RECOGNIZING

THOSE IN NON-R O 1 INSTITUTIONS

MAY ACTUALLY NEED ADDITIONAL

SUPPORT TO READY THEIR RESEARCH

PROGRAMS FOR THEIR FIRST

SUBMISSIONS TO NSF WHETHER IT IS

THROUGH OUR TRADITIONAL PROGRAM

OR AS A CAREER AWARD.

OUR FACULTY EARLY CAREER

DEVELOPMENT PROGRAM AND CAREER,

WE'RE TARGETING THOSE

INSTITUTIONS NOT TYPICALLY

REPRESENTED.

ONE OF THE LAST SLIDES IN THIS

EDUCATION IS REALLY ABOUT OUR

COLLABORATION TO DESIGN, BUILD,

TEST.

THIS IS AN OPPORTUNITY NOT JUST

TO TRANSLATE RESEARCH FROM AN

OPPORTUNITY TO GO FROM LAB TO

FAB, IF YOU WILL, BUT ALSO THE

WORKFORCE TO TRAIN IN THESE

SETTINGS IN INDUSTRY.

I BELIEVE THAT THIS PROVIDES US

WITH A FRAMEWORK TO TALK ABOUT

NEXT STEPS IN CATALYZING OUR

PURPOSEFUL PARTNERSHIPS BETWEEN

NSF AND NIH.

WE HAVE AN UMBRELLA MOU WE JUST

SIGNED WITH NIBIB ALLOWING US TO

BEGIN COLLABORATING IN MANY

DIFFERENT WAYS.

BRUCE HIGHLIGHTED THE

COLLABORATIONS ALREADY, WE HAVE

A SCHOLAR IN RESIDENCE PROGRAM

AT THE FDA WHICH COULD BE OF

INTEREST TO EXTEND TO NIH.

AS WELL AS ONE WITH THE

INTERNATIONAL SPACE STATION.

DATA FOR OUR COLLABORATION

DISCUSSION, IF WE JUST LOOK AT

ANNUAL PUBLICATIONS OVER THE

LAST TEN YEARS ON THE LEFT,

WHERE IN THE ACKNOWLEDGMENTS,

THIS IS PubMed, IN THE

ACKNOWLEDGMENTS IT MENTIONS BOTH

NSF ENGINEERING DIRECTORATE

GRANT AND NIH FUNDING FROM ANY

INSTITUTE, YOU CAN SEE THAT IN

THE DARK BLUE LINE ON THE LEFT.

IN FACT, IT'S EXPANDING.

IF WE LOOK AT THE GOLD LINE,

THAT LINGERS BELOW, THAT IS THE

NIBIB FUNDING.

SO, THERE'S A REAL OPPORTUNITY

FOR EXPANDING OUR PARTNERSHIP

FOR THOSE PEOPLE WHO ARE JOINTLY

FUNDED AND RESEARCH PROJECTS

JOINTLY FUNDED BY NIH,

ENGINEERING, NIBIB, AND WITH THE

NSF ENGINEERING DIRECTORATE.

AT RIGHT YOU CAN SEE WHAT ARE

THE INSTITUTES THAT ARE

REPRESENTED ON THE LEFT IN TERMS

OF FUNDING?

YOU CAN SEE THAT NIGMS IS

FUNDING MOST OF THOSE

COLLABORATIVE PROJECTS, AND YOU

CAN SEE ALL OF THE OTHER

INSTITUTES COMING INTO PLAY

HERE.

I THINK THIS SHOWS US THAT WE

CAN GROW THE PARTNERSHIP,

OBVIOUSLY NOT JUST WITH NIBIB

BUT WITH MANY INSTITUTES AT NIH.

IF WE THINK ABOUT THE

MECHANISMS, I'D LIKE TO PROPOSE

SOME IN THE PART ON THE RIGHT OF

THIS SLIDE.

THIS IS REALLY THE LAST SLIDE.

THE OPPORTUNITY FOR CENTER TO

CENTER COLLABORATIONS BETWEEN,

FOR EXAMPLE, THE BIOENGINEERING

RESEARCH PARTNERSHIPS AND

ENGINEERING RESEARCH CENTERS,

MAYBE CO-FUNDING OF ERCs

BECAUSE THEY MEET BOTH AGENCY

NEEDS.

CO-FUNDING OF CORE AROUND

SOLICITATION PROPOSALS LIKE THE

ONES I'VE SHOWN EARLIER IN THIS

PRESENTATION.

NIH BECOMING A MEMBER IN THOSE

INDUSTRY UNIVERSITY COOPERATIVE

RESEARCH CENTERS.

THINKING ABOUT INTERN AS

SOMETHING THAT COULD HELP

ENERGIZE THE INTERNAL WORKFORCE

IN THE BETA PROGRAM.

RESEARCH EXPERIENCES FOR

UNDERGRADUATES, MENTORS,

TEACHERS, AS WELL AS

PARTICIPATING IN THE START

PROGRAM WITH TECHNOLOGY TRAINING

FOR TECHNICIANS, AND BUILDING

RAMPS BETWEEN NSF AND NIH AND

BETWEEN NIH AND NSF, CREATING

NEW CO-FUNDED SOLICITATIONS.

I THINK THE OPPORTUNITIES ARE

RICH FOR EXPANDING OUR

COLLABORATIONS NOW.

WITH THAT, I'M GOING TO STOP

SHARING AND COME BACK TO ALL OF

YOU.

>> THANK YOU, SUSAN.

THAT WAS A REALLY SPECTACULAR

SUMMARY, INSURE SEPARATIONAL FOR

ALL -- INSPIRATION FOR ALL OF

US.

I'M GOING TO SPEAK SLOWLY, AS I

WAIT TO SEE HANDS COMING UP.

THERE'S MARYELLEN.

WOULD YOU LIKE TO ASK THE FIRST

QUESTION?

>> YES, THANK YOU.

I REALLY APPRECIATE YOU GOING

THROUGH ALL THOSE BECAUSE I'M

NOW MUCH MORE EDUCATED ON NSF

THAN BEFORE.

IT'S ACTUALLY AMAZING HOW MUCH

MORE NSF DOES THAT I DIDN'T KNOW

ABOUT.

I WAS INTRIGUED BY MULTIPLE

THINGS BUT I -- I'LL JUST DO ONE

QUESTION NOW.

YOUR ENGINEERING RESEARCH

CENTERS, I SEE THAT IS SOMETHING

THAT REALLY CAN GROW WITH NIH,

NIBIB.

ARE THOSE BRAND NEW CENTERS OR

ARE THOSE EXTENSIONS OF CURRENT

CENTERS?

ARE THEY MULTI-INSTITUTIONAL?

IS THAT AN AREA WHERE WE COULD

HAVE THIS CROSS-LINK BETWEEN NSF

AND NIBIB?

>> YES.

LET ME MAKE SURE I'M ANSWERING

YOUR QUESTION.

ERCs HAVE BEEN AROUND SINCE

THE MID-'80s.

EACH CENTER PUTS IN A PROPOSAL

AND NOW WITH THE GEN 4 ASKING

FOR A 10-YEAR PLAN.

WHEN YOU HAVE A PLAN FOR FIVE

YEARS WITH THE HOPE YOU'LL GO IN

AND RENEW, YOU HAVE A DIFFERENT

MINDSET THAN HAVING A 10-YEAR

PLAN.

SO BEGINNING WITH THOSE THAT

WERE FUNDED IN 2020 WE ASKED

THEM TO HAVE A 10-YEAR PLAN.

SO, WE'RE GOING TO BE FUNDING

MORE THIS YEAR.

I CAN'T SAY HOW MANY BECAUSE

THEY HAVEN'T BEEN APPROVED YET,

WITHIN NSF, BUT THEY HAVE GONE

THROUGH ALL REVERSE SITE VISITS

AND ON-SITE VISITS.

FIVE I HIGHLIGHTED ARE FIFER

FIVE OF THE CURRENT ROSTER OF

14, OPPORTUNITY TO ENGAGE IN

THOSE, TO ENGAGE IN THOSE THAT

WILL BE FUNDED THIS YEAR THAT I

CANNOT EVEN TELL YOU ABOUT, IN

THEIR FIRST FIVE YEARS.

AND THE POTENTIAL TO SIT AT THE

TABLE WITH LOOKING AT THOSE

SOLICITATIONS THAT WE WILL BE

GETTING FROM THE LETTERS OF

INTENT THIS FALL, ON THROUGH THE

EVALUATION, AND SIT TOGETHER,

EVALUATING THE APPLICATIONS THAT

WE EXPECT TO BE GETTING THIS

FALL, FIRST LETTERS OF INTENT.

I SEE THAT THERE'S THOSE THAT

ARE IN THEIR LAST FIVE YEARS,

THAT ARE JUST BEGINNING THAT,

RIGHT?

THOSE THAT ARE JUST LAUNCHING,

RIGHT?

SINCE THEY ARE AWARDED EVERY

FIVE YEARS WE HAVE THEM ALONG

QUITE A RANGE.

AND THOSE THAT ARE YET TO BE,

THAT HAVE NOT EVEN APPLIED YET.

>> THANK YOU.

>> IF I COULD JUMP IN FOR
JUST A

LITTLE MORE CLARIFICATION, WE

DID START ON AN MOU WITH THE ERC

PROGRAM BEFORE SUSAN CAME,ENED I

GUESS WE WERE A LITTLE

INTERRUPTED BY THE COVID, BY THE

PANDEMIC, AND THAT SIDETRACKED

US A BIT BUT WE CERTAINLY WANT

TO COME BACK BECAUSE ALL OF YOU

PROBABLY PERSONALLY HAD THEM,

I'VE HAD, SO --

>> TYPICALLY NUMBER OF

INSTITUTIONS IS FROM FOUR TO

SIX.

ONE OF THOSE INSTITUTIONS AT

LEAST NEEDS TO BE ON MINORITY

SERVING INSTITUTION,

HISTORICALLY UNDERREPRESENTED.

THERE'S THAT EMPHASIS

THROUGHOUT.

AND WE'RE ACTUALLY IN DISCUSSION

ABOUT HOW WE COULD ACTUALLY

CREATE SOMETHING OTHER THAN A

PLANNING GRANT TO HELP HAVE AN

ENGINEERING RESEARCH CENTER

INITIATION GRANT BECAUSE A

PLANNING GRANT IMPLIES YOU'RE

READY TO GO AND YOU JUST NEED TO

BRING TOGETHER YOUR PARTNERS AND

GENERATE THAT PRELIMINARY

EVIDENCE THAT YOU'RE GOING TO BE

A GREAT CENTER IN THE FUTURE.

SOME PLACES ESPECIALLY NOT R 1

INSTITUTIONS MIGHT NEED HELP

PUTTING TOGETHER A CENTER, WE'RE

TALKING ABOUT CREATING FUNDING

OPPORTUNITIES FOR ENGINEERING

RESEARCH CENTER INITIATION

GRANTS, THEY ARE NOT LIVE, BUT

WE HOPE TO CREATE SOMETHING LIKE

THAT IF BUDGET ALLOWS.

>> PAULA?

>> YES, THANKS, SUSAN.

I'M ACTUALLY A BENEFICIARY OF

NSF AND NIH, RECENTLY THROUGH

EBICS AS AN SPC BUT THROUGHOUT

MY CAREER.

I WAS VERY INTERESTED IN THE

BIOMANUFACTURING EFFORTS THAT

ARE COMING FROM THE ENGINEERING

DIRECTORATE.

THERE'S ALWAYS BEEN SOME PART OF

THE BUDGET THAT IS IN THAT AREA

BUT I'M WONDERING IT SEEMS IT

MAY HAVE GROWN WHICH IS GOOD

BECAUSE IT'S A VERY BADLY NEEDED

AREA FOR RESEARCH.

SO I WAS GOING TO ASK IF THAT

AMOUNT DESIGNATED FOR

BIOINFORMATION INNOVATION AND IF

THERE'S COLLABORATION FOR AN ERC

IN THAT AREA THAT INVOLVES NIBIB

IN BIOPHARMA, IN PARTICULAR IN A

NUMBER OF THE MEDICINES COMING

OUT NOW THAT ARE DIFFICULT TO

SCALE.

I'D LIKE TO HEAR YOUR THOUGHTS

ON THAT.

>> FIRST I DON'T RESTRICT
TOPICS

FOR ERCs, AND APPARENTLY I

HAVE A CONFLICT WITH ONE OF THE

ONES THAT IS BEING EVALUATED

RIGHT NOW SO I KNOW NOTHING

ABOUT THE ONES THAT HAVE BEEN

EVALUATED IN THIS CYCLE, THAT

ARE ABOUT TO BE AWARDED.

SO MANUFACTURING WOULD NOT BE

ELIMINATED AS A DOUBLE NEGATIVE,

RIGHT?

IN FACT WE'VE EVEN HAD

DISCUSSIONS ABOUT WHETHER OR NOT

WE SHOULD HAVE DEAR COLLEAGUE

LETTERS, AS THEY ARE CALLED A

DCL AT NSF, ESPECIALLY

INTERESTED IN.

WE DON'T TYPICALLY DO THAT BUT

IT'S BEEN DONE IN THE PAST.

PAULA, YOU'VE HIGHLIGHTED AN

AREA WHERE WE COULD PLACE AN

EMPHASIS AND, AGAIN, IF THAT

WERE SOMETHING THAT WERE JOINTLY

SPONSORED AND JOINTLY DETERMINED

TO BE AN AREA OF EMPHASIS I

COULD SEE THAT COULD BE ONE

MECHANISM TO ENSURE WE HAVE MORE

THAN THE TYPICAL NUMBER OF

APPLICATIONS IN THAT AREA.

>> THANK YOU.

>> THANKS, PAULA.

RANU HAS A HAND UP NEXT.

>> THANK YOU VERY MUCH.

SUSAN, IT'S WONDERFUL TO HEAR

YOU SPEAKING AS A DIRECTOR.

SO IT'S FANTASTIC.

LOTS TO LEARN.

I'VE BEEN A BENEFICIARY OF BOTH

NSF AND NIH FOR MANY YEARS.

MY QUESTION, WE'RE HEARING A LOT

ABOUT NSF ENGINES OUT OF THE TIP

PROGRAM, I WANTED TO GET AN IDEA

WHERE DO YOU SEE LINK THAT MIGHT

HAPPEN WITH MEDICAL DEVICE

TECHNOLOGIES OR HEALTH-RELATED

ASPECTS IN THE BROADER CONTEXT

OF NSF ENGINES.

>> THANK YOU FOR ASKING
THAT.

SO, BROADER AGENCY SOLICITATION

JUST CAME OUT FOR THE REGIONAL

INNOVATION ENGINES, AND THEY

REALLY -- IT'S AN INTERESTING

MODEL.

THEY ARE INTENDED NOT TO BE A

LONG-TERM INVESTMENT, SO IT'S

VERY DIFFERENT FROM AN

INFRASTRUCTURE GRANT, WHERE ONCE

YOU FUND IT YOU'RE EXPECTING

YOU'LL NEED TO MAINTAIN IT.

IT'S FULLY INTENDED THAT AFTER

FIVE YEARS LOCAL STARTS PAYING

MORE AND MORE OF IT, AND THAT I

BELIEVE IT'S AFTER TEN YEARS

THAT IT LAUNCHES, IT'S

INDEPENDENT, GRADUATED FROM THE

HOME, IF YOU WILL, IT'S NOW

INDEPENDENTLY.

THE GOAL IS TO PROVIDE AN

OPPORTUNITY FOR ON THE WAY TO

INDUSTRY, AND TO ALSO PROVIDE

OPPORTUNITIES FOR INDUSTRY TO

PILOT.

IT'S SO HARD TO BE ABLE TO, AS A

FACULTY MEMBER, TO HAVE ACADEMIA

KNOW THAT SOMETHING IS READY FOR

ADOPTION IN INDUSTRY, AND IT IS

HARD FOR INDUSTRY TO PIVOT AND

TRY SOMETHING NOVEL.

SO, THIS IS AN OPPORTUNITY WHERE

ALL COMERS GET TO USE THESE

FACILITIES.

SPECIFICALLY, THE GOAL IS TO

ALSO CREATE WORKFORCE TRAINING,

SO THESE FACILITIES NOT JUST

BENEFIT RESEARCH TRANSLATION BUT

BENEFIT WORKFORCE TRAINING, AND

THAT THOSE THAT CAN COME THERE

ARE NOT JUST FROM THE REGION.

BUT ULTIMATELY, THESE REGIONAL

ENGINES ARE IN REGIONS, REALLY

BRINGING, IF YOU CAN --

IMPROVING AND ENRICHING THE

GEOGRAPHY OF INNOVATION, TO NOT

JUST BE THOSE AREAS OF OUR

COUNTRY THAT ARE HISTORICALLY

WHERE INNOVATION HAPPENS.

SO THAT'S WHY THESE

F ACILITIES -- NOT FACILITIES,

REGIONAL INNOVATION ENGINES WILL

BE OPEN.

THE GOAL, WE'RE THINKING

DIFFERENTLY ABOUT WHERE THE

INNOVATION AND WHERE THE ENGINES

OF DISCOVERY ARE THAT TRANSLATE

TO INDUSTRY.

AND SO THE GOAL WOULD BE, THIS

IS OPEN TO EVERYONE TO

PARTICIPATE, IN THOSE ENGINES

WHEN THEY ARE ESTABLISHED, AND

THAT ALL INDUSTRY IS THEN -- HAS

EYES ON THIS IMPORTANT

GENERATION OF TRANSLATABLE

TECHNOLOGIES.

>> THANK YOU.

>> YEP.

>> THANKS, RANU.

I SEE JENNIFER WITH YOUR HAND

UP.

>> UNIVERSITY OF ARIZONA,
THANK

YOU FOR THAT TALK.

I HAVE A WHOLE SET OF NOTES OF

EXCITING THINGS.

ONE THING THAT PARTICULARLY

STOOD OUT WAS TRANSFORMING

ENGINEERING EDUCATION.

I THINK THAT'S SO IMPORTANT IF

WE'RE GOING TO HAVE THE

WORKFORCE FOR THE FUTURE THAT WE

NEED.

I GET THE IMPRESSION WITH A FAIR

AMOUNT OF OVERLAP THAT NSF

FOCUSES MORE ON EDUCATION,

CURRICULUM DEVELOPMENT, PERHAPS

OUTREACH, AND NIH FOCUSES MORE

ON RESEARCH TRAINING.

I THINK THOSE TWO ARE SO

INCREDIBLY SYNERGISTIC, I'D LOVE

TO SEE MORE INTERACTION BETWEEN

THE REUs AND REMs YOU

MENTIONED, AND THE R25s OF NIH

TO BE ABLE TO PUT THIS TOGETHER

AND CONVINCE MORE PEOPLE TO BE

FUND AMENTALLY CHANGE THE WAY WE

TEACH ENGINEERING SO THEY SEE

THE SPECTRUM OF HOW ENGINEERING

CAN BE APPLIED.

I WANTED TO POINT OUT I THINK

THAT'S A WONDERFUL AREA WHERE

I'D REALLY LOVE TO SEE MORE

INTERACTION.

GREAT IDEA.

>> THANKS.

>> THANKS, JENNIFER.

AND THERE'S MANU.

>> HELLO, ALWAYS GREAT TO
SEE MY

FORMER FEARLESS LEADER, BEING

MORE FEARLESS LEADING OTHER

ORGANIZATIONS.

THANK YOU FOR THAT, SUSAN.

I WAS EXCITED ABOUT NEWER THINGS

I HADN'T HEARD ABOUT PREVIOUSLY.

ONE OF THE ONES POTENTIAL

PARTNERSHIP OF INTERNS, EVEN

WITH GOVERNMENT AGENCIES AND

NIH.

>> YES.

>> I'M A PART AT GEORGIA
TECH,

FIRST INTERN, SO MANY OF THE

GRADUATE STUDENTS HAVE STARTED

TO JUMP ON THAT PROGRAM NOW.

PARTICULARLY IN THAT DEPARTMENT,

SO THERE'S REALLY EXCITEMENT

THERE.

WE WEREN'T FULLY AWARE OF THAT

GOVERNMENT AGENCIES WERE ALSO A

GREAT SOURCE, A GREAT LANDING

SPACE.

I THINK THAT'S SOMETHING THAT

NOW WE'RE SHARING WITH THE WORLD

AND I'LL MAKE SURE WE TELL OUR

STUDENTS.

I HAD ANOTHER QUESTION ABOUT THE

RESEARCH INITIATION FOR FACULTY

MEMBERS, THAT ARE NOT ATTENDING

R 1 UNIVERSITIES.

NUMBER ONE, EXCITING PROGRAM.

I'M CURIOUS HOW THAT WOULD LOOK

TO THE UNIVERSITY OR DOES THAT

LOOK LIKE A K99, WHERE THE

APPLICANT IS APPLYING SEPARATELY

AND THEY TAKE THAT WITH THEM TO

AN R2 OR SOME OTHER TYPE OF

UNIVERSITY?

WHAT DOES THAT LOOK LIKE FOR THE

CANDIDATE OR INSTITUTION?

>> THANKS FOR THAT
QUESTION.

AND MONU, AS AN EXAMPLE, AIR

FORCE PROVIDES THE ENGINEERING

DIRECTORATE WITH A MILLION

DOLLARS A YEAR BECAUSE THEY

REALLY WANT TO RECRUIT TO THE

AIR FORCE RESEARCH LABS.

SO THERE'S A PARTICULAR DRAW

THERE.

AND THEY ARE SO PLEASED BECAUSE

OTHERWISE THE CURRENT Ph.D.

STUDENTS WOULD HAVE NO IDEA WHAT

THEIR CAREER PATH WOULD BE LIKE.

IT GIVES THEM AN OPPORTUNITY TO

SEE WHAT IT'S LIKE TO BE IN THE

AIR FORCE RESEARCH LABS, AND

GIVES THE AIR FORCE RESEARCH

LABS AN OPPORTUNITY TO SEE THEM

IN THEIR OWN LABS AND OFFER

POSITIONS.

WHEN I THINK ABOUT BETA, I THINK

ABOUT THE OPPORTUNITY TO RAISE

AWARENESS OF EXISTENCE OF BETA

AND BETA AS A CAREER PATH, THERE

COULD BE INTRAMURAL NIH LABS

INTERESTED IN RECOGNIZING AND

CREATING MORE VISIBILITY FOR

WHAT THEY DO, ALSO GETTING THAT

FIRST LOOK AT STUDENTS.

RESEARCH INITIATION AWARDS,

IMAGINE I'M A FACULTY MEMBER,

LANDED AT INSTITUTION Y.

I'M THERE.

I ACTUALLY NEED MORE RESOURCES,

NEED RESOURCES FOR THE PEOPLE IN

MY LAB, FOR CRITICAL EQUIPMENT,

TO BUY TIME, SUPPLIES FOR A KEY

STUDY.

YOU NEED TO PROPOSE WHAT YOU'RE

GOING TO DO BUT LIKE SABBATICAL

NOT HELD EXACTLY TO THOSE PLANS,

THE GOAL IS THIS IS CRITICAL

EARLY STAGE FUNDING THAT ALLOWS

YOU TO PREPARE GREAT APPLICATION

WHETHER FOR STANDARD PROPOSAL OR

FOR A SOLICITATION OR EVEN FOR

CAREER AWARD.

SO, I WOULD SAY THAT THE

EXPECTATION IS THESE ARE GOING

TO BE EARLY STAGE, LIKE

ASSISTANT PROFESSOR, BUT NOT A

POSTDOC APPLYING.

>> AND I SEE TEJAL.

>> HI, SUSAN.

SO NICE TO SEE YOU.

THANK YOU.

A BEAUTIFUL PRESENTATION.

ONE OF THE THINGS THAT I WAS

CURIOUS ABOUT WAS YOU MENTIONED

THE ERCs AND IN PARTICULAR

THINKING ABOUT INSTITUTIONS THAT

MAY NOT BE READY FOR A CENTER

GRANT BUT PERHAPS PUTTING AN

INITIATION GRANT.

ONE OF THE THINGS WE'VE BEEN

TALKING ABOUT HERE IN COUNCIL

ARE ALSO HBCUs OR COMMUNITY

COLLEGE THAT DON'T HAVE

ENGINEERING OR IN PARTICULAR

BIOENGINEERING, THIS DISCUSSION

LED BY GILDA AND ROD, AND HOW WE

MIGHT SUPPORT THE GROWTH OF

DEPARTMENTS OF BIOENGINEERING OR

ENGINEERING WITHIN OTHER

INSTITUTIONS.

AND SO I WONDERED IF THERE ARE

ANY THOUGHTS AROUND HOW PERHAPS

NSF COULD PARTNER WITH THE NIBIB

TO THINK ABOUT NEW APPROACHES.

WE SORT OF TALKED ABOUT HOW

WHITAKER REALLY BROUGHT TO BEAR

NEW BIOENGINEERING DEPARTMENTS

BUT THERE'S REALLY NO MECHANISM

ANYMORE, AND SO IT'S REALLY UP

TO AGENCIES SUCH AS NIH AND NSF

TO TRY TO BUILD THAT

INFRASTRUCTURE.

ANY COMMENTS OR THOUGHTS PERHAPS

AROUND THAT?

>> SO, ONE SORT OF
THINKING

OUTSIDE THE BOX WAY TO TAKE ONE

OF OUR EXISTING MECHANISMS AND

USE IT FOR THIS PURPOSE WHILE

NOT CREATING A DEPARTMENT

SOMETIMES IT BEGINS WITH

COURSES.

SO I'VE HAD A CONVERSATION WITH

A FACULTY MEMBER WHO CONTACTED

ME, AND I SUGGESTED THAT, YOU

KNOW, AN IUCRC COULD HAVE

INDUSTRY AT THE TABLE, AND

ACADEMIC INSTITUTIONS, AND BE

FOCUSED ON CURRICULUM

DEVELOPMENT.

PILOTS, AND THEN INDUSTRIES AT

THE TABLE WITH SAYING THIS WOULD

BE MOST IMPACTFUL IN TERMS OF

TRAINING OUR WORKFORCE.

NOW IMAGINE IF THE INSTITUTIONS

AT THE TABLE ARE ACTUALLY

MINORITY SERVING INSTITUTIONS,

OR TWO-YEAR COMMUNITY COLLEGES,

AND YOU STILL HAVE INDUSTRY

PARTNERS AT THE TABLE, AND

YOU'RE THINKING ABOUT HOW -- SO

I DO NOT LIMIT MYSELF TO

THINKING ABOUT CREATING BRIDGES

FROM COMMUNITY COLLEGES TO

FOUR-YEAR INSTITUTIONS.

I THINK IT'S IMPORTANT TO CREATE

BRIDGES FROM COMMUNITY COLLEGES

TO WHATEVER YOUR NEXT IS.

AND IT MIGHT ACTUALLY BE GOING

OUT INTO THE WORKFORCE.

I THINK IT'S ALSO IMPORTANT FOR

US TO BE THINKING ABOUT

RETRAINING A WORKFORCE IN SKILL

SETS, AND THINK ABOUT THE IDEA

OF HAVING, USING THAT MECHANISM

OF THE IUCRC, WHERE INDUSTRIES

AT THE TABLE CAN SAY THESE ARE

THE MODULES WE NEED TO RETRAIN

THE WORKFORCE.

AND THE ACADEMIC INSTITUTIONS

THAT ARE AT THE TABLE COULD BE

PROFESSIONAL TRAINING

INSTITUTIONS, RIGHT?

IT COULD ACTUALLY BE R1

INSTITUTIONS BUT WE USE AN IUCRC

AS MECHANISM FOR EARLY STAGE

RESEARCH, BUT EDUCATIONAL

RESEARCH AND CURRICULA

DEVELOPMENT IS PEDAGOGICAL

RESEARCH, THEY HAVEN'T BEEN USED

THAT WAY HISTORICALLY.

WHEN I THINK ABOUT ESTABLISHMENT

OF NEW DEPARTMENTS, THE WHITAKER

FOUNDATION HAS BEEN INSTRUMENTAL

IN CREATING THAT BUT IT DID IT

IN A VERY DELIBERATE WAY WITH

CREATING PILOTS AND TEMPLATES,

SO I THINK THERE'S AN IMPORTANT

CONVERSATION THAT WE COULD HAVE

BETWEEN NSF AND NIH,

SPECIFICALLY NIBIB, WHERE WHAT

ARE THE ELEMENTS OF SUCCESSFUL

DEPARTMENTS, AND WHAT ARE THE

CRITICAL ELEMENTS THAT NEED TO

BE THERE.

AS MANU WELL KNOWS, WHEN YOU'RE

A DEPARTMENT THAT SPANS TWO

INSTITUTIONS, LITERALLY

CONCEIVED FROM THE START AS

BEING PART OF A PUBLIC AND

PRIVATE INSTITUTION, ONE OF US

IN THE SCHOOL OF MEDICINE AT

EMORY AND COLLEGE OF ENGINEERING

AT GEORGIA TECH, SOME THOUGHT

WENT INTO WHAT DOES THAT

STRUCTURE LOOK LIKE, HOW WILL WE

ANTICIPATE SOME CHALLENGES?

SAME THING NEEDS TO BE DONE FOR

INSTITUTIONS THAT DO NOT YET

HAVE BIOMEDICAL ENGINEERING OR

BIOENGINEERING IN THE LINEUP.

I'D BE HAPPY FOR NSF TO

PARTICIPATE IN THIS IMPORTANT

CONVERSATION, WHAT CRITICAL

ELEMENTS NEED TO BE THERE TO BE

SUCCESSFUL.

>> THANK YOU, SUSAN.

LOTS OF WORK TO DO ON THAT ONE.

ZANE, I SEE YOUR HAND UP AS

WELL.

>> THANKS, BRUCE.

SUSAN, THANK YOU FOR THE TALK.

I'M JUST GOING TO PROVIDE SOME

SUPPORT TO THE IMPORTANCE OF ALL

THESE INITIATIVES.

THE FDA, WE'RE INVOLVED WITH A

WHOLE VARIETY OF DIFFERENT ERC,

IUCRCS, INTERN PROGRAM, SCHOLARS

IN RESIDENCE, PRIMARILY INVOLVED

WITH PASS UP RECENTLY, "CELL"

NET, STUDENTS COME IN, YOU

MENTIONED INDUSTRY AT THE TABLE,

GOVERNMENT AGENCIES AT THE

TABLE, OPPORTUNITIES THERE FOR

DIRECTIONS.

WE FOUND IT TO BE A VERY

VALUABLE PROGRAM, ALL THESE

PROGRAMS, TO BE VERY VALUABLE AT

THE FDA TO SET OUR DIRECTION AT

TIMES AND HELPING OUT THE DEVICE

DEVELOPMENT INFRASTRUCTURE SPACE

SO I WANTED TO HIGHLIGHT THAT

BECAUSE WE'RE ACTIVE MEMBERS IN

THIS AND LOOK FORWARD TO FURTHER

ADVANCING THAT AND SEEING IT

GROW OVER TIME.

>> GREAT TO HEAR THE
PERSPECTIVE

FROM AN AGENCY.

THANK YOU.

>> AN ZANE, YOU'RE BEING
MODEST.

ZANE LED THE CHARGE FOR US TO

DEVELOP IUCRC IN COLLABORATION

WITH FDA.

WE MADE A LOT OF PROGRESS BEFORE

THE PANDEMIC.

THE PANDEMIC KIND OF KNOCKED US

OFF PATH BUT IT ALSO REVEALED TO

US WHERE THE KEY OPPORTUNITIES

ARE.

I WOULD SAY MUCH OF OUR EFFORT

HAS BEEN INVOLVED IN TRYING TO

UNDERSTAND REGULATORY SCIENCE,

AND LET'S JUST SAY COLLABORATE

WITH THE FDA AND POTENTIALLY

INSPIRE THEM TO CHANGE SOME

PRACTICES, TO BE MORE

ACCOMMODATING FOR THE RANGE OF

NEW TECHNOLOGIES THAT COULD BE

INTRODUCED TO ACHIEVE REGULATORY

AUTHORIZATION.

SO, THAT HAS BECOME AN

INCREDIBLY IMPORTANT TOPIC FOR

ALL OF US, AND I PROBABLY

UNDERESTIMATED THAT, EVEN THOUGH

WE KNEW IT WAS IMPORTANT AND

WANTED TO DO AN IUCRC IN THIS

AREA, IT'S ESSENTIAL.

>> AND I WOULD ADD THE
INSURANCE

INDUSTRY AS WELL.

IT'S NOT ENOUGH TO DEVELOP A NEW

DEVICE, NEW THERAPY, NEW

DIAGNOSTIC, IF IT CAN'T BE

APPROVED AND CAN'T BE ORDERED

AND UTILIZED THEN WE'RE REALLY

NOT ABLE TO COMPLETE THE

MISSION.

>> YES.

AS WE FOUND OUT.

SO RANU, IS IT OKAY IF I SKIP

YOU BECAUSE SAM HASN'T ASKED A

QUESTION?

>> I WILL ALWAYS BE
GRATEFUL TO

THE NSF FOR LAUNCHING MY CAREER,

THIS IS SOMETHING THAT'S GREAT.

YOU TOUCHED ON SEVERAL POINTS

THAT ARE VERY EXCITING, ONE IS

EXPERIENTIAL LEARNING THAT WE

BELIEVE IS CRITICAL FOR US, AS

WE DEVELOP THE NEXT GENERATION

OF ENGINEERS DOWN THE LINE.

I WOULD REALLY LIKE TO HEAR AND

LEARN MORE ABOUT WHAT IS PLANNED

FOR NEW INSTITUTIONS TO

INCORPORATE THAT INTO THE THEIR

PROGRAM.

THE OTHER ASPECT IS THE BIG

COMPETITION RIGHT NOW THAT

ACADEMIC INSTITUTIONS HAVE

RELATIVE TO INDUSTRY, RECRUITING

ENGINEERS FOR GRADUATE PROGRAMS.

THIS IS NATIONWIDE, VERY

EXPENSIVE, TO RECRUIT THESE

PEOPLE TO DO WORK, AS WELL AS

OUR POSTDOCS, PLANS THAT NIH AND

NSF COULD DO TO SUPPORT US IN

RETAINING AND TRAINING THESE NEW

GENERATION OF STUDENTS BEFORE

THEY LEAVE FOR INDUSTRY DOWN THE

LINE, SO IT'S A VERY GOOD THING

THAT WE'RE HAVING TO CREATE

OPPORTUNITIES FOR OUR TRAINEES

TO GO TO INDUSTRY, WE ALSO NEED

THE WORKFORCE IN ACADEMIA TO

SUSTAIN RESEARCH AND DEVELOPMENT

DOWN THE LINE INTO THE FUTURE.

>> I THINK INCLUDING THOSE

INSTITUTIONS THAT HAVE NOT BEEN

ENGAGED IN RESEARCH EXPERIENCES

FOR UNDERGRADUATES IS SOMETHING

THAT -- THERE ARE TWO SIDES.

THERE ARE STUDENTS AT THOSE

INSTITUTIONS WHO YOU WOULD WANT

TO MAKE SURE THAT THEY KNOW

WHAT'S AVAILABLE NATIONALLY, AS

OPPORTUNITIES FOR THEM.

OKAY?

AND I THINK THAT THE WAY THAT

RESEARCH EXPERIENCES FOR

UNDERGRADS ARE MADE AVAILABLE

IS -- COULD BE IMPROVED TO

CREATE MORE TRANSPARENCY OF

THOSE OPPORTUNITIES THAT

STUDENTS MAY BE INTERESTED IN

ENGAGING IN AND CREATE A HIGHER

VISIBILITY FOR THEM.

IT WOULD BE GREAT TO INCREASE

THE NUMBER.

THAT'S WHERE CO-FUNDING COULD

HAPPEN.

WE OFTEN USE THEM AS SUPPLEMENTS

ON TOP OF EXISTING AWARDS SO

IT'S AN OPPORTUNITY TO

SUPPLEMENT YOUR GRANT,

ESPECIALLY A LARGE CENTER WITH

MULTIPLE INSTITUTIONS, LIKE AN

ERC, WITH RESEARCH EXPERIENCES

FOR UNDERGRADUATES.

SO RATHER THAN WAIT FOR THE

APPLICATIONS WE PUSH OUT

OPPORTUNITIES FOR SUPPLEMENTS.

THEY COULD COME WITH A A

MANDATE OF THE DEMOGRAPHIC OF

STUDENTS AND THEIR INSTITUTIONS

ARE ALSO FOCUSED ON CREATING

BROADER ACCESS TO THE LABS AND

RESEARCH PROGRAMS, WHICH ARE SO

IMPORTANT FOR INSPIRING THEM TO

PURSUE A CAREER IN -- NOT IN

INDUSTRY BUT ACTUALLY IN

RESEARCH, RIGHT?

AND ACADEMIA.

I KNOW AS AN UNDERGRAD MY FIRST

RESEARCH EXPERIENCE WAS NOT IN

HIGH SCHOOL, I SEWED CLOTHES AND

WORKED IN A BAKERY IN HIGH

SCHOOL.

AFTER MY FRESHMAN YEAR I WORKED

IN A LAB IN THE MAYO CLINIC I

SAW AND WAS TURNED ON TO A

CAREER IN RESEARCH.

INCREASING VISIBILITY AND NUMBER

OF THESE EXPERIENCES I THINK IS

EXTREMELY IMPORTANT.

WITH REGARD TO RETAINING OUR

GRADUATE STUDENTS AND POSTDOCS

IN ACADEMIA, I'M BEGINNING

CONVERSATIONS ABOUT THE IDEA OF

PERHAPS MAYBE THE MODEL MIGHT BE

CREATING THE OPPORTUNITY FOR

HAVING PROFESSORS OF A PRACTICE

WHO ENGAGE IN -- ON CAMPUS BUT

ARE ALSO IN INDUSTRY.

AND SO THE IDEA OF ACTUALLY

CREATING AN IMPACTFUL ROUTE FOR

ENGAGING WITH STUDENTS ON A

CAMPUS WHEN YOU ACTUALLY HAVE

BOTH AN INDUSTRY POSITION AND A

PART-TIME ACADEMIC POSITION,

MIGHT NOT LEND ITSELF TO HAVING

RESEARCH LAB BUT WOULD LEND

ITSELF TO HAVING IMPACT IN THE

CLASSROOM AND INSTRUCTIONAL LABS

FOR STUDENTS.

THAT COULD BE USED AS A MODEL

THAT WE THINK ABOUT HOW WE WOULD

DEVELOP IT FURTHER, BUT I THINK

WE NEED TO OPEN OUR MINDS TO

WHAT IT LOOKS LIKE TO BE A

FACULTY MEMBER AND TO RECOGNIZE

THAT THERE MIGHT BE MULTIPLE

MODELS AND THAT RAISING NOT JUST

VISIBILITY BUT PRESTIGE OF

HAVING THAT TYPE OF MODEL

WHETHER WE BRING INDUSTRY,

ENGINEERS AND BIOMEDICAL

ENGINEERS INTO OUR ACADEMIC

SETTING THAT IS REWARDING FOR

EVERYONE.

>> RANU, I THINK YOU'RE
THE LAST

QUESTION.

>> YES, SO SUSAN, EXACTLY
WHAT

YOU SAID IN THE LAST PART IS

WHAT I WAS GOING TO ASK YOU

ABOUT.

BECAUSE EARLIER THERE WAS A

MENTION ABOUT SOME SO-CALLED

EARLY CAREER FACULTY OR NOT

POSTDOCS BUT OTHERS GOING

FORWARD, AND ABLE TO GET GRANTS.

I KNOW LIKE NSF CAREER AWARDS

WERE TIED TO BEING A TENURE

TRACK FACULTY MEMBER.

SO AS YOU'RE THINKING ABOUT

THESE NEW MODELS, THIS IS

EXACTLY WHAT YOU'RE TALKING

ABOUT, PROFESSORS OF PRACTICING,

I WANTED TO HEAR WHAT

CAPABILITIES ARE GOING TO BE

AVAILABLE OR WHAT THE THOUGHT

PROCESSES ARE TO GROW THIS

ENTIRE NEW SECTOR OF FACULTY,

THAT STRADDLE INDUSTRY AND THE

UNIVERSITY BUT ALSO MAY BE

CLINICAL SPACE AND INDUSTRY, AND

EVEN RESEARCH TRACK FACULTY WHO

DO NOT THEN JUST JUMP OUT OF

THEIR RESEARCH TRACKS AND SAY,

OKAY, NOW I GOT NIH GRANT, NOW I

GOT NSF GRANT SO I'M GOING TO

BECOME A TENURE TRACK FACULTY SO

HOW CAN NSF, NIH, PROMOTE THAT

KIND OF AN EXPANSION OF THE

RESEARCH WORK FORCE AND THINK

TANKS NOT JUST TIED TO TENURE

TRACK ACADEMIC STRUCTURE?

>> CERTAINLY THESE --
THANK YOU

FOR THE QUESTION.

IT'S A WONDERFUL QUESTION.

I WOULD SAY THAT THE ORIGIN OF

THIS IDEA OF HAVING MORE

INDUSTRY MEMBERS ENGAGING ON

CAMPUS AS CITIZENS, NOT JUST

GUEST LECTURERS, CAME FROM THREE

SETS OF PROBLEMS WHERE THIS

COULD BE AN INTERESTING

SOLUTION.

ONE WAS RECOGNIZING THE VALUE OF

REAL WORLD EXPERIENCE THEY OFFER

TO THE CAMPUS, FOR THOSE ENGAGED

IN RESEARCH AS WELL AS FOR THOSE

WHO ARE -- FOR OUR STUDENTS.

THE SECOND IS THE PIPELINE AND

DIVERSITY OF OUR PIPELINE IS NOT

GOOD.

SO ONE WAY TO DIVERSIFY OUR

FACULTY AT MORE SENIOR LEVELS IS

ACTUALLY TO THINK OF OTHER

PATHWAYS TO GET TO THE SENIOR

FACULTY MEMBER, RIGHT?

SO IT COULD BE THAT THESE ARE

SENIOR MEMBERS OF INDUSTRY, NOT

JUST NEWLY MINTED POSTDOCS WHO

HAVE GONE TO INDUSTRY, THAT'S AN

IMPORTANT WAY THAT WE CAN

CIRCUMVENT THE TYPICAL PIPELINE

ROUTE FOR ENRICHING THE

DIVERSITY OF OUR SENIOR FACULTY.

AND THEN FINALLY IT CAME UP IN A

DISCUSSION THAT I HAD WITH A

DEAN WHO SAID IT'S SALARIES THAT

I NEED TO OFFER SOMEONE WHO

IS -- WHO COULD GO TO INDUSTRY

IS JUST -- I CANNOT BE

COMPETITIVE.

I'M LOSING THEM BASED ON THE

ECONOMIC DECISION OF THIS

POSTDOC OR GRADUATE STUDENT.

AND SO HOW DO WE MANAGE TO

PROVIDE A SALARY THAT LITERALLY

IS JUST A PORTION OF THEIR

SALARY AND NOT HAVING TO HAVE AN

ENTIRE -- FUND AN ENTIRE SALARY

AND THIS INDIVIDUAL IS SAYING I

COULD EASILY -- MORE EASILY SELL

A PART-TIME POSITION AT THIS

RATE TO MY PROVOST THAN A

FULL-TIME FACULTY POSITION

SALARY THAT'S AT A RATE THAT

WOULD THROW US OUT OF BALANCE IN

TERMS OF EQUITY ON THE CAMPUS.

I THOUGHT THAT WAS INTERESTING.

SO WHAT WE CAN DO TO FUND THAT,

ENCOURAGE THAT, I'M NOT SURE BUT

I WELCOME THAT CONVERSATION.

>> THANK YOU.

I THINK THAT'S GOING TO BE VERY

IMPORTANT FOR OUR FUTURE.

>> I THINK WE'LL WRAP IT
UP

THERE.

I BUILT IN MY HEAD A LITTLE BIT

OF A BUFFER TIME.

I KNEW WE WOULD HAVE LOTS OF

QUESTIONS.

SUSAN, JUST A BRILLIANT AND

VISIONARY PRESENTATION.

I TOOK TONS OF NOTES.

I KNOW EVERYONE LEARNED A LOT

FROM YOUR REMARKS.

AND FROM ANSWERS TO THE

QUESTIONS, LOTS FOR US TO DO.

IT'S KIND OF, AS YOU POINTED

OUT, A NON-TRADITIONAL

APPEARING, NIBIB AND NSF, PAIRED

WITH APPLICATION-ORIENTED INSURE

-- INSTITUTES, WE CAN DO IT.

LET'S ALL THANK SUSAN AGAIN, A

ROUND OF APPLAUSE.

>> THANK YOU.

I LOOK FORWARD TO WHAT WE CAN DO

TOGETHER.

BYE-BYE.

>> ABSOLUTELY.

THANK YOU, SUSAN.

THANKS TO ALL OF YOU FOR YOUR

QUESTIONS.

WE'LL TAKE JUST A MOMENT TO

PERHAPS STRETCH, THIS IS YOUR

STRETCHING MOMENT.

AND I'M GOING TO SHARE MY

SLIDES.

WE'LL CONTINUE WITH THE

DIRECTOR'S REPORT.

THIS IS A TOUGH ONE.

IT'S ALWAYS VERY DIFFICULT TO

SAY GOOD-BYE TO OUR FELLOW

COUNCIL MEMBERS.

YOU NEVER GO AWAY.

ACTUALLY WE HAVE COLLABORATORS

AND COUNCIL MEMBERS WHO ARE

MAKING CONTRIBUTIONS THROUGHOUT

THEIR CAREERS OF COURSE AS HAVE

PAULA, MARYELLEN AND BRUCE.

THEY WERE VERY ACTIVE OF COURSE

BEFORE THEY JOINED COUNCIL.

WE'VE BEEN SO FORTUNATE TO HAVE

THE THREE OF YOU AS MEMBERS OF

COUNCIL REPRESENTING THREE

UNIQUE, AT LEAST THREE UNIQUE

DIMENSIONS, GOING INTO HIGHER

ORDER MULTI-DIMENSIONAL SPACE,

PAULA IN CHEMICAL ENGINEERING,

AND ENGINEERING DRUG DELIVERY

SYSTEMS USING POLYMERS AND

NANOPARTICLES.

MARYELLEN FOR YOUR AMAZING WORK

IN COMPUTER-AIDED DIAGNOSTICS

AND COMPUTATIONAL IMAGING, GOING

BACK TO RADIOLOGY AND

RADIOLOGICAL SCIENCES.

WELL, YOU WERE ALWAYS THERE.

BUT NO LONGER ON COUNCIL,

ROTATING OFF.

AND BRUCE ALSO IN IMAGING AS

DIRECTOR OF THE MARTINEZ CENTER,

AND EXPERT IN MRI AND

NEUROSCIENCE, NEUROIMAGING.

THANK YOU TO THE THREE OF YOU

FOR YOUR AMAZING CONTRIBUTIONS.

YOU SET THE BAR FOR SPEAKING UP

AT COUNCIL, MAKING CONTRIBUTIONS

THAT ARE VERY GENEROUS AND

THOUGHTFUL AND ALWAYS UNIQUE.

SO WE REALLY APPRECIATE YOUR

WORK AND SUPPORT.

AND LOOK FORWARD TO CONTINUING

TO WORK WITH YOU.

I'D LIKE TO RECOGNIZE SOME NEW

STAFF MEMBERS WHO HAVE COME IN

TO NIBIB, AND IT REALLY GIVES ME

A LOT -- IT'S A SPECIAL PLEASURE

TO RECOGNIZE THE THREE AT THE

TOP AND TO OUR TEAM FOR DOING

SUCH A WONDERFUL JOB RECRUITING

THEM, THANK YOU FOR YOUR WORK TO

BRING THESE SUPER-TALENTED

PEOPLE INTO THE NIBIB.

TINA HAS WORKED AT NHGRI, WORKED

IN ACADEMICS, AND INDUSTRY, AND

NOW JOINING THE DIVISION OF

INTERDISCIPLINARY TRAINING.

AND KARI IS A NEUROSCIENTIST AND

NEUROENGINEER, Ph.D. IN

BIOMEDICAL ENGINEERING,

EXPERIENCE IN THAT AREA, AND

ALSO IN THE BRAIN INITIATIVE,

UNDERGRAD IS MECHANICAL

ENGINEER.

WE WOULD LIKE TO CONGRATULATE

KAREN OLSON AND TARIQ WHO HAVE

BEEN PROMOTED TO FEDERAL

POSITIONS, CONTRACTORS

PREVIOUSLY.

AND SPECIAL NOTE OF

CONGRATULATIONS TO TODD.

EVERYONE ON THE CALL KNOWS TODD,

NOW THE DIRECTOR OF OUR OFFICES

OF PROGRAM EVALUATION AND

STRATEGIC PARTNERSHIPS, I THINK

I GOT THAT ACRONYM CORRECT.

AND THIS IS A NEWLY CREATED AND

EXPANDED OFFICE THAT TODD HAS

DEFINED.

HE'S ONE OF THE LONGEST SERVING

IF NOT THE LONGEST SERVING

MEMBER OF NIBIB, ORIGINAL

EMPLOYEE, IT'S QUITE FITTING

THAT HE LEADS THAT OFFICE SO

CONGRATULATIONS, TODD.

THANK YOU.

A FEW OTHER CONGRATULATIONS IN

ORDER, IN OUR INTRAMURAL

PROGRAM, I'D LIKE TO POINT OUT

THAT DR. KAITLIN SADTLER, CHIEF,

YOU'VE HEARD UPDATES, SHE'S

NAMED TO THE WORLD ECONOMIC

FORUM, 2022 CLASS OF YOUNG

GLOBAL LEADERS, THERE SHE IS I

THINK IN DUBAI, GIVING A

PRESENTATION.

BACKGROUND, THERE ARE 110 YOUNG

GLOBAL LEADERS LESS THAN 40

YEARS OLD SELECTED YECH EACH

YEAR.

THERE ARE EIGHT FROM ACADEMIA IN

THIS CLASS, A THINK TANK, THE

CATEGORY SHE WAS IN, ONE OF

EIGHT IN THIS UNIQUE CATEGORY,

PRETTY SPECTACULAR.

20 ARE FROM NORTH AMERICA BUT

SPAN DIFFERENT TOPIC AREAS.

JUST EIGHT, ALL AROUND THE WORLD

FROM THE ACADEMIC SETTING.

AND IT'S A THREE-YEAR LEADERSHIP

DEVELOPMENT PROGRAM.

WE LOOK FORWARD TO HEARING MORE

ABOUT THIS.

SO HOPEFULLY YOU'LL KEEP US

POSTED ON PROGRESS AND

ACTIVITIES IN THIS AREA.

IN HER LAB WE WANT TO GREAT A

POST DOC FELLOW, COMPLETED FOR A

RESEARCH SCHOLAR PRINCIPAL

INVESTIGATOR APPOINTMENT, THESE

PARTICIPANTS HAVE MENTORED

POSITION, WILL CONTINUE TO HAVE

MENTORED FACULTY DEVELOPMENT AND

DEVELOP DEDICATED DIVERSITY,

EQUITY, INCLUSION AND

ACCESSIBILITY PLAN THEY ARE

CONTRIBUTING TO, A COMPETITIVE

POSITION, AND IT MAKES THEM

COMPETITIVE INSIDE AND OUTSIDE

THE NIH AND WILL SET UP A UNIT

FOR NANOENGINEERING AND

MICROPHYSIOLOGIC SYSTEMS.

THIS IS FUNDED BY THE OFFICE OF

THE DIRECTOR AT THE NIH AT A

LEVEL OF APPROXIMATELY $300,000

PER YEAR FOR THREE YEARS.

AND HER RESEARCH WILL BE IN

INTEGRATING BIOENGINEERING

APPROACHES WITH ASPECTS OF

MECHANISTIC BIOLOGY, AND SHE

WILL FOCUS A LOT ON DEVELOPING

THERAPIES FOR IMMUNE-RELATED

THYROID CONDITIONS.

SO THANK YOUS TO MEMBERS OF

NIBIB WHO LEFT BUT MUCH LIKE

COUNCIL MEMBERS THEY HAVE LEFT

AND HAVE REMAINED CONNECTED.

WE'VE ALL HAD THE GREAT PLEASURE

TO WORK WITH ILANA, JOAN AND

TONY, THREE PROGRAM DIRECTORS

WHO ARE NOW AT NHLBI, NCI AND

NIAMS, RESPECTIVELY.

THEY HAVE MADE ENORMOUS

CONTRIBUTIONS TO OUR PROGRAMS

BUT WE STILL WORK TOGETHER WITH

THEM IN PROGRAMS FROM SMALL

BUSINESSES AND SMALL BUSINESS

SBIR GRANTS AND WORK AT THE

OFFICE OF RESEARCH AND WOMEN'S

HEALTH, RADx PROGRAMS, WE'VE

CREATED MANY LASTING AVENUES FOR

COLLABORATION, EXCITED TO

CONTINUE TO WORK WITH ALL OF

THEM.

AT THIS POINT I'M GOING TO TURN

IT OVER TO MY COLLEAGUE, DEPUTY

DIRECTY DIRECTOR HEEMSKERK FOR A

BUDGET UPDATE.

>> THANK YOU, BRUCE.

I'M GLAD I'M DOING THIS IN A

YEAR WHEN THE BUDGET NEWS IS

RELATIVELY GOOD.

OUR APPROPRIATION SUMMARY IS

HERE, NIH RECEIVED $45.2 BILLION

THIS YEAR, WHICH REPRESENTS 5%

INCREASE OVER FY 21.

AND SOME OF THAT 5% INCREASE IS

FOR SPECIAL EARMARKED PROGRAMS,

AND MOST OF THE I.C.s

INCLUDING NIBIB GOT A 3.4%

INCREASE.

AND FOR US, THAT REPRESENTS $425

MILLION IN TOTAL, WHICH IS

$13.8 MILLION ABOVE WHAT WE GOT

IN FY 21.

AND WE'VE BEEN ABLE TO ACHIEVE A

PAYLINE THIS YEAR OF 19th

PERCENTILE FOR R01s, AND

BECAUSE NEW INVESTIGATORS GET A

A 5% BUMP UP, THAT REPRESENTS

24th PERCENTILE FOR NEW

INVESTIGATORS.

BRUCE, IF YOU ADVANCE TO THE

NEXT SLIDE.

I JUST WANT TO CALL EVERYONE'S

ATTENTION TO OUR EXTRAMURAL

BUDGET WORKING GROUP.

THIS IS A GROUP LED BY DEB KELLY

AND HER TEAM WHO DO ANALYSIS AND

TRACKING AND MODELING THAT WE

NEED TO COME UP WITH OUR

FINANCIAL MANAGEMENT PLAN EACH

YEAR.

THERE ARE MANY UNCERTAINTIES

INCLUDING HOW MANY GRANTS WILL

BE ASSIGNED TO NIBIB, AND WHAT

THE INDIVIDUAL BUDGETS OF THOSE

GRANTS WILL BE.

THEY TEND TO INCREASE EVERY YEAR

RATHER RELIABLY AND SO

TRANSFORMING WHAT WE GET IN OUR

APPROPRIATION INTO A PAYLINE IS

AN ONGOING INTENSIVE EFFORTS

THAT INVOLVES DATA ANALYSIS AND

MODELING AND DISCUSSION WITH

LEADERSHIP OF THE INSTITUTE.

THE OUTPUTS ARE ON THE NEXT

SLIDE.

YOU'LL REMEMBER THAT LAST YEAR

IN FY 21 WE WERE ABLE TO ACHIEVE

A 16th PERCENTILE PAYLINE,

ONE OF THE LOWEST WE'VE SEEN IN

THE PAST FEW YEARS.

AND IN ORDER TO ACHIEVE THIS

LEVEL BECAUSE OF ALL OF THE

SORTS OF VARIABLES I MENTIONED,

WE NEEDED TO TURN A NUMBER OF

DIALS WITH BUDGET CUTS TO FREE

UP ENOUGH MONEY TO FUND AS MANY

INVESTIGATORS AS POSSIBLE.

AND SO IN ADDITION TO OUR

STANDARD EVERY YEAR CUTS TO

R01s AND U01s, WE ADDED WITH

SOME PAIN 10% CUT TO THE P41s

WHICH WE DON'T LIKE TO CUT

BECAUSE THEY HAVE TAPPED VERY

HEAVILY BURDENED BUDGETS.

AND WE SPECIALLY DON'T LIKE TO

CUT OUR NON-COMPETING GRANTS IN

THE OUT YEARS WHEN WE'VE MADE A

COMMITMENT TO FUND AT A

PARTICULAR LEVEL.

BUT LAST YEAR BEING DIFFICULT,

WE ENACTED A 2% CUT AND ACHIEVED

16th PERCENTILE PAYLINE.

YEAR WOULD BE BETTER, IN FACT IT

IS.

WE WERE ABLE TO RESTORE THE P41

AND NON-COMPETING CUTS THIS YEAR

AND ACHIEVED 19th PERCENTILE

WITH ROUTINE CUTS.

THE NEXT SLIDE REMINDS YOU THAT

WE ALSO HAVE A LARGE COVID-19

SPECIFIC BUDGET.

THAT CONTINUES AGAIN THIS YEAR.

YOU SEE THE APPROPRIATED BUDGET

IN BLUE FOR EACH IN FISCAL

YEAR, COVID IN ORANGE.

THIS YEAR $682 MILLION EARMARKED

FOR COVID.

AND THAT'S ABOUT 1.5 TIMES WHAT

OUR APPROPRIATED BASE BUDGET IS.

SO WE HAVE BEEN OPERATING IN THE

LAST THREE FISCAL YEARS AS

ALMOST TWO INSTITUTES IN ONE.

IF YOU GO TO THE NEXT SLIDE,

BRUCE, I JUST WANT TO REMIND YOU

OF WHERE MOST OF THE MONEY IS

GOING BUT I WOULD LIKE TO KIND

OF UNPACK IN THE NEXT FEW SLIDES

FOR YOU REALLY WHAT MAKES UP OUR

COVID-SPECIFIC BUDGET.

WE INITIALLY RECEIVED $500 IN FY

20 FROM CONGRESSIONAL SUPPLEMENT

TO EXPAND THE NIBIB POINT OF

CARE TECHNOLOGY RESEARCH

NETWORK.

THE ASK WAS THAT WE QUICKLY

DEVELOP TESTS FOR COVID-19.

AND WE RECEIVED THIS FUNDING

BECAUSE WE HAD THE POCTRN

NETWORK ON WHICH WE COULD BASE

TEST DEVELOPMENT EFFORT.

THE NETWORK HAS FOUR ACADEMIC

CENTERS AND IS OVERSEEN BY A

COORDINATING CENTER AT MGH, AND

WITH THIS $500 MILLION WE WERE

ABLE TO -- WHICH WE RECEIVED IN

APRIL OF 2020 WE WERE ABLE TO

EXPAND THE NETWORK BY

ESTABLISHING A VALIDATION CORE

AT EMORY, AND CLINICAL STUDIES

CORE AT UMass.

AND THEN OVERSEES A DEPLOYMENT

CORE WITH RESPONSIBILITY FOR

THINGS GENERALLY OUT OF SCOPE

FOR POCTRN AND NIH AS A WHOLE,

THINGS LIKE MANUFACTURING AND

COMMERCIALIZATION.

AND SO WE BUILT A NETWORK WITH

REALLY UNIQUE CAPABILITY IN THE

GOVERNMENT TO NOT ONLY SOLICIT

REVIEW AND FUND APPLICATIONS

VERY QUICKLY, BUT THE ABILITY TO

TEST AND VALIDATE TECHNOLOGIES

IN DEVELOPMENT AND DE-RISK THOSE

TECHNOLOGIES, AND TO GIVE EXPERT

GUIDANCE TO THE COMPANIES

DEVELOPING TASKS NOT ONLY ON

TECHNOLOGY DEVELOPMENT AND

CLINICAL STUDIES BUT FOR

REGULATORY AUTHORIZATION,

MANUFACTURING,

COMMERCIALIZATION.

AND THE NETWORK HAS GROWN NOW TO

THE POINT WHERE WE HAVE OVER 900

CONTRIBUTORS TO THE PROGRAM FROM

THE GOVERNMENT, ACADEMIA,

INDUSTRY, AND NON-PROFIT

SECTORS.

SO, THIS $500 MILLION OF INITIAL

FUNDING, IF YOU GO TO THE NEXT

SLIDE, BRUCE, HAS GROWN IN TOTAL

TO $1.7 BILLION IN THE LAST

THREE FISCAL YEARS.

WHAT I'D LIKE TO DO IS UNPACK

THAT A LITTLE BIT FOR YOU.

IT'S SORT OF AN INTERESTING

STORY HOW THIS MONEY HAS COME TO

RADx BECAUSE OF ITS UNIQUE

CAPABILITIES.

SO, THE FIRST PART OF THE PIE

HERE WHICH REPRESENTS $950

MILLION IS THREE YEARS OF

FUNDING FOR RADx, FIRST $500

WE GOT AND THEN TO EXPAND, AND

$350 MILLION IN 22 TO FOCUS ON

NEXT GENERATION TEST

DEVELOPMENT.

THE NEXT CATEGORY OF FUNDING WE

RECEIVED, IF YOU ADVANCE ONE,

BRUCE, IS FUNDING THAT WE GOT

BECAUSE OTHER AGENCIES WERE ABLE

TO RELY ON THIS INFRASTRUCTURE

WE HAD ESTABLISHED, AND THE

EXPERTISE WE ATTRACTED, TO HELP

ACHIEVE THEIR MISSION.

SO YOU SEE RADx ATP, ANOTHER

ONE OF THE RADx COMPONENT

PROGRAMS, DESIGNED TO EXPAND

LABORATORY TESTING IN THE

COUNTRY.

THAT ALSO WAS STARTED IN EARLY

2020 WITH CONGRESSIONAL

SUPPLEMENT FUNDING TO THE NIH

OFFICE OF THE DIRECTOR.

AND HAVING ESTABLISHED RADx

TECH, WHAT OUR POCTRN BASED

PROGRAM IS CALLED, THE DECISION

WAS MADE THAT WE WOULD USE THAT

SAME INNOVATION FUNNEL APPROACH

TO IDENTIFY COMPANIES THAT COULD

EXPAND LABORATORY TESTING AT

HIGH CAPACITY AND FUND THOSE

COMPANIES.

SO, WE BASICALLY EXECUTED THAT

PROGRAM FOR THE OFFICE OF THE

DIRECTOR.

BARDA INITIALLY WAS ALSO GIVEN A

MILLION DOLLARS TO DEVELOP TESTS

FOR THE COUNTRY EARLY IN THE

PANDEMIC.

AND WHEN WE HAD ATTRACTED OUR

MANY, MANY PROMISING COMPANIES

TO THE RADx TECH PROGRAM, AND

IDENTIFIED THOSE THAT HAD STOOD

SOME VERY GOOD CHANCE OF

SUCCESS, BARDA SUPPLIED US WITH

$308 MILLION TO DEVELOP TESTS

THROUGH RADx COMPLEMENTARY TO

WHAT THEY WERE TESTING.

AND MORE RECENTLY, ASPR

IDENTIFIED RADx COMPANIES THAT

COULD HELP WITH THEIR MISSION OF

MAINTAINING PREPAREDNESS IN THE

COUNTRY, SO COMPANIES THAT COULD

MAINTAIN A WARM BASE DURING

TIMES WHEN CASES WERE LOW, AND

THEN QUICKLY SCALE UP WHEN

SURGES MIGHT EMERGE.

SO, RADx HAD THIS UNIQUE

INFRASTRUCTURE THAT WAS ABLE TO

SUPPORT THE MISSIONS OF OTHER

AGENCIES AND INSTITUTES AT NIH.

THEN THERE ARE A FEW EXAMPLES, I

WILL SHOW YOU, OF PARTICULAR

NEEDS THAT WE DIDN'T NECESSARILY

PREDICT AT THE OUTSET OF THE

PANDEMIC BUT THINGS, PROBLEMS

EMERGED, PROBLEMS AROSE DURING

THE PANDEMIC AS WE ALL KNOW.

AND RADx WAS A UNIQUE

GOVERNMENT RESOURCE THAT COULD

TAKE ON THESE PROBLEMS VERY

QUICKLY AND ADDRESS THEM WITH A

LOT OF SORT OF NIMBLENESS AND

FLEXIBILITY.

SO THE VARIANT TASKS FORCE IS A

GREAT EXAMPLE.

AS VARIANTS BEGAN TO EMERGE,

FIRST DELTA AND THEN OMICRON,

EVERYBODY WAS WONDERING IN THE

FACE OF THESE NEW MUTATED

VIRUSES ARE THE TESTS STILL

GOING TO BE -- ARE THE TESTS

STILL GOING TO PERFORM?

AND SO THE VARIANT TASK FORCE

WAS FORMED AT EMORY, AND WITH

INPUT FROM THE COORDINATING

CENTER AT CIMIT TO SET UP A

BIOINFORMATICS PROGRAM TO ANNUAL

IDES MUTATIONS AND TEST PRIMERS

AND WET LAB TESTING OF ANTIGEN

TESTING WITH VARIANT SAMPLES TO

ENSURE THE TESTS REMAINED ABLE

TO DETECT VIRUS EVEN IN THE FACE

OF VARIANTS.

THE NEXT IS THE COVID TEST, A

PROGRAM RUN OUT OF THE OFFICE OF

THE DIRECTOR, LAUNCHED BASED ON

DIGITAL PLATFORM THAT RADx

TECH DEVELOPED THROUGH CARE EBO,

THIS WAS A TEST, FREE TEST

DISTRIBUTION PROGRAM, THAT

OPERATIONALIZED SENDING TESTS TO

PEOPLE'S HOMES, AND IN SPECIFIC

COMMUNITIES, AND WAS -- REALLY

HELPED INFORMED THE

ADMINISTRATION'S $1,000, 1 --

ONE BILLION DOLLAR TEST

DISTRIBUTION WE SEE NOW.

NEXT, ITAP, INDEPENDENT TEST

ASSESSMENT PROGRAM, A CLOSE

COLLABORATION WITH THE FDA, SET

UP TO ADDRESS THE PROBLEM WE

JUST NEEDED MORE TESTS, WHEN

OMICRON WAS SURGING THERE WAS A

LOT OF FRUSTRATION THAT TESTS

WERE -- HOME TESTS IN PARTICULAR

WERE READILY AVAILABLE IN MANY

OTHER COUNTRIES BUT NOT THE U.S.

AND SO WHAT WE DID WAS SET UP A

COLLABORATION WITH THE FDA TO

ATTRACT HIGH VOLUME PRODUCERS

FROM OTHER COUNTRIES TO SELL

TESTS IN THE U.S. BY HELPING

THEM GET EMERGENCY USE

AUTHORIZATION, WORKING WITH THE

FDA, COLLECTING INDEPENDENT

DATA, AND PROVIDING IT TO THE

FDA ON AGREED TEMPLATES SO THEY

COULD MAKE APPROVALS QUICKLY,

AUTHORIZATIONS QUICKLY.

IN FEBRUARY OF THIS YEAR WE AS A

RESULT HAD 1.2 BILLION TESTS

SOLD IN THE COUNTRY.

THE LAST MOST RECENT FUNDING

RECEIVED IS FOR THE ACCESSIBLE

TESTING PROGRAM.

THE HOME TEST DISTRIBUTION

PROGRAM AT COVID.GOV REVEALED

THAT THERE REMAINED AN UNMET

NEED FOR TESTS THAT COULD BE

TAKEN INDEPENDENTLY BY PEOPLE

WITH LOW VISION AND MOTOR

DISABILITY AND COGNITIVE

DISABILITY.

AND SO RADx HAS TAKEN ON THE

CHARGE OF MODIFYING EXISTING

TESTS TO MAKE THEM MORE

ACCESSIBLE, AND WE HAVE PLANS TO

LAUNCH A NEW FUNNEL TO DEVELOP

TESTS WITH USER CENTRIC APPROACH

THAT WILL BE ACCESSIBLE TO

EVERYONE.

SO, I WILL STOP THERE AND TURN

IT BACK TO BRUCE.

THAT IS OUR BUDGET UPDATE.

THANK YOU, BRUCE.

>> THANK YOU, JILL, FOR
THE VERY

COMPREHENSIVE UPDATE.

AND IT WILL I THINK GIVE SOME

FOUNDATIONER SOME ADDITIONAL

INFORMATION THAT I COMMUNICATED

IN THE REPORT HERE.

LET ME PICK UP WITH OUR DEBUT

AWARDS, DESIGN BY UNDERGRADUATE

TEAMS.

AND I KNOW I DON'T NEED ANY

INTRODUCTION ABOUT THIS AWARD

PROGRAM.

IT'S PROBABLY I THINK OUR IN

SOME WAYS OUR MOST IMPACTFUL AND

INSPIRATIONAL AWARD PROGRAM.

AND LED BY OUR TRAINING

DIVISION, THERE ARE $130,000 IN

PRIZES WITH SOME NEW AWARDS,

WE'VE DISCUSSED THIS BUT I

WANTED TO DRAW EVERYBODY'S

ATTENTION TO THE SUBMISSION

DEADLINE WHICH IS AT THE END OF

MAY.

IF YOUR TEAMS AND COLLEAGUES

HAVE NOT STARTED THEIR

APPLICATIONS, GET THEM TO START.

PLEASE SEND IN APPLICATIONS BY

SUBMISSION DEADLINE.

WE'RE HOPING TO CONTINUE TO

EXPAND AND INCREASE THE NUMBER

OF AWARDS AND SIZE OF THE

AWARDS.

AND I'D LIKE TO HIGHLIGHT THAT

THERE'S ALSO THE WINNERS, SOME

WINNERS, WILL RECEIVE

COMMERCIALIZATION TRAINING.

THAT IS GOING TO BE DRIVEN BY

SOME OF OUR COMMERCIALIZATION

PROGRAMS.

SO THOSE ARE TO THE ONES WHO

RECEIVED SOME NIH AWARDS.

THIS IS IN COLLABORATION WITH

VENTURE WELL.

SO IT'S AN AMAZING PROGRAM AND

JUST ENCOURAGE ALL OF YOU TO

SPREAD THE WORD AND MAKE SURE WE

HAVE PLENTY OF APPLICATIONS FOR

THIS.

YOU'VE FOLLOWED OUR NIH

TECHNOLOGY ACCELERATOR

CHALLENGE.

THIS IS A PARTNERSHIP WITH NIBIB

AND GATES FOUNDATION.

INTERESTING PROTOTYPE FOR

COLLABORATIVE TYPES OF EFFORTS

THAT COULD SERVE AS SOMETHING

FOUNDATIONAL FOR EXAMPLE WITH

THE NSF.

THE 2020 CHALLENGE FOR PLATFORM

CONCEPTS AND PROTOTYPES OF

NON-INVASIVE MULTIPLEX

DIAGNOSTIC TECHNOLOGIES FOR

SICKLE CELL, MALARIA, A TEAMA,

-- ANEMIA, AN AWARD TO BUCCAL

MUCOSA, CAPILLARY BLOOD CELLS

FOR CLASSIFICATION, MORPHOLOGY

COUNTING, THIS IS WORK LED BY

NICK DURR AT JOHNS HOPKINS AND

GREG MACKAY, AND THIS IS NOW

RECEIVED FOLLOW-UP FUNDING FROM

GATES SO IT'S REALLY MOVING

BEAUTIFULLY.

IT'S A TERRIFIC EXAMPLE OF THE

PARTNERSHIP THAT WE HAVE WITH

THE GATES FOUNDATION AND HOW

THEY CAN ACCELERATE

COMMERCIALIZATION,

MANUFACTURING, MARKETING, AND SO

FORTH OF TECHNOLOGIES.

OUR CURRENT ONE IS MATERNAL

HEALTH LAUNCHED IN 2021.

AND THESE ARE FOR POC MOLECULAR,

CELLULAR, METABOLIC SENSING,

DIAGNOSTIC TECHNOLOGIES TO

REDUCE MATERNAL MORBIDITY AND

MORTALITY, FEATURING A

PARTNERSHIP WITH NICHD, AND WE

HAVE BOTH AN INTEREST IN HAVING

PLATFORM TECHNOLOGIES AND DESIGN

AS WELL AS ARTICULATING A

PATHWAY FOR TRANSLATION AND USE

IN GLOBAL HEALTH SETTINGS, AGAIN

OWING TO OUR STRONG

COLLABORATION WITH GATES, AND

THE FOUR MAJOR AREAS OF INTEREST

ARE IN INFECTION, HYPERTENSIVE

DISEASE, PLACENTAL IMAGE,

HEMORRHAGE, APPLICATIONS ARE IN

NOW, AWARDS ANNOUNCED IN

MID-JULY.

WE MENTIONED IN OUR PREVIOUS

COUNCIL MEETING A CONCEPT

CLEARANCE FOR POCTRN, AND IN

RECORD SPEED WE HAVE A NOTICE OF

INTENT TO PUBLISH, THIS WHICH

WE'RE EXPECTING AROUND JULY, END

OF JULY THIS YEAR, BUT THIS

NOTICE IS NOW POSTED FOR POCTRN

SETTINGS, POCTRN CENTERS, AND I

THINK EVERYONE IS FAMILIAR WITH

THE FOUNDATIONAL IMPORTANCE OF

POCTRN IN WHAT NIBIB DOES AND

INCREASINGLY ITS CONTRIBUTION TO

IN VITRO DIAGNOSTICS AND POINT

OF CARE TECHNOLOGIES THROUGHOUT

THE WORLD.

SO WE'RE HOPING TO CONTINUE AND

EXPAND AND BUILD ON THIS, AND

KEEP YOUR EYES OPEN FOR THIS

PUBLICATION DATE FOR THE FOA.

WE ALSO TALKED PREVIOUSLY ABOUT

HOW TO RETHINK WHAT WE'RE DOING

AND EXPAND OPPORTUNITIES WITH

DRPs, THIS ANNOUNCEMENT IS

PUBLISHED, APPLICATION DUE DATES

FOR WHAT IS A NEWLY RECONFIGURED

BPI, THAT'S A PARTNERSHIP THAT'S

WITH INDUSTRY SO IT'S A KIND OF

CONTRACTION OF OUR PROGRAM

NAMES, SO IT'S BPI,

BIOENGINEERING PARTNERSHIPS WITH

INDUSTRY.

AND THE APPLICATION DUE DATES

HERE ARE MAY 26 AND SEPTEMBER

26, OF 2022, AND THIS SHOULD GO

THROUGH 2024, WE'RE HOPING FOR

REALLY OUTSTANDING RESPONSE TO

THIS.

AND JUST WANT TO NOTE AS

PREVIOUSLY WE HAVE THE NEI AND

NIA AND NCI ON BOARD.

A QUICK UPDATE ON D.E.I.

ACTIVITIES, LED BY ZANE ARAM, WE

HELD OUR MEETING ON THE NINTH OF

MAY, AND FIRST SOME UNITE

UPDATES.

THERE'S BEEN LOTS OF PROGRESS IN

THIS AREA, 15 DIFFERENT TEAMS

FORMED, AND THEY ARE PUSHING TO

BRING, TO ADVANCE IDEAS ALONG.

ONE OF THESE IDEAS IS

INSTITUTIONAL EXCELLENCE IN DEIA

PRIZE, AN RFA PUBLISHED.

YOU CAN ACCESS THAT URL BY GOING

TO OUR WEBSITE, AND PLEASE WE'RE

HOPING THAT OUR COMMUNITY WILL

RESPOND TO THIS RFI, TO GIVE

COMMENTS THAT ARE UNIQUE TO OUR

COMMUNITY AND TUNED SO WE CAN

MAKE SURE, WE HOPE, WE'LL HAVE

PRIZEs THAT ARE ISSUED IN OUR

COMMUNITY.

THIS IS A KIND OF A TEST

EXAMPLE, AND WE'RE HOPING THAT

THERE WILL BE A RECURRING TYPE

OF PROGRAM BUT WE'RE HOPEFUL,

WE'D LIKE TO SEE A STRONG

RESPONSE FROM THE BIOENGINEERING

COMMUNITY.

ALL OF THE INSTITUTES, CENTERS

AND OFFICES ARE PARTICIPATING IN

RECRUITMENTS FOR DEIA SCIENTIFIC

PROGRAM OFFICERS, THESE ARE

ONGOING, AND WE'RE ALSO ENGAGED

IN THAT NOW.

AND JUST DRAWING ATTENTION TO

THE LINK ON UNITE, THERE ARE

UPDATES THAT YOU CAN FOLLOW

QUITE A LOT HAS HAPPENED SINCE

THE LAST COUNCIL MEETING.

IN TERMS OF OUR SPECIAL

DIVERSITY FOCUSED FUNDING

OPPORTUNITIES, OUR TWO R01s,

BOTH FOR TECHNOLOGY DEVELOPMENT

TO REDUCE HEALTH DISPARITIES,

AND NEW INVESTIGATORS TO PROMOTE

WORKFORCE DIVERSITY, SO THOSE

APPLICATION DATES HAVE CLOSED.

BUT AT THE SUGGESTION OF OUR

WORKING GROUP TO ADD ADDITIONAL

WORKING -- ADDITIONAL DUE DATES,

WE'RE IN PROCESS OF THAT

DISCUSSION, AND HOPEFULLY WE'LL

BE ABLE TO DO THAT.

WE HAVE NOT BEEN ABLE TO MAKE

ANY CHANGES PRIOR TO THIS

COUNCIL MEET BUG -- MEETING BUT

WE'RE HOPEFUL TO INFORM YOU IN

THE COMING MONTHS.

WE HAVE OUR R21 MECHANISM, SMALL

GRANTS FOR NEW INVESTIGATORS TO

PROMOTE DIVERSITY.

AND JUST WANT TO DRAW YOUR

ATTENTION TO THE FACT THAT THERE

ARE STILL ACTIVE DUE DATES,

THREE DUE DATES PER YEAR IN

THIS, SO UPCOMING IS JUNE 16,

OCTOBER 16, AND WE'RE VERY

HOPEFUL THAT OUR COMMUNITY WILL

BE RESPONDING STRONGLY TO THIS

R21.

WE'VE HAD RECENT ACTIVITY, FOCUS

ON ENTREPRENEURSHIP THROUGH THE

CIMIT CRASH COURSE, THE

COMMERCIALIZATION ACCELERATOR,

LED BY THE CIMIT POCTRN TEAM,

AND TIFFANI LASH LET THIS

EFFORT.

THERE WERE SEVEN TEAMS IN THIS

CRASH COURSE FOCUSED ON

DIVERSITY, AND AT LEAST ONE OF

ITS CORE MEMBERS CAME FROM AN

UNDERREPRESENTED GROUP.

THERE WERE DIVERSE MENTORS.

WE HAVE PARTICIPANT EVALUATION

WITH FEEDBACK FROM ALL

PARTICIPANTS, IN GENERAL THE

FEEDBACK HAS BEEN VERY POSITIVE

AND THERE'S A CONSENSUS ON

PLANNING TO CONTINUE TO USE THE

TOOLS THAT WERE DEVELOPED, AND

BUILD ON THE PROGRESS THAT'S

BEEN MADE.

OUR NEXT STEPS ARE HOPEFULLY TO

BUILD ON THESE EXPERIENCES AND

FEEDBACK TO DESIGN AN ONGOING

CONTINUING DIVERSITY-FOCUSED

ENTREPRENEURSHIP TRAINING

PROGRAM.

WE'VE ALSO BEEN INVOLVED WITH

THE OFFICE OF RESEARCH ON

WOMEN'S HEALTH, AND EXTENSIVELY

IN MANY ACTIVITIES, ONE I'D LIKE

TO DRAW YOUR ATTENTION TO JUST

HAPPENED LAST WEEK.

A SYMPOSIUM ON REIMAGINING WOMEN

IN THE BIOENGINEERING TECHNOLOGY

AND DATA SCIENCE ECOSYSTEM.

THE GOAL OF THIS IS TO REALLY

LEAD TO DESIGNING AND BUILDING A

SCIENTIFIC RESEARCH ECOSYSTEM

THAT MAXIMIZES OPPORTUNITIES FOR

WOMEN FROM DIVERSE BACKGROUNDS

THROUGH ALL CAREER STAGES, AND

DEVELOPS AND SUSTAINS SCIENTIFIC

WORKFORCE, CAN ADAPT TO MANY

SECTORS.

AND FINALLY BUILDS TEAMS ACROSS

THESE SECTORS AND CREATES NEW

CROSS-SECTOR OPPORTUNITIES FOR

MENTORSHIP AND SPONSORSHIP.

AND THE ORGANIZING COMMITTEE

INCLUDE JOAN GRIEVE AND TIFFANI

LASH.

OUR FEATURED SPEAKERS FOR THIS

INCLUDED DR. CLAYTON, OFFICE OF

RESEARCH IN WOMEN'S HEALTH, AND

DR. TABAK, ACTING DIRECTOR OF

NIH.

BUT ALSO OUR COUNCIL MEMBER AND

COLLEAGUE DR. GILDA BARABINO,

AND DR. CHRISTINE GRANT, NORTH

CAROLINA STATE UNIVERSITY.

DR. DAVID WILKES, WHO IS A

FORMER DEAN OF SCHOOL OF

MEDICINE AND DEAN EMERITUS AT

UNIVERSITY OF VIRGINIA, AND TWO

OTHER INDIVIDUALS WHO WERE

REALLY PRETTY IMPRESSIVE, NOLA

MASTERSON WHO LEADS AN ANGEL AND

VENTURE INVESTMENT FUND FOCUSED

ON WOMEN'S HEALTH, AND IS THE

LEAD FOR FEMTEC 1 AND 2 FUNDS,

AND WENDY CHUN-HOON.

I HAD THE PLEASURE OF MODERATING

INCREDIBLE SPEAKERS AND

INTERACTION AND DISCUSSION,

HOPEFULLY WE'LL BE CONTINUING TO

WORK WITH THE OFFICE OF OF

RESEARCH AND WOMEN'S HEALTH TO

CAPTURE THIS CONTENT AND

DISSEMINATE.

A LOT OF EXCITEMENT WAS

GENERATED OVER THESE TWO DAYS.

FINALLY, THE ONE LAST THING TO

MENTION HERE, WE DISCUSSED THIS

IN OUR WORKING GROUP, WE'VE

TARGETED THIS OPPORTUNITY TO

ESTABLISH BIOMEDICAL MEDICAL

ENGINEERS PROGRAMS AT HBCUs,

AN AMBITIOUS GOAL FOR THE ENTIRE

COMMUNITY.

JUST POINTING OUT REMARKABLE

GROWTH ALL AROUND THE COUNTRY

THAT WE'VE SEEN SINCE THE

ESTABLISHMENT OF NIBIB IN 2000,

AND THE OPPORTUNITY HERE IS TO

GET SIMILAR TYPE OF GROWTH OR TO

HELP STIMULATE GROWTH WITHIN

HBCUs AND OTHER COMMUNITIES,

COLLEGES, THAT HAVE NOT BEEN

ABLE TO ACCESS THIS KIND OF

ACADEMIC TRAINING OR GROW IT,

WITHIN THEIR COLLEGES AND

UNIVERSITIES.

SO, IN TERMS OF WHAT WE'VE DONE

SO FAR, WE'VE REALLY CREATED A

STRATEGY FOR THINKING ABOUT HOW

WE CAN DO FUNDRAISING IN

COLLABORATION WITH FOUNDATION

FOR NIH, WHICH FOCUSES ON

FORMING PUBLIC/PRIVATE

PARTNERSHIPS, HELPING LEAD THEM,

WHICH IS EXACTLY WHAT WE NEED TO

DO FOR THIS.

THEY ARE SUPPORTIVE AND READY TO

PARTNER IN OUR NEXT STEPS, AND

OUR NEXT ACTION IS FOR THE

CO-CHAIRS OF OUR DEIA COMMITTEE

TO CONVENE A ROUNDTABLE SO THAT

WE CAN BEGIN TO UNDERSTAND A

LITTLE BIT BETTER THE UNIQUE

NEEDS AND PRIORITIES AND BUILD

MORE EXCITEMENT SO THAT THE FNIH

CAN BECOME A TARGET OF

FUNDRAISING FOR THIS TYPE OF

EFFORT.

NOW I'D LIKE TO TOUCH BRIEFLY ON

PROGRESS IN THE PANDEMIC

RESPONSE.

AND OUR TWO MAJOR AREAS, THREE

MAJOR AREAS OF INVERSE.

ININVESTMENT IN IMAGING AND IN

VITRO DIAGNOSTICS AND DIGITAL

HEALTH PLATFORMS.

OUR BIG STRUCTURE THAT WE'VE

HELPED CREATE IS THE MEDICAL

IMAGING AND DATA RESOURCE

CENTER, MIDRC, A LOT HAS

HAPPENED SINCE THE PREVIOUS

MEETING.

I'LL TOUCH ON A FEW HIGHLIGHTS.

FIRST, THERE'S BEEN A

SIGNIFICANT INCREASE IN NUMBER

OF IMAGES INGESTED, OVER 120,000

HAVE BEEN INGESTED IN MIDRC,

30,000 REPRESENTING ABOUT 11,000

PATIENTS HAVE BEEN RELEASED IN

THE OPEN COMMONS.

THAT'S ABOUT 2.5 TERABYTES OF

DATA, A REALLY BIG JUMP SINCE

THE PREVIOUS TIME WE DISCUSSED.

THERE ARE ABOUT 150 DATA USERS

FROM OVER 100 INSTITUTIONS, AND

13 PUBLICATIONS NOW.

THERE ARE 40 CONTRIBUTING SITES,

SPANNING ACROSS 23 STATES.

SO, THE GROWTH JUST IN THE LAST

FEW MONTHS HAS BEEN QUITE

ENORMOUS.

THERE'S BEEN SIGNIFICANT

PROGRESS IN INTRAOPERABILITY,

SOMETHING WE HOPE FOR

CLOUD-BASED DATA STRUCTURES.

THERE'S SUCCESSFUL PILOT GOING

ON WITH THE BIODATA CATALYST

WHICH IS NHLBI DATA STRUCTURE,

ONGOING PILOT AT NCATS WHICH IS

PROBABLY THE BIGGEST COVID DATA

REPOSITORY THAT I'M AWARE OF,

WITH POTENTIAL FOR LINKING UP TO

MIDRC, AND THERE'S A FEDERATED

LEARNING PILOT WITH ARGONNE LAB.

THERE ARE 2500 PATIENTS

ABSOLUTELY ESSENTIAL IN ORDER TO

VALIDATE THE PERFORMANCE OF

ALGORITHMS AND ACCELERATE FDA

CLEARANCE AND ULTIMATELY TO

DEPLOY THESE ALGORITHMS

CLINICALLY, SO CONGRATULATIONS

TO THE MIDRC TEAM, MARYWELLEN IS

THE PRINCIPAL INVESTIGATOR,

WORKING CLOSELY WITH ALL OF

THESE PROFESSIONAL SOCIETIES,

THIS HAS BEEN A TRUE SPECTACULAR

NETWORK THAT'S GROWN AND MADE

PROGRESS JUST IN THE LAST FEW

MONTHS.

IN TERMS RADx, HERE IS A SORT

OF BOTTOM LINE WHAT'S HAPPENED.

YOU CAN SEE ON THE LEFT IS A

PLOT OF THE CUMULATIVE

AUTHORIZED TESTS AND TEST

PRODUCTS, AND I HAVE AN ARROW

POINTING TO WHERE WE WERE AT

JANUARY COUNCIL, IN DECEMBER

2021.

THERE WERE 1.5 BILLION TESTS AND

TEST PRODUCTS WHICH WE THOUGHT

WAS SPECTACULAR AT THE TIME.

THIS HAS GROWN EVEN MORE.

IF WE LOOK THROUGH MARCH OF

2022, IT'S INCREASED TO

2.3 BILLION, DRIVEN IN PART BY

THE DRAMATIC EXPANSION OF THE

OMICRON VARIANT AROUND THAT

TIME.

SO, THIS REPRESENTS AS OF MARCH

ABOUT 260 MILLION TESTS AND TEST

PRODUCTS PER DAY THAT WE'RE

CONTRIBUTING TO, 44 EMERGENCY

USE AUTHORIZATIONS, NINE OVER

THE COUNTER, EIGHT OF THESE

ANTIGEN, ONE IS PCR AND RT LAMP

APPROACH.

THIS IS DRIVING A MAJOR PARADIGM

SHIFT, TECHNICALLY IN FEBRUARY,

ASTOUNDING, WHERE IF YOU GO BACK

TO WHEN THIS PROGRAM BEGAN IN

APRIL OF 2020 THE COUNTRY WAS

DOING LESS THAN 8 MILLION TESTS,

ALL LABORATORY TESTS.

AND IF YOU LOOK AT FEBRUARY OF

2022, THERE WERE OVER A BILLION

TESTS BEING DONE IN THE UNITED

STATES, AND ABOUT 1 BILLION OF

THEM WERE OVER THE COUNTER TESTS

THAT WERE PRIMARILY RAPID

ANTIGEN TESTS.

A FRACTION OF TESTS BEING DONE

IN LABORATORIES HAS STEADILY

DIMINISHED OVER TIME.

IF YOU LOOK ON THE RIGHT, YOU

UPPER RIGHT IN THIS PLOT, THE

TESTS REPORTED ARE PRIMARILY THE

LABORATORY TESTS, AND THESE ARE

CONSISTENTLY LESS THAN ABOUT 100

MILLION PER MONTH IN THE

SNAPSHOT FROM NOVEMBER TO MARCH

OF THIS YEAR.

WHILE THERE'S BEEN ENORMOUS

GROWTH IN OVER THE COUNTER

TESTS, ON A MONTH BY MONTH

BASIS, AND THIS HUGE NUMBER IN

FEBRUARY WAS DRIVEN BY OF COURSE

THE CONCERN OVER THE OMICRON

SURGE MADE POSSIBLE THROUGH OUR

EFFORTS AS JILL NOTED TO HELP

SUPPORT THE AUTHORIZATION OF

LARGE VOLUME MANUFACTURERS, MOST

OF WHICH FROM OUT OF THE UNITED

STATES.

AND THIS RAISES AN INTERESTING

QUESTION, BECAUSE IF A VERY

SMALL FRACTION OF TESTS ARE

ACTUALLY REPORTED, DO WE REALLY

HAVE AN UNDERSTANDING OF WHERE

THE PANDEMIC IS AND HOW FAST

IT'S MOVING?

SO LED BY ANDREW AND KRISHNA,

WE'VE BEEN WORKING ON DIGITAL

PLATFORMS FOR TWO YEARS BUT

THINGS ARE COMING TOGETHER

INCLUDING HAVING A SNAZZY

ACRONYM, MOBILE APPLICATION

RECORDING SYSTEM, MARS.

AND THE FIGURE ON THE BOTTOM

RIGHT GIVES YOU A PICTORIAL

REPRESENTATION OF WHAT THIS IDEA

IS, SO IT CAN TAKE ANY TEST

MANUFACTURER'S INFORMATION FROM

ANY APP , OR THIRD PARTY, APPLY

STANDARD DATA ELEMENTS, STANDARD

DATA STRUCTURE, AND THEN SEND IT

THROUGH THE AMERICAN PUBLIC

HEALTH LABORATORIES TO DATA

HUBS, WHICH CAN THEN TRANSMIT

THIS INFORMATION BOTH TO FEDERAL

HEALTH DATABASES, AS WELL AS

STATE HEALTH DATABASES.

SO THIS IS A REALLY IMPORTANT

ADVANCE.

THEY HAVE BEEN WORKING VERY

CLOSELY WITH ALL THE

MANUFACTURERS, AND IT'S

EXCITING, I-HEALTH ACCOUNTS FOR

300 MILLION TESTS IN THE UNITED

STATES ALONE A MONTH, AT LEAST

CERTAINLY IN THE MONTH OF THE

HIGHEST SURGE, IS THE FIRST ONE

ON BOARD, SO THEIR APP IS NOW

REPORTING IF YOU CHOOSE TO

SELECT THE REPORTING BUTTON, IT

WILL MOVE THROUGH THIS KIND OF

STRUCTURE, AND JUST IN THE FIRST

FEW DAYS WHICH THIS JUST

LAUNCHED LAST WEEK, WITH THE

I-HEALTH ACCESSIBILITY, ROUGHLY

30,000 TESTS THAT HAVE BEEN

REPORTED THROUGH THE I-HEALTH

APP.

WE WILL GO THROUGH ALL THE

MANUFACTURERS, AND NOT

SURPRISINGLY MANUFACTURERS ARE

EXCITED AND EAGER TO BE

PARTICIPANTS IN SOMETHING THAT

DOES FACILITATE A STANDARDIZED

FORMAT FOR COMMUNICATION OF TEST

RESULTS.

HAVING THAT MANY TESTS THAT ARE

BEING USED, AGAIN, ONE BILLION

TESTS DISTRIBUTED IN FEBRUARY IN

2022, CALLS INTO QUESTION LOTS

OF DISCUSSIONS ABOUT THE TEST

PERFORMANCE, HOW DO RAPID

ANTIGEN TESTS WORKING WITH

DIFFERENT VARIANTS.

HOW DO THE DIFFERENT TESTS

COMPARE TO ONE ANOTHER.

AND WE'VE BEEN SUPPORTING MORE

THAN 7,000 SUBJECT LONGITUDINAL

SERIAL ANTIGEN STUDY.

I'D LIKE TO SUMMARIZE A FEW OF

THE IMPORTANT OBSERVATIONS FROM

THIS.

THIS IS CENTERED AS JILL POINTED

OUT IN CLINICAL STUDIES CORE AT

THE UNIVERSITY OF MASSACHUSETTS,

AND YOU CAN SEE THESE ARE TWO

PLOTS OF RECEIVER OPERATOR

CURVES ON THE Y-AXIS IS THE

PROBABILITY OF A POSITIVE OVER

THE COUNTER TEST, X-AXIS ARE FOR

CT VALUES OF THE COMPARATOR

TESTS, IN THIS CASE RT-PCR FROM

ROCHE, AND THE PLOT ON THE LEFT

SHOWS FUNDAMENTALLY THAT ANTIGEN

TESTS WORK EQUALLY WELL WITH

OMICRON AND DELTA, IF YOU RECALL

THAT WAS A POINT OF CONCERN IN

DECEMBER OF LAST YEAR, WHEN THE

FDA FIRST POSTED ON THE WEBSITE

THAT IT'S POSSIBLE RAPID ANT GEN

TESTS MAY HAVE REDUCED

SENSITIVITY TO OMICRON.

WE'VE SHOWN THIS IS NOT A

CLINICAL SIGNIFICANT

OBSERVATION, AS YOU LOOK ACROSS

USERS AND PLATFORMS THIS REALLY

SHOWS OMICRON AND DELTA ARE

DETECTED WITH COMPARABLE

SENSITIVITY.

ON THE RIGHT ANTIGEN PLATFORMS

ARE COMPARABLE PERFORMANCE,

COMPARING IN THE PLOT ON THE

RIGHT BINAX, BD AND THE

QLIKVIEW.

DIGGING DEEPER, WHY PEOPLE WERE

OFTEN SO CONFUSED ABOUT THEIR

USE AND THINK THAT MAYBE THEY

DON'T WORK THAT WELL IS THE FACT

THAT THIS ROC CURVE IS AS ALL OF

YOU KNOW HIGHLY NON-LINEAR.

SO, FOR HIGH VIRAL LOADS, FOR

EXAMPLE FOR CT COUNTS THAT ARE

LESS THAN 25 OR 26, THIS IS

ROUGHLY ON THE ORDER OF ABOUT A

MILLION COPIES PER MIL, RAPID

INTENT GENERAL TESTS WORK WELL

WITH WITH THOSE GREATER THAN

80%, THE BAR FOR EMERGENCY USE

AUTHORIZATION.

LARGE CHANGES IN CT YOU CAN TO

THE RATE FAIRLY LARGE CHANGES,

ONLY MODEST IN PTA AT THAT

POINT.

BUT FOR INTERMEDIATE VIRAL

LOADS, 20 20 TO 30, CAN VARY

FROM 30% TO 80%, SMALL CHANGES

IN CT CAN LEAD TO LARGE CHANGES.

FOR LOW VIRAL LOADS, QUITE POOR

ON THE ORDER OF 15% TO 40%, AND

SMALL CHANGES IN CT IN THIS VERY

LOW REGION ARE LEADING TO ONLY

MODEST CHANGES IN PPA SO YOU

DON'T GET THAT MUCH OF AN

IMPROVEMENT UNTIL YOU ARE AT

VERY, VERY HIGH VIRAL LOADS.

SO THIS IS WHY WE AND EXPERTS

RECOMMEND IN THE CASE OF WEAK

POSITIVES, TO DO SERIAL TESTING.

AND THIS IS THIS HAS BEEN AN

IMPORTANT OBSERVATION THAT HAS

INFORMED THE FDA IN THE WAY THAT

THEY DO THEIR AUTHORIZATIONS.

SO, THE POSSIBILITY OF ANTIGEN

TEST TURNING POSITIVE AFTER A

WEEK RT-PCR IS INCREASING OVER

TIME, WITHIN 24 HOURS OF WEAK

POSITIVE, 50% REGION, WITHIN 48

HOURS THEY MOVE TO BETTER THAN

90%.

THAT'S REGARDLESS OF WHETHER

IT'S OMICRON OR DELTA, IN FACT

IN OUR DATA LOOKS LIKE OMICRON

PERFORMED ACTUALLY A LITTLE BIT

BETTER THAN DELTA.

SO THIS IS THE UNDERSCORED

IMPORTANCE OF SERIAL TESTING.

AND IF PEOPLE ARE ALWAYS

WONDERING THE FDA AUTHORIZATION,

HERE IS A SNAPSHOT OF THE

PUBLISHED AUTHORIZATIONS OF

DIFFERENT RAPID ANTIGEN TESTS,

I'VE HIGHLIGHTED TWO EXTREMES

THAT WE HELPED GET AUTHORIZATION

THROUGH OUR PROGRAM, BOSUN HAS A

PA 82.7, ROACH PPP 95.3, ARE

THESE REALLY VERY DIFFERENT IN

PERFORMANCE?

AND THE DEVIL IS IN THE DETAILS.

ON THE RIGHT YOU CAN SEE A PLOT

FROM THE BOWS UNAUTHORIZATION,

SHOWING PPA AS A FUNCTION OF

WEAK POSITIVE SUBJECTS, AND IF

YOU LOOK BETWEEN TEN AND TWENTY

OR TEN AND THIRTY PER CENT, DATA

THAT COMES FROM THE FDA'S

WEBSITE, INSTRUCTIONS FOR USE,

SHOWS THAT THE PPA ACTUALLY

DECLINES WITH INCREASING

FRACTION OF WEAK POSITIVES, AND

OF COURSE THIS IS EXPECTED WHEN

YOU CONSIDER THE ROC CURVES

NON-LINEARITY, IF YOU MIX IN

MORE WEAK POSITIVES IN YOUR

TOTAL POPULATION, YOU'LL HAVE

POORER AND POORER CLINICAL STUDY

PERFORMANCE.

SO, I THINK THE BIG INNOVATION

AND BIG ACHIEVEMENT IS THROUGH

OUR WORK WITH THE FDA, THEY HAVE

ALLOWED CONSIDERATION OF ALL OF

THIS DATA AND THEY MAKE AN

AUTHORIZATION CALL BASED ON 10%

OF WEAK POSITIVES.

AND THAT'S WHERE YOU SEE THE

82.7 PPA BUT IF YOU DID A STUDY

WITH A 30% REPRESENTATION OF

WEAK POSITIVES THEN YOU WOULD

SEE LESS THAN 70% PPA AND YOU

WOULD ACTUALLY NEVER GET TESTS

AUTHORIZED IF YOU HAD HIGH

FRACTION OF WEAK POSITIVES IN

YOUR CLINICAL STUDY DATA.

HERE'S THE 80% AUTHORIZATION

BAR.

IF YOU EXTRAPOLATE TO

APPROACHING 0% WEAK POSITIVE,

YOU SEE STRONG PERFORMANCE, 90

TO 95% CHANGE SO THESE PPAs

ARE MORE A REFLECTION OF THE

POPULATION OF WEAK POSITIVES

THAT WERE IN THOSE CLINICAL

STUDIES THAN THEY ARE OF THE

ANALYTICAL DIFFERENCES BETWEEN

THESE DIFFERENT TESTS.

SO, LET ME TRY TO SUMMARIZE WITH

SOME ONGOING CHALLENGES, WITH

THE DIGITAL HEALTH REPORTING

OVER THE COUNTER TESTS BEING

DISTRIBUTED AT SUCH SCALE, AND

TELEMED INFRASTRUCTURE, WE'RE

REALLY HOPING TO HAVE A KIND OF

DIAGNOSTIC-LED PRECISION

MEDICINE OCCUR AT HOME.

IT'S NOW POSSIBLE TO IMAGINE

TEST TO TREAT NETWORKS, WE KNOW

THESE ARE BEING BUILT FOR POINT

OF CARE TESTING AND TREATMENT,

IN BRICK AND MORTAR PHARMACIES,

BUT IT'S SOMETHING THAT WE

SHOULD EXPECT AND HOPE TO BE

ABLE TO ACCOMPLISH FROM YOUR

HOME.

THE SECOND IS TO IMPROVE

PERFORMANCE AND INFORMATION

CONTENT OF THESE TESTS, AS JILL

MENTIONED, SOME OF OUR FUNDING

IS TO IMPROVE ACCESSIBILITY,

IT'S REALLY DIFFICULT TO DO

THESE TESTS WITH IMPAIRMENT IN

VISION OR FINE MOTOR

COORDINATION OR COGNITIVE

IMPAIRMENTS, INSTRUCTIONS FOR

USE CAN BE COMPLICATED, THERE

ARE MANY STEPS TO FOLLOW.

AND THEY ARE SMALL HARD TO SEE

LINES FOR A LOT OF TESTS,

CERTAINLY ONES WITHOUT READERS.

AND WE CONTINUE TO HOPE TO

ADVANCE NEXT GENERATION

PERFORMANCE, SO THERE ARE A

NUMBER OF TESTS WE HAVE WITHIN

THE NETWORK THAT ARE STILL BEING

SUPPORTED, THAT WORK BETTER THAN

RAPID ANTIGEN TESTS, LATERAL

FLOW ASSAYS, BOTH FOR INDIVIDUAL

ANALYTES AS WELL AS MULTIPLEX

TESTS WITH EVEN VARIANT

CAPABILITIES, SO WE'RE

CONTINUING TO ADVANCE THIS AREA.

REGULATORY, WE'VE SEEN --

[AUDIO DISTORTION]

LIMITED LIFE, WE'RE LOOKING AT

CHALLENGES OF GETTING

MANUFACTURERS TO CONVERT TO FULL

CLEARANCE USING VARIETY OF

DIFFERENT PATHWAYS TO HAVE

LONG-TERM IMPACT AND ULTIMATELY

WE'VE BEEN VERY ENGAGED AS HAVE

PARTNERS ACROSS THE GOVERNMENT

IN PANDEMIC PREPAREDNESS AND

HAVE BEEN A KEY CONTRIBUTOR TO

THIS PLANNING, BUT UNCERTAINTY

WITH RESPECT TO CONTINUING

FUNDING ACROSS THE GOVERNMENT,

THAT'S CLEARLY AT RISK, AND

NOBODY HAS DEFINITIVE ANSWER FOR

THAT YET.

SO I WOULD LIKE TO CONCLUDE WITH

A BRIEF UPDATE ON ARPA-H.

WE'VE DISCUSSED THIS AT VARIOUS

TIMES IN COUNCIL.

HERE'S THE TIMELINE.

YOU'VE SEEN OSTP AND NIH

COMMENTARY IN "SCIENCE," YOU'VE

HEARD ABOUT CONGRESS PASSING IN

MARCH, THE OMNIBUS WITH

$1,000,000,000.000000000

AVAILABLE FOR THREE YEARS,

DIRECTOR TO BE APPOINTED BY

THEMENT.

BY THE PRESIDENT.

IN APRIL OF THIS YEAR ARPA-H WAS

TRANSFERRED TO NIH.

AND THAT'S SPECIFICALLY FROM THE

HHS DIRECTOR TO THE NIH, ARPA-H

DIRECTOR WILL REPORT TO HHS

SECRETARY WITH DOTTED LINE

REPORT, TO THE NIH DIRECTOR, AND

IN THE PRESIDENT'S FY23 BUDGET

REQUEST THERE'S AN ADDITIONAL $5

BILLION THAT WOULD ADD TO THE $1

BILLION THAT'S AVAILABLE TO GET

IT LAUNCHED, AND THAT'S

AVAILABLE FOR THREE YEARS.

AND THERE'S BEEN LOTS OF WORK

WITHIN THE NIH BY LEADERSHIP TO

REALLY IDENTIFY KEY ELEMENTS OF

HOW IT WILL WORK, AND I'M

SHOWING THESE EIGHT MAJOR

ELEMENTS BECAUSE, WELL, BECAUSE

THEY ARE FANTASTIC.

AND ALSO OVERLAP WITH HOW WE RUN

OUR PROGRAM AT NIBIB, SO IT'S

GOING TO BE A PROGRAM MANAGER

CENTRIC TYPE OF ORGANIZATION,

LEAN AND NIMBLE, HIGH RISK, HIGH

REWARD, TIME BOUND AND URGENT.

SO STAFF WILL WORK IN THREE TO

FIVE-YEAR TERMS, INCLUDING

LEADERSHIP OF ARPA-H, MISSION

DRIVEN, INDEPENDENT, AUTONOMOUS,

ACTIVE PROGRAM MANAGEMENT WITH

QUANTITATIVE METRICS AND

ULTIMATELY ACCOUNTABILITY WITH

TECHNICAL GATE AND STAGE GATING

FOR THEIR PROJECTS.

HERE'S THE TIMELINE FOR FUTURE

ACTIVITIES.

SO YOU CAN SEE THIS IS VERY

AMBITIOUS BECAUSE HERE IS WHERE

EVERYONE IS NOW, A SEARCH IS

GOING ON FOR AN INAUGURAL

DIRECTOR.

THERE MAY BE AN INTERIM DIRECTOR

WHO IS APPOINTED.

THIS SHOULD HAPPEN, KEEP YOUR

EYES OPEN FOR THIS IN THE NEXT

FEW MONTHS.

THERE WILL BE A SMALL NUMBER OF

PROGRAM MANAGERS WHO ARE ALSO

HIRED, AND OPERATIONAL TEAM WILL

BE BUILT.

OVERALL, WE ANTICIPATE ABOUT 100

FTEs WILL BE HIRED OVER THE

COURSE OF THE NEXT YEAR.

THE FIRST AWARDS AT LEAST ON THE

TIMELINE TARGETED HERE COULD BE

MADE AS SOON AS A YEAR FROM NOW

IN MARCH OF 23.

I WILL STOP WITH THAT, AND SEE

IF WE HAVE TIME FOR QUESTIONS.

>> I SEE MANU WITH A HAND
UP.

>> THANKS, BRUCE.

WHAT STUCK TO ME, RADx MARS

PROJECT, MUCH NEEDED, AS WE'RE

LOSING COUNTS ON THE

OVER-THE-COUNTER TESTS, NEW

HURDLE TO OVERCOME, I GUESS

MAYBE YOU MENTIONED THIS, ARE

THERE QUESTIONS ABOUT AUTOMATED

REPORTING, PRIVACY, RESISTANCE

TO A POSITIVE TEST,

DE-IDENTIFYING, IS ANY OF THAT

INCLUDED IN PLANS TO GET THE

MOST ROBUST DATA WITHOUT CLANS

FOR PEOPLE TO DECLINE?

>> YES, GREAT QUESTION.

THIS HAS BEEN A TOPIC OF

CONVERSATION SINCE THE VERY

BEGINNING.

THE DATA IS FULLY -- IT'S

VOLUNTARY IN TERMS OF REPORTING.

IT'S FULLY ANONYMIZED.

AND IT'S JUST BEEN KIND OF A

BATTLE FOR THE HEARTS AND MINDS

OF THE PUBLIC HEALTH AND

EPIDEMIOLOGY UNIVERSE TO SAY,

YEAH, HOME TESTING IS IMPORTANT.

IF YOU RECALL, THE GROWTH OF

HOME TESTING, EVEN IF YOU GO

BACK TO THE PREVIOUS COUNCIL

MEETING THERE WAS NOTHING QUITE

AS SPECTACULAR AS WHAT WE SAW IN

JANUARY.

THAT JOLTED A LOT OF PEOPLE INTO

REALIZATION AND NOW WE'VE SEEN A

NEWS REPORTS SAYING OH MY GOSH,

ALL THE TESTING IS BEING DONE AT

HOME, AND WE HAVE NO IDEA WHAT

THE CASES ARE.

SO, THAT'S HELPED STRENGTHEN OUR

ARGUMENTS.

WE'VE SEEN A CONVERSION

ESPECIALLY IN CDC, I WOULD SAY

LABORATORY AND COMMUNITY WAS

KNISH LIP OUT OF THE GATE REALLY

OPPOSED TO THE IDEA OF HOME AND

OVER THE COUNTER TESTING, THEY

SHOULD BE ORDERED BY PHYSICIANS

IN LABORATORIES WITH DATA

ELEMENTS WE ALL UNDERSTAND.

WE WENT TO THE SAME

ORGANIZATION, AMERICAN PUBLIC

HEALTH LABORATORIES, TO DO THE

ACTUAL MESSAGING A CONTRACT WITH

APHL HANDLING THE MESSAGING

ITSELF, SENT TRANSMITTING THE

DATA, WE'VE EXECUTED A CONTRACT

WITH THEM THAT HELP JUMP START

STUFF.

BUT THIS IS -- IT'S A

SPECTACULAR ACCOMPLISHMENT I

THINK.

AND HOPEFULLY WE CAN BUILD ON

THIS AND GROW BECAUSE THESE

COMMON DATA ELEMENTS AND THIS

DATA STRUCTURE HL7 AND FHIR THIS

IS WHAT WE NEED FOR HOME

TESTING, PERIOD.

IT HASN'T EXISTED BEFORE.

>> SIMON AND THEN KATHY.

>> I WANT TO TAKE US BACK
TO

JILL'S PRESENTATION ON THE

BUDGET TOWARDS THE BEGINNING.

IT'S GREAT THE PAYLINE IS UP AT

19% FOR R01s, MORALE BOOSTING,

CLOSE TO 10% IT'S A DEPRESSING

SITUATION SO I THINK THAT'S

REALLY WONDERFUL.

I DID WANT TO SORT OF RAISE A

LITTLE DISCUSSION ABOUT THE 15%

CUT.

I UNDERSTAND THE RATIONALE BUT

GET THE SENSE FROM TALKING TO

FOLKS A COUPLE WAYS PEOPLE

APPROACH THIS.

THE SEASONED INVESTIGATORS, THIS

CUT IS PUBLISHED, RIGHT?

THEY KNOW IT'S COMING.

WHEN THEY WRITE PROPOSALS THEY

BUILD CONTINGENCIES TO ABSORB

THAT CUT, I SUSPECT IT LEADS TO

PEOPLE INFLATING BUDGETS A BIT.

CONCERN I HAVE THOUGH I THINK

THIS IS A DISADVANTAGE PERHAPS

FOR THE LESS SEASONED

INVESTIGATORS, JUNIOR FOLKS WHO

PERHAPS DON'T KNOW THIS AS WELL.

AND I'VE HAD EXAMPLES OF PEOPLE

COMING TO ME AND SAYING, YOU

KNOW, I CAN'T DO THE WORK NOW.

I PLANNED A VERY REALISTIC

BUDGET, EXPENSIVE PIECE OF

EQUIPMENT IN MY BUDGET, WHICH

NOW I DON'T THINK I CAN BUY,

THIS REALLY IS A MAJOR ISSUE.

AND SO, YEAH, I HAVE A CONCERN

PERHAPS NOT A LEVEL PLAYING

FIELD, PERHAPS BY DOING THIS

WE'RE DISADVANTAGING THE

YOUNGEST INVESTIGATORS WHO TRY

AND BUDGET VERY HONESTLY AND

DON'T KNOW THIS CUT IS COMING.

>> SO DIFFERENT INSTITUTES
HAVE

DIFFERENT POLICIES WITH STANDARD

ADMINISTRATIVE CUTS, FOR NIBIB

THE 15% CUT TO LARGE R01s AND

U01s EXCLUDES EARLY-STAGE

INVESTIGATORS.

WE LEAVE THOSE BUDGETS ALONE AND

APPLY THEM ONLY TO ESTABLISHED

INVESTIGATORS.

>> VERY GOOD TO HEAR, I
DIDN'T

KNOW THAT.

>> YOU KNOW, I WOULD ALSO

ENCOURAGE IF YOU ALL AS LEADERS

IN YOUR UNIVERSITIES AND FIELDS

ENCOUNTSER PEOPLE WHO ARE FACING

DILEMMAS, WE HAVE AN INCREDIBLE

GROUP OF PROGRAM DIRECTORS,

PLEASE REACH OUT TO THEM AND

BRING THESE ISSUES UP.

THEY MAY HAVE IDEAS.

THEY ALWAYS HAVE IDEAS.

THAT'S FOR SURE.

>> THANK YOU, SIMON.

AS WELL, JILL.

KATHY?

>> YES, THANK YOU.

I HAVE TWO QUESTIONS.

THEY ARE NOT RELATED.

AND, AGAIN, IT'S SO IMPRESSIVE

TO ME THE IMPACT THAT NIBIB HAS

HAD PARTICULARLY IN THE PANDEMIC

RESPONSE, VERY EXCITING.

MY TWO QUESTIONS, ONE FOLLOWS ON

MANU'S BUILDING ON WHAT MANU

SAID, I'M CURIOUS IF THERE'S A

WAY TO SOMEHOW ADD INCENTIVE,

BECAUSE MY UNDERSTANDING FROM

WHAT YOU PRESENTED, PEOPLE HAVE

TO DOWNLOAD AN APP, UPLOAD

RESULTS VOLUNTARILY, AND I JUST

THINK THAT THERE'S -- IF THERE'S

A WAY TO INCENT PEOPLE, IF THERE

WERE SOME POSITIVE SOMETHING

PEOPLE GOT NOT JUST FROM SHARING

THEIR TEST RESULTS BUT MAYBE

BEING NOTIFIED AS SUMMARY PLOT

FROM THE AREA, INFORMATION IN

THE AREA, SOMETHING TO HELP

MOTIVATE THEIR PARTICIPATION,

I'M NOT SURE WHAT IT WOULD BE

BUT THAT MIGHT REALLY HELP

PEOPLE TO PARTICIPATE THERE.

I DON'T KNOW IF PEOPLE ARE

CONSIDERING INCENTIVIZING OR

NOT.

THAT WAS QUESTION ONE.

AND QUESTION TWO WAS FOLLOWING

ON YOUR EUA CONVERSION, NOT

RELATED, QUESTION TWO, IT'S

REALLY EXCITING YOU'VE WORKED

WITH THE FDA AND IMPACTED HOW

THEY ARE APPROVING THINGS.

THAT IS TERRIFIC.

BUT I'M WONDERING ON THE

CONVERTING EUAs TO PERMANENT

APPROVALS OF THE TESTS, YOU

LISTED SEVERAL, DE NOVO, PMA,

ALL THE DIFFERENT APPROACHES,

WONDERING IF THE PLAN TO GIVE

KIND OF A GUIDANCE OF THIS IS

THE BEST WAY TO CONVERT MOVING

FORWARD?

SO THAT IT BECOMES LESS COMPLEX

FOR COMPANIES?

I THINK THAT WOULD HELP

ACCELERATE THE PROCESS.

THANKS.

>> THANKS, KATHY.

YES.

YES, YES, YES TO ALL OF THESE.

FOR SURE INCENTIVES, WE DID

EXPERIMENT.

WE GAVE INCENTIVES WHEN WE

ROLLED OUT SAY YES COVID TEST

PROGRAM TO INSPIRE PEOPLE TO

REPORT.

WE ARE HOPEFUL THAT WE'VE BEEN

WORKING ALL ANGLES AND AS MUCH

PRESSURE AS WE CAN PUT, I DON'T

KNOW IF YOU'VE GONE TO THE

COVID.GOV WEBSITE.

SO, THIS IS WHERE YOU CAN GO FOR

YOUR FREE TEST DISTRIBUTION,

IT'S BEEN AN ENORMOUSLY POPULAR

AND HIGHLY TRAFFICKED WEBSITE.

I'VE BEEN ASKING FOR A BUTTON

SINCE IT WAS LAUNCHED, SEEMS SO

LOGICAL BUT WELCOME TO

COMPLEXITY OF OWNERSHIP OF

WEBSITES.

AND SOME PERHAPS IRRATIONAL

FEARS ABOUT, YOU KNOW, THE

GOVERNMENT TAKING YOUR

INFORMATION AND THOSE SORTS OF

THINGS, SO WE'RE STILL WORKING

ON THAT AVENUE.

I BELIEVE THAT THAT WOULD BE

ENORMOUS.

IT WOULD BE SO POWERFUL.

SOME OF THE APPS ARE INTEGRAL TO

THE REPORTING SYSTEM.

SO, PEOPLE ARE ALREADY USING

THEM WITH SOME OF THE

MANUFACTURERS, FOR EXAMPLE, IL

ILLUME, SYNCHRONIZES TO USUAL

SMARTPHONE.

WE'RE WORKING ON ALL ANGLES,

TRYING TO OVERCOME BIASES ABOUT

HOW ALL THIS WORKS, WE'VE COME

VERY FAR.

WHEN I FIRST STARTED TALKING

ABOUT PEOPLE JUST SAID WHY WOULD

ANYBODY WANT THEIR HOME TEST

REPORTED?

I SHOULD NOTE THERE'S SOME

REALLY INTERESTING THINGS THAT

HAPPENED IN THE COUNTRY, SOME OF

YOU MAY HAVE FOLLOWED WHAT

HAPPENED IN UTAH.

CMS INVESTIGATION, WHISTLEBLOWER

WHO SHOWED TENS OF THOUSANDS OF

TESTS AT POINT OF CARE SETTINGS

BY THE COMPANY CONTRACTED FOR

THE STATE PUBLIC HEALTH

AUTHORITIES THERE WERE

COMPLETELY WRONG.

IT WAS AN OPERATIONS AND

LOGISTICS NIGHTMARE.

THERE'S NOT A LOT OF WIDESPREAD

PUBLICITY BUT IT UNDERSCORES

DOING A TEST AT HOME RATHER THAN

GETTING IN A CAR LINE WHERE

PERHAPS YOU'RE UNDERSTAFFED AND

MAYBE NOT PAYING ATTENTION TO

THE INSTRUCTIONS FOR USE, YOU

HAVE MUCH MORE STAKE IN IT AT

HOME.

SO, THE HOME TESTS PEOPLE HAVE

SPOKEN, PEOPLE WOULD LIKE TO

HAVE HOME TESTS, EVEN WITH ALL

OF THEIR COMPLEXITIES AND

DIFFICULTIES.

AND I WOULD TRUST THOSE MUCH

BETTER PERHAPS THAN IN SOME

POINT OF CARE SETTINGS, EXACTLY

THE SAME TEST.

FOR THE SECOND PART ON THE FDA

APPROVAL, SO TELL ME AGAIN THE

SPECIFIC CONCERN?

>> WELL, THERE ARE JUST
MANY

DIFFERENT AVENUES, EACH WITH

DIFFERENT EXPERIENCE.

YOU COULD NAVIGATE STREAMLINING

THAT TO SAY IF YOU HAVE EUA

APPROVAL FOR AT-HOME TEST YOU

SHOULD DO, YOU KNOW, THE DE

NOVO.

>> YES.

>> IF COULD YOU MAKE A
PATHWAY

THAT EVERYONE COULD PURSUE AS

OPPOSED TO HAVING SO MANY

OPTIONS.

>> ABSOLUTELY.

SO, THAT IS OUR ABSOLUTE GOAL.

YOU'RE COMPLETELY ALIGNED WITH

US.

WE WANT TO STREAMLINE STUFF.

FDA DOESN'T ALWAYS DO OUT OF THE

BOX WHAT WE WANT THEM TO DO.

SO WE LEARNED THAT.

ZANE IS SMILING, KNOWINGLY.

I THINK ONCE WE GET THIS REALLY

FULLY SYNCHRONIZE AND LAUNCHED,

AND HAVE ACTIVE MEETINGS ON THIS

EVEN AS WE SPEAK, WE WILL BE

ABLE TO IDENTIFY THE MOST

EFFICIENT PATHWAYS.

NOTHING WILL BE ABSOLUTELY

STREAMLINED.

I CAN TELL YOU THAT.

ONCE YOU GO TO FULL

AUTHORIZATION, THERE ARE HIGHER

LEVEL OF BARS.

AND THOSE ARE PARTICULARLY

CHALLENGING AS YOU SEE

PREVALENCE DROPPING.

AND CLINICAL STUDIES COULD

REALLY REQUIRE QUITE A LOT OF --

THEY COULD BE VERY COSTLY SO

WE'LL BE DOING EVERYTHING WE CAN

TO WORK WITH MANUFACTURERS TO

DISSEMINATE METHODS AND

PRACTICES, TO REDUCE MYSTERY OF

IT.

I'M GUESSING THAT MUCH WILL TAKE

PLACE THROUGH THE 510(K) PROCESS

BUT IN VITRO DIAGNOSTICS I'VE

HAD EXPERIENCE BEFORE AND DIDN'T

REALIZE THAT THEY ARE TREATED

DIFFERENTLY IN THEIR 510(K)

PROCESS THAN SORT OF TRADITIONAL

MEDICAL DEVICES THAT I KNOW YOU

AND I AND MANY OF YOU ON THE

CALL HAVE BEEN INVOLVED IN, IN

THE SENSE OF PREDICATE, THE

PREDICATE COMPARATOR.

I WON'T GO INTO DETAILS.

WE CAN TALK OFFLINE.

I'VE LEARNED MORE THAN I WOULD

LIKE TO KNOW.

AND IT'S GOING TO BE A CHALLENGE

FOR SURE.

>> CAN I JUST ADD TO THAT,

BRUCE, YOU KNOW, THE FDA HAS

RESOURCES IN PLACE WHERE YOU CAN

GO AND FIND OUT ABOUT THE

VARIOUS MECHANISMS.

YOU CAN ALSO, I WOULD STRONGLY

SUGGEST, THAT COMPANIES START

ASKING AND COME IN EARLY AND

START ASKING THOSE QUESTIONS

ABOUT WHICH MECHANISM THEY ARE

GOING TO NEED TO USE.

THE EUAs, ALL OF THOSE DEVICES

CAME THROUGH WITH LESS

INFORMATION THAN WHAT WOULD

TRADITIONALLY BE REQUIRED.

THERE'S A SAFETY RISK, LONG TERM

USE, WE'VE GOT TO SHOW THAT

THAT'S, YOU KNOW, THAT WE'VE

ADDRESSED THAT IN THE LONGER

TERM OF THIS.

SO THERE ARE MECHANISMS IN PLACE

BY WHICH YOU CAN ASK QUESTIONS

RIGHT NOW, TODAY, AND START

DEVELOPING YOUR FRAMEWORK, AND

INFORMATION YOU NEED.

YOU'RE DEVELOPING AS YOU HAVE

YOUR DEVICE IN THE MARKET

ALREADY.

>> YEAH, BUT, YOU KNOW,
THERE'S

ANOTHER INTERESTING POINT TO

THAT THOUGH, ZANE, THE EUAs

ARE LIKE PRE-MARKET APPROVALS IN

A SENSE, AND SO WE'VE CONDUCTED

EXTENSIVE POST MARKET STUDIES.

I GIVE A SNAPSHOT FROM THE

UMass STUDY OVER 7,000

INDIVIDUALS BINAX, QLIKVIEW, BD,

ENORMOUS VAST AMOUNTS OF DATA

WITH COMPARATOR, SO YOU WOULD

THINK MAYBE THE FDA COULD ACCEPT

THAT AND THEN BRING THEM IN

THROUGH ESSENTIALLY A PMA WITH

THAT DATA.

SO WE'VE ASKED.

AND WE'RE NOT GIVING UP.

AND THEY WILL BE EVALUATING.

IF WE CAN GET THAT GOING AND GET

A DE NOVO WITH THOSE, THAT WOULD

REALLY HELP ADVANCE AND

ACCELERATE THINGS.

>> MARYELLEN?

>> YES, I WANT TO MAKE A
NOTE ON

THE MIDRC, I'M ROTATING OFF, I

WANT TO GIVE A PUBLIC THANK YOU

TO NIBIB FOR THEIR LEADERSHIP

AND SUPPORT.

MIDRC COULD NOT HAVE HAPPENED

WITHOUT THAT.

AND AS WE BUILT THE PLANE WHILE

FLYING IT, WE'VE ACCOMPLISHED A

LOT, WE HAVE A LOT MORE STILL TO

ACCOMPLISH.

I'M HAPPY TO REPORT ON THAT ON

THAT FINAL NUMBER OF CURRENT

IMAGING STUDIES, YOU CAN ADD

5,000 TO THAT NUMBER NOW.

WE JUST HAD A BIG PUSH.

AND LOOKING FORWARD TO MORE

ADVICE AND LEADERSHIP FROM NIBIB

ON IT.

THANK YOU.

>> THANK YOU.

IT'S THE PROGRESS JUST IN THE

LAST QUARTER HAS BEEN STUNNING.

IT'S JUST REALLY TAKEN OFF.

THE EFFORT OF EVERYONE IS COMING

THROUGH.

EXCITED TO BE PART OF IT.

SO THANK YOU FOR ALL YOUR WORK.

YES, LOOKING FORWARD TO MORE

DISCUSSIONS.

>> THANK YOU, MARYELLEN.

RANU?

>> BRUCE, A LOT OF
INFORMATION,

FANTASTIC INFORMATION, AND

DELIVERED VERY COHERENTLY AND

UNDERSTANDABLY TO ALL OF US.

QUESTION FOR YOU, AS I'M LOOKING

AT THE NEW ARPA STUFF COMING ON

HERE, ONE I KNOW THE STAGE GATED

APPROACH WHICH YOU'RE EXPERTS AT

BUT ARE WE LOOKING AT

PARTNERSHIPS HERE LIKE TALKING

WITH NSF AND THINGS HAPPENS,

MARCH 2023, THEY ARE SAYING

FIRST CALLS THAT ARE COMING OUT,

ARE WE LOOKING AT MAYBE EARLY

ENGAGEMENT FOR THIS ARPA-H MODEL

THAT WE ARE, YOU KNOW, CON

JOINTLY SUPPORTING PROGRAMS, FOR

EXAMPLE THE MED TECH PROGRAM

THAT HAS STAGE GATED AND MOVING

FORWARD?

>> THAT'S A REALLY GOOD

QUESTION, RANU.

I STILL -- I KIND OF FEEL

LIKE -- IT'S STILL TO BE

WRITTEN, THAT THE BIG

OPPORTUNITIES FOR ARPA-H WILL BE

FOR OUR COMMUNITY, SO WE ARE

COMMUNITIES ENGAGED IN DESIGN

BUILD TEST PROJECT, ARPA WILL

SUPPORT THAT.

I DON'T KNOW IF THERE WILL BE

THAT MUCH INTERMINGLING OR

INTERMIXING OF RESOURCES AND

MANAGEMENT.

I THINK THERE'S A LOT OF

ATTENTION BEING PAID TO --

BECAUSE YOU HEAR A LOT OF VOCAL

CRITICISMS ABOUT ARPA-H, NEVER

AT THE NIH, AND SO I THINK THE

DESIGNERS OF THE ARPA-H PROGRAM

ARE REALLY BEING CAREFUL, NOT TO

HAVE IT APPEAR TO BE YET ANOTHER

NIH PROGRAM AS USUAL.

I THINK IT WILL BE STOOD UP WITH

ITS OWN SORT OF INDEPENDENT

IDENTITY.

THAT JUST HAPPENS TO NEED OUR

COMMUNITY TO RESPOND.

AND TO BE ACTIVE.

I DON'T KNOW IF THERE WILL BE

TOO MANY INTERACTIONS OR

COLLABORATIONS WITH NIBIB PER SE

OTHER THAN STRATEGIC DISCUSSIONS

OR SHARING OF EXPERTISE BUT

FUNDAMENTALLY IT'S OUR

COMMUNITY.

SUSAN'S COMMUNITY, ENGINEERING

DIRECTORATE AT NSF AND OUR

COMMUNITY, NIBIB COMMUNITY, I

HOPE WILL BENEFIT.

SO WHEREVER IT GOES, WHETHER

IT'S NIH OR WHO KNOWS IF

THERE'S -- THIS IS NOT WRITTEN

IN STONE YET.

IT'S STILL A POINT OF DISCUSSION

AND YOU'VE HEARD SOME VERY VOCAL

OPPONENTS IF OF IN CONGRESS TO

ULTIMATE ESTABLISHMENT AT NIH.

I THINK OTHER INSTITUTES THAT

HAVE NETWORKS, FOR EXAMPLE, FOR

CLINICAL STUDIES IN PLACE MOST

NOTABLY NCI AND NCATS AND NIAID

AND NHLBI MAY BE MAY THE MORE

BENEFICIARIES, FAST TRACKED TO

ROLL OUT THERAPEUTIC OR

DIAGNOSTIC TECHNOLOGIES FOR

RAPID ASSESSMENT.

STILL TO BE DETERMINED.

BUT I THINK FUNDAMENTALLY IT'S

OUR PEOPLE THAT ARE GOING TO

BENEFIT A LOT.

>> THANK YOU.

>> THAT'S ALL THE HANDS
THAT ARE

RAISED.

SHALL WE TRANSITION TO OUR BRAIN

REPORT FROM BRUCE ROSEN?

>> ABSOLUTELY.

>> OKAY.

VERY GOOD.

WE'LL HAVE A BRAIN UPDATE FROM

BRUCE ROSEN, OUR REPRESENTATIVE

TO THE BRAIN.

THANK YOU, BRUCE.

>> THANKS VERY MUCH.

THIS REPORT IS A BOOK END TO MY

EXPERIENCES ON THE COUNCIL.

I ACTUALLY AT MY INTRODUCTION TO

THE COUNCIL BEFORE I WAS A

MEMBER BUT IN PROVIDING A BRAIN

UPDATE, AND OF COURSE THIS IS MY

LAST PRESENTATION SO I'M VERY

HAPPY TO DO THAT AND I'M SURE

YOU'RE LOOKING FORWARD TO SOME

FRESH BLOOD WITH THIS.

LET ME GO AHEAD AND SHARE MY

SLIDES.

AND PUT THAT INTO FULL SCREEN.

OUR TIME IS SHORT.

APOLOGIES UP FRONT.

I'LL TRY TO MOVE THROUGH RATHER

QUICKLY.

LET'S GO.

SORRY.

ONE THING I DID WANT TO JUST

MENTION, BRAIN IS AT THIS POINT

ALL OF YOU I KNOW, IS REALLY A

COLLABORATIVE ADVENTURE FROM A

LARGE NUMBER OF INSTITUTES, AND

YOU CAN SEE THE LIST OF PROGRAM

PEOPLE FROM ACROSS THE

NEUROSCIENCE ORIENTED INSTITUTES

INVOLVED.

OF COURSE, NIBIB IS VERY WELL

REPRESENTED AMONGST THIS GROUP.

AND THESE PROGRAM OFFICERS ARE

ORGANIZED IN A NUMBER OF TEAMS,

EVERYTHING FROM INDIVIDUAL CELLS

AND CIRCUITS TO DATA,

INFORMATICS, AND NOW A NEW TEAM

FOCUSED ON THE NON-HUMAN PRIMATE

MARMOSET MODELS.

BUDGET-WISE THIS HAS BEEN A

SUCCESS STORY FROM BRAIN'S

PERSPECTIVE.

>> BRUCE?

>> YEAH?

>> DAVID GEORGE.

MAY I INTERRUPT?

I'M SEEING A ZOOMED IN VERSION.

I DON'T KNOW IF OTHERS CAN

COMMENT, LIKE ABOUT THE TOP 50%

LEFT OF YOUR SLIDES.

PERHAPS YOU COULD SHARE AND

UNSHARE AND MAYBE IT WILL COME

IN.

>> ARE YOU IN PRESENTATION
MODE?

>> THAT'S BETTER.

WE CAN SEE YOUR NOTES BUT WE CAN

SEE THE SLIDES.

>> LET'S LEAVE IT IT THAT
WAY.

SORRY ABOUT THAT.

>> NO WORRIES.

>> SURE.

>> JUST TO NOTE WHEN
"BRAIN" WAS

FIRST CONCEPTUALIZED, THE HOPE

WAS, AND REALLY JUST A HOPE,

THEY WOULD REACH SOMETHING CLOSE

TO $500 MILLION A YEAR.

AND REMARKABLY THEY HAVE MANAGED

TO HIT THAT TARGET.

AND AS YOU CAN SEE FUTURE YEARS,

THERE'S ESTIMATED TO BE A

SIGNIFICANT BUMP UP.

I'LL TALK A LITTLE BIT LATER

ABOUT HOW THOSE RESOURCES WILL

BE USED, BUT IT'S BEEN

IMPRESSIVE THAT THE GROUP HAS

MANAGED TO GET THE MANDATE FROM

MANY SOURCES TO BE ABLE TO HIT

ITS ORIGINAL TARGET OF HALF A

BILLION A YEAR FUNDING.

THERE HAVE BEEN A NUMBER OF

WORKSHOPS THE "BRAIN" GROUP HAS

ORGANIZED OVER THE YEARS.

AND SOME ESPECIALLY RECENTLY,

SUSAN, WE MAY HAVE TALKED ABOUT

IT THE LAST COUNCIL, I WON'T

REVIEW, IS SERIES OF WORKSHOPS

ON THE HUMAN CELL CENSUS, WE'LL

TALK ABOUT THAT, AND BRAIN

CONNECTIVITY, BOTH RELATE TO THE

GOALS THAT WILL COME UP LATER.

OF COURSE THERE WAS A SERIES

FOCUSED ON NON-INVASIVE IMAGING

TECHNOLOGIES LED BY NIBIB

PROGRAM CENTER, STAY TUNED TO

THIS, THERE MAY WELL BE A

PROGRAM ANNOUNCEMENT THAT WILL

COME OUT FROM THIS WORK IN THE

FUTURE BUT THIS I THINK LAST ONE

WILL BE OF CERTAIN INTEREST TO

NIBIB COMMUNITY.

MORE RECENT WORKSHOPS, ONE ON

QUANTIFICATION OF MEASUREMENTS

OF BEHAVIOR, AND SECOND FOCUSED

ON IMAGING THE BRAIN ACROSS THE

LIFESPAN.

BOTH OF THESE WILL ALSO HAVE

RELEVANCE TO OUR COMMUNITY.

CERTAINLY IN THE BRAIN BEHAVIOR

LINKAGE, ONE OF THE GOALS IS TO

BE ABLE TO CAPTURE NEURAL

ACTIVITY AND BEHAVIORS IN REAL

TIME AND USE THIS TO DEVELOP

CLOSED LOOP MODELS.

THIS CERTAINLY IS DOMAIN WHERE

NOVEL TOOL DEVELOPMENT WILL BE

CRITICAL.

HERE'S JUST AN EXAMPLE OF SOME

OF THE WORK THAT HAS BEEN GOING,

ONGOING HERE, AND YOU CAN SEE

THAT THEY VISUALIZE THIS VERY

MUCH FOCUSED ON TECHNOLOGICAL

NEEDS FOR MINIATURIZATION,

CLOSED LOOP, NOVEL SENSORS, DATA

SYNCHRONIZATION, AS WELL AS

COMPUTATIONAL FRAMEWORK, NIBIB

PROGRAM OFFICER GRACE TANG HAS

BEEN ACTIVELY INVOLVED IN THIS

WITH BOTH DATA INFRASTRUCTURE,

MACHINE LEARNING, A.I.

APPROACHES, ET CETERA.

OUR COMMUNITY HAS A LOT TO OFFER

THIS PROGRAM.

I JUST DID WANT TO SHOUT OUT FOR

BRUCE TROMBERG THE IMPORTANCE OF

OPTICAL TECHNIQUES, IN THESE

MEASUREMENTS, THIS IS A NICE

EXAMPLE RECENTLY PUBLISHED IN

NEURON, OPTICAL TOMB TO MEASURE

BOTH BEHAVIOR AND CIRCUIT

FUNCTION, WITH DIRECT RECORDING

OF NEURONAL BEHAVIOR, AS WELL AS

BEHAVIOR OF THE ANIMAL

MACROSCOPICALLY, ALL USING

OPTICAL SENSING TECHNIQUES.

ACROSS THE LIFESPAN IS ANOTHER

DOMAIN THAT BRAIN IS MOVING

TOWARDS.

I HIGHLIGHTED HERE THINGS AGAIN

OF INTEREST TO THIS COMMUNITY.

AGAIN, THEY ARE INTERESTED AT

TOOLS AND METHODS TO MEASURE

CHANGING CELL ACTIVITY,

CONNECTIVITY, AND ACTIVITY OVER

TIME LONGITUDINALLY, AND OF

COURSE TO TRANSLATE THIS INTO

HUMANS REQUIRES THE USE OF

NON-INVASIVE TECHNIQUES.

FURTHER WANT TO EXTEND TO FETAL

AND NEONATAL IMAGING AGAIN,

DOMAINS THAT NIBIB HAS BEEN

SPONSORING TECHNOLOGY

DEVELOPMENT IN OVER THE YEARS.

AND I THOUGHT IT WAS INTERESTING

THAT JOHN NGAI, THE MOST RECENT

MEETING ALSO, GAVE A SHOUT OUT

TO ULTRA LOW FIELD M.R.'S

POTENTIAL TECHNOLOGY, AND THIS

IS ANOTHER DOMAIN THAT'S BEEN

PIONEERED BY NIBIB AND ITS

INVESTIGATORS.

THIS SHOULD BE A WONDERFUL

APPLICATION OF THAT NOVEL

TECHNOLOGY.

BRAIN HAS BEEN WORKING ON A

NUMBER OF INFORMATICS RELATED

INITIATIVES.

ONE, SO CALLED BRAIN WORKS IS TO

TRY TO ORGANIZE ALL OF THIS DATA

AND I PULLED UP THIS PICTURE

THEY SHOWED TO POINT OUT THE

RELEVANCE, YOU NOTICE THE MOST

PROMINENT DOMAINS HERE, MAGNETIC

RESONANCE IMAGING BEING ONE, AND

THAT ALSO INCLUDES OTHER BRAIN

MAPPING METHODS LIKE

ELECTROPHYSIOLOGY, TECHNIQUES

FOR BRAIN MAPPING, OPTICAL BASED

TEX TECHNIQUES AND

OPTOGENETICS, AND A SHOUT OUT TO

ENGINEERING PRINCIPLES, SIGNAL

TO NOISE MADE IT TO THE LIST,

SOMETHING OUR COMMUNITY OF

COURSE UNDERSTANDS QUITE WELL.

FINALLY THE FOCUS OF THE BRAIN

INITIATIVE ON TOOL BUILDING HAS

PUSHED THEM TO DEVELOP TOOLS TO

ALLOW EASY ACCESS TO THE WIDE

RANGE OF TOOLS THAT ARE BEING

DEVELOPED FROM "BRAIN," AND THIS

TOOL MAKERS'S RESOURCE IS BEING

STOOD UP TO BRING IN ONE PLACE A

VERY WIDE VARIETY OF

COMPUTATIONAL TOOLS.

ANOTHER REALLY INTERESTING AND

COMPLICATED FACET OF THE BRAIN

INITIATIVE IS THE ETHICAL

IMPLICATIONS FOR THE ABILITY TO

UNDERSTAND THE HUMAN BRAIN AND

ITS LINKS TO BEHAVIOR.

FROM THIS HAS COME DEVELOPMENT

OF NEUROET ETHICS WORKING GROUP,

ONE THAT'S ESPECIALLY

INTERESTING, THEY HAD A

COMPETITION TO ENCOURAGE HIGH

SCHOOL STUDENTS TO DESCRIBE IN

BRIEF ESSAYS OR VIDEOS ETHICAL

IMPLICATIONS OF EMERGING BRAIN

TECHNOLOGIES.

AND ALTHOUGH THIS IS AS YOU CAN

SEE THE DATE OF SUBMISSION IS

COMING ON, I THINK IT'S JUST ONE

WAY TO HIGHLIGHT THE IMPORTANCE

THAT THE ETHICAL CONSIDERATIONS

HAVE IN THE BRAIN INITIATIVE'S

WORK.

LIKE ALL NIH INSTITUTES,

IMPROVING DIVERSITY, EQUITY, AND

INCLUSION, BRAIN HAS A NUMBER OF

INITIATIVES, TARGETING TRAINING

OF NEXT GENERATION OF SCIENTIFIC

LEADERS, BRINGING IN NEW

PARTNERSHIPS, FOSTERING A MORE

INCLUSIVE ENVIRONMENT, I'LL JUST

POINT OUT ONE INTERESTING FACT

WHEN I SAW THE SLIDES LOOKING

THROUGH THE DIVERSITY THAT

ENGINEERING EXPERTISE IS

CONSIDERED PART OF THE DESIRE

FOR INCREASING DIVERSITY WITHIN

THE BRAIN COMMUNITY, AND AT 33%

NOT DOING BADLY BUT GIVEN THE

FOCUS ON TOOL BUILDING FOR BRAIN

I THINK IT'S A DOMAIN WE COULD

PROBABLY IMPROVE UPON.

BUT I DID WANT TO TALK ABOUT ONE

INITIATIVE THAT I THOUGHT WAS

ESPECIALLY INTERESTING THAT

"BRAIN" HAS BEEN PUSHING, THIS

IS THIS PLAN FOR ENHANCING

DIVERSE PERSPECTIVES, NOW A

REQUIREMENT ON NINE OF THE

DIFFERENT BRAIN INITIATIVE

FELLOWS, AND YOU ALSO SEE THAT

SEVERAL OTHER INSTITUTES, BOTH

COMMON FUND AND NIBIB, ARE ALSO

NOW REQUIRING THIS PLAN FOR

ENHANCING DIVERSE PERSPECTIVE

REQUIREMENT IN THEIR GRANTS.

I CAN SAY THAT THIS IS A NEW

INITIATIVE, BUT THE PROGRAM

PEOPLE HAVE BEEN WORKING

ACTIVELY TO HELP GUIDE

INVESTIGATORS TOP COME UP WITH

CREATIVE IDEAS, TAKING THE

PLANS, INVESTIGATORS ARE TAKING

SERIOUSLY, WHEN IT COMES TO

DETERMINING PAYLINES.

CURIOUS TO SEE HOW THIS DEVELOPS

OVER TIME BUT A CREATIVE

INITIATIVE AND NICE TO SEE NIBIB

PARTICIPATING IN IT.

FINALLY I WANT TO TALK ABOUT NEW

FUNDING OPPORTUNITIES BRAIN IS

FOCUSED ON, MANY YOU'VE SEEN

BEFORE, TWO OF SPECIAL INTEREST

TO OUR COMMUNITY, ONE IS

TECHNOLOGY AND RESOURCE

DISSEMINATION, MANY ADVANCED

TECHNOLOGIES THAT HAVE DEVELOPED

IN BRAIN INVOLVE MECHANICS EVER

OUR OWN COMMUNITY, DESIGNED TO

PROMOTE WAYS TO DISSEMINATE TO A

BROADER COMMUNITY OF USERS,

IMPORTANT OF BRAIN'S DESIRE TO

PUSH THIS OUT TO AS BROAD A

COMMUNITY AS POSSIBLE.

THE OTHER WHICH I'LL TALK ABOUT

MORE WHEN WE TALK ABOUT IS BRAIN

CONNECT.

BRAIN IS FOCUSING ON SUGGESTION

THAT CAME FROM THE BRAIN 2.0

REPORT, THAT THERE WERE A NUMBER

OF SO CALLED TRANSFORMATIVE

PROJECTS THAT THE BRAIN

INITIATIVE COULD INVEST IN, OVER

THE NEXT FIVE YEARS.

AND THE PROGRAM PEOPLE INVOLVED

IN BRAIN TOOK THAT VERY

SERIOUSLY AND CAME UP WITH THREE

SO-CALLED TRANSFORMATIVE

PROJECTS THAT THEY ARE FOCUSING

ON.

ONE IS TO EXTEND THE BRAIN CELL

ATLASES TO HUMANS.

SECOND IS TO USE THAT MOLECULAR

INFORMATION TO IMPROVE OUR

PRECISION ACCESS TO THE CELL

TIMES WITHIN THE BRAIN.

AND THE THIRD IS TO MAP OUT

BRAIN CONNECTIVITY.

SO THE FIRST OF THESE SO-CALLED

BRAIN ATLAS I THINK IS PERHAPS

ONE OF THE GREATEST SUCCESS

STORIES OF THE BRAIN INITIATIVE.

THE PLAN IS TO BUILD ON THE

SUCCESS OF THE MOUSE BRAIN ATLAS

AND SHIFT EMPHASIS TO HUMANS.

YOU CAN SEE THAT THERE'S ALREADY

BEEN SIGNIFICANT AMOUNT OF

RESOURCES PUT TO THE BRAIN CELL

ATLAS, AS WELL AS ITS COMPANION

CELL ACCESS, ACCELERATED LAUNCH.

THE CELL CENSUS IS NOW MOVING UP

SCALE FROM MICE TO NON-HUMAN

PRIMATES AND TO HUMANS.

THIS HAS BEEN REALLY A WONDERFUL

EXAMPLE OF TRUE TEAM SCIENCE.

YOU CAN SEE THAT IN THIS EXAMPLE

THERE ARE MORE THAN 250

INVESTIGATORS INVOLVED, ALMOST

90 DIFFERENT AFFILIATIONS ACROSS

ALMOST 50 INSTITUTIONS.

SCIENTISTS INSIDE AND OUTSIDE

THE U.S. INVOLVED.

REALLY MAKING QUITE A REMARKABLE

PROGRESS.

I THINK THE REAL CHALLENGE FOR

THE GROUP AND THE FUTURE IS TO

SCALE UP FOR A MOUSE, TO HUMANS.

THE KEY, ONE KEY AREA WHERE OUR

COMMUNITY WILL MAKE AN IMPORTANT

CONTRIBUTION IS THAT WE'VE MADE

TREMENDOUS PROGRESS OVER THE

LAST FEW YEARS IN UNDERSTANDING

THE MACROSCOPIC ANATOMY OF THE

BRAIN, THE GOAL TO TRY TO PUT

THE CELLULAR SCALE INFORMATION

INTO THE CONTEXT OF THE

MACROSCOPIC UNDERSTANDING OF THE

BRAIN.

SOMEWHAT INTERESTINGLY, I'D SAY

THIS IS STILL A WORK IN

PROGRESS, IN TERMS OF HOW THEY

ARE CONCEPTUALIZING THE HUMAN

CELL ATLAS BUT IT'S A DOMAIN

THAT I KNOW NIBIB INVESTIGATORS

WILL HAVE A LOT TO CONTRIBUTE

TO.

THIS IS ONE EXAMPLE FROM EARLIER

STUDIES PERFORMED UNDER THIS,

BASICALLY SHOWING THAT WE ALL

KNOW, FOR EXAMPLE, THAT

PARKINSON'S DISEASE IS

DEGENERATIVE PROCESS INVOLVING

DOPE DOPAMINERGIC NEURONS,

IDENTIFYING SUBPOPULATIONS THAT

SEEM TO BE DISEASE VULNERABLE

AND OTHERS SEEM TO BE CELL

PROTECTED.

SO THIS GIVES SIGNIFICANT HOPE

THAT BY UNDERSTANDING WE CAN

THEN UNDERSTAND WHICH NEURONS

MAY BE PROTECTED, WHAT MOLECULAR

PROPERTIES ARE, PERHAPS

SELECTIVELY TARGET THEM THROUGH

THE CELL ARMAMENTARIUM WORK TO

ENHANCE THEIR FUNCTION TO

REPLACE FUNCTION OF THOSE

NEURONS THAT ARE LOST.

THIS ADDRESSES THE ISSUE OF

PRECISION ACCESS, ARMAMENTARIUM,

WITH THE DETAILED INFORMATION ON

BRAIN CELL SUBTYPES AND

MOLECULAR UNDERPINNINGS GIVES US

THE OPPORTUNITY TO TARGET THESE

CELLS, VERY SELECTIVELY.

THERE'S BEEN A LOT OF PROGRESS

ON THIS FRONT, BEING ABLE TO

TARGET BOTH NEURONS AND

NON-NEURONAL CELLS WITHIN THE

BRAIN, AND FROM STANDPOINT OF

HUMAN THERAPEUTICS IT'S A

REMARKABLY IMPORTANT AND

POTENTIALLY VERY IMPACTFUL

DIRECTION THAT WILL COME FROM

THE BRAIN INITIATIVE.

AND FINALLY, I'D LIKE TO BRIEFLY

TALK ABOUT THIS BRAIN CONNECT

PROJECT, AGAIN THIS IS ONE THAT

I THINK OUR COMMUNITY WILL HAVE

A LOT TO CONTRIBUTE TO.

IT'S REALLY ENVISIONED AS AT

LEAST A 10-YEAR PROJECT, THE

FIRST PHASE OF WHICH WILL BE TO

TRY TO DEVELOP FUNDAMENTAL TOOLS

TO ALLOW US TO SCALE UP THE

STUDIES THAT ARE BEING

PERFORMED.

AND THEN THE SECOND TEN YEARS

WILL BE TO ROLL THAT OUT IN

PRODUCTION, TO BE ABLE TO MAP

THE ENTIRE BRAIN.

THERE ARE ESSENTIALLY TWO SCALES

THAT ARE ENVISIONED.

ONE IS TO STUDY THE MOUSE AT A

SYNAPSE BY SYNAPSE LEVEL.

TYPICALLY WITH ELECTRON

MICROSCOPY TECHNIQUES TO

LITERALLY MAP EVERY SYNAPSE IN

THE BRAIN AS CONNECTIVITY TO

EVERY OTHER, SHOULD BE POSSIBLE

IN THE NEXT DECADE IN THE MOUSE

BRAIN, A DAUNTING TASK.

IN LARGER BRAINS, PRIMATES OR

NON-HUMAN PRIMATE, AXON LEVEL

MAP OF CONNECTIVITY, VISION FOR

HOW BRAIN CONNECTS WILL WORK IN

THE FIRST FACE TO BUILD CENTERS

AROUND EACH OF THE TWO SCALES,

SO SEPARATE SET OF CENTERS ONE

FOCUSED ON MOUSE, ONE ON LARGER

BRAINS, AND IN ADDITION TO THESE

COMPREHENSIVE CENTERS HAVE

FUNDING FOR SINGLE COMPONENT

PROJECTS THAT ALLOW NEWER

TECHNOLOGIES TO BE EVALUATED,

AND POTENTIALLY RISKIER

APPROACHES TO BE EVALUATED AND

BROUGHT INTO THE COMPREHENSIVE

CENTERS AS THE TECHNOLOGY PROVES

OUT.

WHY MIGHT THIS BE IMPORTANT?

WELL, JOHN RECENTLY SHOWED THAT

TWO EXAMPLES FROM WORK ON

IMPROVING DEEP BRAIN STIMULATION

FOR DEPRESSION, BOTH OF WHICH

REALLY SHOW THE IMPORTANCE OF

UNDERSTANDING THE CONNECTIVITY

STRUCTURE OF THE BRAIN, ONE AS

SHOWN HERE BY SHETH ET AL., THE

SECOND LOOKING AT DEPENDENT

CHANGES BUT IN EACH CASE HAVING

PRECISION UNDERSTANDING OF THE

NETWORKS FOR TARGETING DEEP

BRAIN TREATMENT WHETHER FOR

DEPRESSION, NEUROPSYCHIATRIC

DISORDERS, WHETHER DEEP IN THE

BRAIN OR IN THE CORTICAL

SURFACE, THE FUNDAMENTAL WIRING

DIAGRAM OF THE BRAIN IS STILL

VERY POORLY UNDERSTOOD, AND IT

WILL BE QUITE IMPORTANT

OPPORTUNITY FOR US TO CONTRIBUTE

TECHNOLOGIES THAT WILL ALLOW US

TO ULTIMATELY DEVELOP THESE MAPS

AND FROM THOSE MAPS IMPROVE.

WITH THAT I WILL SAY IF YOU'D

LIKE TO LEARN MORE, SORRY FOR

RUSHING THROUGH THIS TALK, BUT I

CONSIDER THESE BRAIN ANNUAL

MEETINGS TO BE AMONGST THE VERY

BEST SCIENTIFIC MEETINGS THAT I

GO TO.

IF YOU'RE INTERESTED IN LEARNING

MORE ABOUT THAT THE BRAIN

INITIATIVE IS DOING, SEEING THE

TECHNOLOGY THAT'S BEING

DEVELOPED, I'M GETTING INVOLVED,

I I WOULD ENCOURAGE YOU TO

CONSIDER THIS MEETING WHICH IS

COMING UP IN JUST A MONTH OR SO.

AND WITH THAT, I'LL STOP

SHARING, IF I CAN FIGURE OUT HOW

BEST TO DO THAT.

THERE WE GO.

VERY GOOD.

THANK YOU ALL VERY MUCH FOR YOUR

ATTENTION.

>> THANK YOU, BRUCE.

>> THANKS, BRUCE.

PRETTY SPECTACULAR TOUR.

VERY IMPRESSIVE.

WE HAVE TIME FOR SOME QUESTIONS.

I SEE A HAND UP.

>> I HAVE A QUESTION FOR
BRUCE

AND BRUCE.

CAN YOU HEAR ME OKAY?

I'VE GOT A PRETTY BAD COLD.

BRUCE ROSEN, THIS LAST SLIDE YOU

SHOWED WAS PRETTY INTRIGUING,

WITH A CLOSED LOOPED DBS.

CAN YOU CLARIFY THAT A BIT?

WHAT'S BEING DETECTED,

STIMULATION, WHAT SIGNAL

TRIGGERS THE STIMULATION?

>> WELL, SO, YOU KNOW, THE
TRICK

OF COURSE IS TO BE ABLE TO

MEASURE ELECTROPHYSIOLOGICAL

SIGNALS COMING FROM DEEP IN THE

BRAIN AS WELL AS TO GENERATE

SIGNALS TO STIMULATE THE BRAIN.

AND THE TRICK IS THAT YOU HAVE

TO LOOK FOR SIGNATURES WITHIN

THE ELECTRICAL SIGNALS COMING

FROM THERE CORRELATED TO THE

CHANGE --

>> (INAUDIBLE).

>> EXACTLY.

AS USE THEM AS A WAY TO THEN USE

THAT TO THEN TRIGGER THE

STIMULATION.

THE INTERESTING CHALLENGE OF

COURSE IS FUNDAMENTAL KNOWLEDGE

OF WHAT THOSE NEURONAL SIGNALS

ARE TELLING US ABOUT IS REALLY

EMPIRICAL DETERMINATION.

LOTS, AGAIN, FOR YOUR COMMUNITY

TO DO.

LOTS OF APPLICATIONS FOR A.I. TO

BE ABLE TO LOOK THROUGH THE

COMPLEX DATA THAT'S COMING OUT

BUT I THINK INCREASINGLY THIS IS

HOW THESE DEEP BRAIN STIMULATORS

ARE BEING BUILT.

I THINK WE'LL SEE MORE AND MORE

OF THESE CLOSED LOOP SYSTEMS

COMING ONLINE.

>> OKAY.

THANK YOU.

A QUICK QUESTION FOR BRUCE T.

BRUCE, I JOINED A BIT LATE, AS

JILL WAS CONCLUDING HER REMARKS.

BUT I THINK YOU SAID THAT THE

EVENTUAL SITE OF ARPA-H IS NOT A

SETTLED ISSUE YET, DID I

UNDERSTAND THAT CORRECTLY?

>> THAT'S MY
UNDERSTANDING, ROD,

YES.

YOU KNOW, THERE'S STILL

CONGRESSIONAL HEARINGS ONGOING

AND SOME HAVE EXPRESSED VOCALLY

THEIR CONCERN ABOUT HOUSING IT

AT THE NIH.

I THINK IT IS A PRESIDENTIAL

PRIORITY.

AND SO I THINK THERE'S PROBABLY

A PRETTY GOOD CHANCE IT WILL

EXIST SOMEPLACE.

THERE'S BEEN ENORMOUS AMOUNT OF

WORK, PEOPLE HAVE WORKED ALL

ACROSS THE NIH TO DEMONSTRATE

THE VALUE FOR HOUSING IT AT NIH.

THERE ARE A LOT OF PRACTICAL

SYNERGIES, JUST IN TERMS OF

BEING ABLE TO HANDLE THE

BUREAUCRACY OF SUBMISSION OF

IDEAS AND AWARDS, AND AS YOU

KNOW VERY WELL ALL THOSE

SYNERGIES CAN BE IMMEDIATELY

UTILIZED TO GET A PROGRAM UP AND

RUNNING.

BUT FROM WHAT I UNDERSTAND, IT'S

NOT A DONE DEAL.

>> I UNDERSTAND.

WELL, FOR WHAT IT'S WORTH I

THINK IT WOULD BE A REAL MISSED

OPPORTUNITY IF IT WASN'T AT THE

NIH.

>> AND THAT'S -- YOU
SHOULD ADD

YOUR VOICE TO THAT.

THAT'S CERTAINLY -- IT'S A TOPIC

THAT'S UNDER PRETTY INTENSIVE

DISCUSSION.

>> THANK YOU.

GREAT JOB, BRUCE.

>> THANKS.

>> THANK YOU.

SEEING NO MORE QUESTIONS OR

COMMENTS, BRUCE TROMBERG, BEFORE

WE ADJOURN WOULD YOU LIKE TO

MAKE ANY FINAL REMARKS?

BEFORE WE ADJOURN OPEN SESSION,

I SHOULD CLARIFY.

>> RIGHT.

YEAH, WE'RE DOING VERY WELL.

SO, I'D LIKE TO THANK EVERYONE

FOR THEIR ENGAGEMENT AND

PARTICIPATION IN THIS OPEN

SESSION.

AND I GUESS THAT'S FORMAL NOTE

TO ADJOURN.

DAVID, DO YOU HAVE AP -- ARE WE

GOING TO USE OUR 15-MINUTE

BREAK?

>> YEAH, LET'S TAKE ABOUT
A

10-MINUTE BREAK, SO BEFORE WE

ADJOURN LET ME REMIND EVERYONE,

COUNCIL AND MY COLLEAGUES IN THE

CLOSED SESSION, IT'S A SEPARATE

ZOOM MEETING ROOM.

WE'LL DROP OUT OF THIS AND SO

LET'S GO FOR 3:10.

NOW WE'LL OFFICIALLY ADJOURN THE

OPEN SESSION OF COUNCIL.

I WANT TO THANK OUR SPECIAL

GUESTS, BOTH IN THE VIDEO

CONFERENCE ROOM AND OUR VISITORS

ONLINE FOR ATTENDING THE

VIDEOCAST.

THE OPEN SESSION OF THE 59th

MEETING OF THE NIBIB NATIONAL

ADVISORY COUNCIL IS HEREBY

ADJOURNED.